Nanobody derivatization for molecular study and perturbation of cancer cell invadopodia by Hebbrecht, Tim
   
 
 
 
 
 
 
 
 
 
Nanobody derivatization for molecular study and 
perturbation of cancer cell invadopodia 
 
 
 
 
 
Tim Hebbrecht 
 
Promotor: Prof. Dr. Jan Gettemans 
 
2019 - 2020 
 
 
 
Thesis submitted to fulfil the requirements for the degree of  
Doctor (PhD) of Biomedical Sciences  
 
Department of Biomolecular Medicine 
Faculty of Medicine and Health Sciences 
Ghent University  
  
Nanobody derivatization for molecular study and perturbation of cancer cell 
invadopodia 
By Ir. Tim Hebbrecht 
 
Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences 
Campus Rommelaere 
Albert Baertsoenkaai 3 
9000 Gent 
Belgium 
 
Cover illustration 
Photographs were taken by Tim Hebbrecht at the Rommelaere complex. The picture in 
front is the AF488 signal detected inside the FastGene FAS-digi Geldoc device (NIPPON 
genetics, Dueren, Germany). The picture at the back is a view through a window showing 
the historical charms of the Rommelaere complex. 
 
Promotor 
Prof. Dr. Jan Gettemans 
Nanobody lab 
Department of Biomolecular Medicine 
Faculty of Medicine and Health Sciences 
Campus Rommelaere 
Ghent University 
 
Dean    
Prof. dr. Piet Hoebeke 
 
Rector    
Prof. dr. ir. Rik Van de Walle 
 
 
The author and promotor give the authorization to consult and copy parts of this work for 
personal use only. Every other use is subject to the copyright laws. Permission to 
reproduce any material contained in this work should be obtained from the author.  
 
Tim Hebbrecht was supported by the Concerted Actions Program (GOA) of Ghent 
University and an Emmanuel van der Schueren grant of the Flemish cancer society (Kom 
op tegen kanker).  
   
Advisory Committee 
Prof. Dr. Marleen Van Troys 
Department Biomolecular Medicine 
Ghent University 
 
Prof. Dr. Ir. An Hendrix 
Department of Human Structure and Repair 
Ghent University 
 
Examination Committee: 
Chairman 
Prof. Dr. Bruno Verhasselt 
Department of Diagnostic Sciences 
Ghent University 
 
Members 
Dr. Cécile Vincke 
Department of Bioengineering Sciences 
VUB 
 
Prof. Dr. Frank Peelman 
Department of Biomolecular Medicine 
Ghent University 
 
Prof. Andre Skirtach 
Department of Biotechnology 
Ghent University 
 
Dr. Stephan Stremersch 
Department of Pharmaceutics 
Ghent University 
 
Prof. Dr. Nadine Van Roy 
Department of Biomolecular Medicine 
Ghent University 
  I 
Table of Contents 
Table of Contents .......................................................................................................... I 
List of Abbreviations .................................................................................................... V 
List of Tables ............................................................................................................... XI 
List of Videos ............................................................................................................... XI 
List of Figures ............................................................................................................ XIII 
Summary .................................................................................................................. XV 
Samenvatting .......................................................................................................... XVII 
 
Part I General introduction ........................................................................................... 1 
 A nanobody or VHH ............................................................................... 3 Chapter 1
 The discovery of heavy chain antibodies ............................................... 3 1.1
 Nanobodies .......................................................................................... 5 1.2
1.2.1 VH versus VHH ........................................................................................................ 5 
1.2.2 Advantages and disadvantages of nanobodies ...................................................... 7 
1.2.3 Nanobody generation ........................................................................................... 11 
1.2.4 Nanobody interference with protein functions .................................................... 13 
 Nanobody applications ....................................................................... 14 1.3
1.3.1 Research purposes ................................................................................................ 14 
1.3.2 Therapeutic and diagnostic purposes ................................................................... 18 
 Non-immunoglobulin based molecules ............................................... 20 1.4
 II 
 Labelling and microscopy ................................................................... 23 Chapter 2
 Fusion proteins ................................................................................... 23 2.1
 Coupling mechanisms for the labelling of nanobodies ......................... 25 2.2
2.2.1 Self-labelling enzymes ........................................................................................... 25 
2.2.2 Enzymatic recognition tags ................................................................................... 26 
2.2.3 Chemical ways for labelling nanobodies ............................................................... 28 
2.2.4 Other strategies .................................................................................................... 30 
2.2.5 An alternative method: the genetic incorporation of unnatural amino acids ..... 32 
2.2.5.1 Non-canonical amino acid options ............................................................ 34 
2.2.5.2 Optional chemical reactions after the incorporation of an unnatural 
amino acid .................................................................................................. 36 
2.2.6 A label-free strategy .............................................................................................. 37 
 Cancer, metastasis and cellular protrusions ........................................ 39 Chapter 3
 Cancer and metastasis ........................................................................ 39 3.1
 The actin cytoskeleton ........................................................................ 40 3.2
 Actin-based protrusions, a way to move the cell ................................. 42 3.3
3.3.1 Lamellipodia and filopodia .................................................................................... 43 
3.3.2 Invadosomes: podosomes and invadopodia ........................................................ 43 
3.3.3 Focal adhesions ..................................................................................................... 45 
3.3.4 Formation of an invadopodium ............................................................................ 45 
3.3.4.1 Initiation ..................................................................................................... 46 
3.3.4.2 Overview of the initiation .......................................................................... 47 
3.3.4.3 The initiation leads to the invadopodium precursor ................................. 49 
3.3.4.4 Maturation and ECM degradation ............................................................. 51 
 Neural Wiskott-Aldrich syndrome protein or N-WASp ........................ 54 3.4
3.4.1 Wiskott-Aldrich syndrome .................................................................................... 54 
3.4.2 Wiskott-Aldrich syndrome protein family ............................................................ 54 
3.4.3 N-WASp ................................................................................................................. 55 
3.4.3.1 The domains of WASp and N-WASp .......................................................... 56 
3.4.3.2 From an auto-inhibition state to an activated protein.............................. 57 
  III 
Part II Scope ............................................................................................................... 59 
 Scope .................................................................................................. 61 Chapter 4
 
Part III Results ............................................................................................................ 63 
 VCA nanobodies target N-WASp to reduce invadopodium Chapter 5
formation and functioning ......................................................................................... 65 
 Introduction ........................................................................................ 65 5.1
 Research paper ................................................................................... 66 5.2
5.2.1 Abstract ................................................................................................................. 66 
5.2.2 Introduction .......................................................................................................... 67 
5.2.3 Results ................................................................................................................... 68 
5.2.3.1 N-WASp recognising of VCA nanobodies .................................................. 68 
5.2.3.2 Mitochondrial outer membrane anchoring and intracellular 
displacement of N-WASp ........................................................................... 69 
5.2.3.3 Affinity and stoichiometry of 4 selected VCA Nbs .................................... 73 
5.2.3.4 The VCA Nbs interfere in the binding between N-WASp and its 
direct interaction partner Arp2/3, but not actin ....................................... 74 
5.2.3.5 VCA nanobodies reduce cancer cell invadopodium formation ................. 75 
5.2.3.6 The VCA Nbs reduce overall matrix degradation ...................................... 77 
5.2.4 Discussion .............................................................................................................. 79 
5.2.5 Materials and methods ......................................................................................... 82 
5.2.6 Acknowledgments ................................................................................................. 87 
 Nanobody click chemistry for convenient site specific fluorescent Chapter 6
labelling, single step immunocytochemistry and delivery into living cells by 
photoporation and live cell imaging ........................................................................... 89 
 Introduction ........................................................................................ 89 6.1
 Research paper ................................................................................... 90 6.2
6.2.1 Abstract ................................................................................................................. 90 
6.2.2 Introduction .......................................................................................................... 91 
6.2.3 Results ................................................................................................................... 92 
6.2.3.1 CuAAC reaction .......................................................................................... 93 
6.2.3.2 Single step immunocytochemistry with click chemistry labelled 
cortactin and β-catenin nanobodies. ........................................................ 97 
6.2.3.3 Delivering a fluo-nanobody in living cells by photoporation improves 
the applicability of nanobodies in immunocytochemistry. ....................... 99 
 IV 
6.2.4 Discussion ............................................................................................................ 101 
6.2.5 Material & methods ............................................................................................ 105 
6.2.6 Supplementary information ................................................................................ 110 
6.2.6.1 Incorporation of an azido/alkyne functional group into a nanobody ..... 110 
6.2.6.2 Additional information for CuAAC ........................................................... 111 
6.2.7 Acknowledgments ............................................................................................... 111 
Part IV General discussion & conclusions ................................................................... 113 
 General discussion and conclusions .................................................... 115 Chapter 7
 VCA nanobodies, a tool to study N-WASp functioning in the 7.1
invadopodium pathway ..................................................................... 115 
 Fluorescent nanobodies, an emerging tool for microscopic 7.2
purposes in fixed and living cells ........................................................ 119 
 Conclusion and future perspectives ................................................... 127 7.3
Addendum ................................................................................................................ 131 
Curriculum Vitae ....................................................................................................... 135 
Bibliography ............................................................................................................. 141 
Acknowledgments - Dankwoord ............................................................................... 165 
  V 
List of Abbreviations 
AahI′  Androctonus australis hector toxin 
Ab Antibody 
ADAM A disintegrin and metalloprotease  
ADCC Antibody-dependent cytotoxicity  
ADCC Antibody-dependent cellular cytotoxicity  
ADF Actin depolymerizing factor or cofilin 
AdPROM affinity-directed protein missile 
AF488 Alexa Fluor 488 
AF647 Alexa Fluor 647 
AhA Azidohomoalanine 
AID Auxin-inducible degron 
Anap 3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic acid 
Arg Abl-related gene 
Arp2/3 Actin-related protein 2/3  
ASC Apoptosis-associated speck-like protein  
ASO Antisense oligonucleotide 
ATP Adenosine triphosphate 
AuNP Gold nanoparticles  
AzK Nε-(2-azidoethoxy)carbonyl-L-lysine 
BARAC Biarylazacyclooctynone compound 
BSBMB Belgian Society of Biochemistry and Molecular Biology 
BTTAA 2-[4-((bis[(1-tert-butyl-1H-1,2,3-triazol-4-yl)methyl]amino)methyl)-1H-1,2,3-
triazol-1-yl]acetic acid 
BTTES 2-[4-((bis[(1-tertbutyl-1H-1,2,3-triazol-4-yl)methyl]amino)-methyl)-1H-1,2,3-
triazol-1-yl]ethyl hydrogen sulfate 
CAS9 CRISPR-associated gene  
CBD Chitin binding domain 
CD7 Cluster of Differentiation 7 
Cdc42 Cell division cycle 42 
CDR Complementarity determining region  
CEA Carcinoembryonic antigen (or CD66e)  
CH Constant domain of heavy chain 
CIP4 Cdc42-interacting protein 4 
CouAA (S)-1-carboxy-3-(7-hydroxy-2-oxo-2H-chromen-4-yl)propan-1-aminium 
 VI 
CRIB Cdc42- and Rac-interactive binding region 
CRIG Cancer Research Institute Ghent 
CRISPR Clustered regularly interspaced short palindromic repeat DNA sequences 
CRL Cullin-RING E3 ubiquitin ligase 
CSF-1 Colony-stimulating factor-1 
c-Src Cellular Src kinase  
CuAAC Cu(I)-catalyzed Azide-Alkyne Click Chemistry  
Cy5 Cyanine 5 
Cy7 Cyanine 7 
dAb Single domain antibody  
Dansyl Ala Dansylalanine 
DBCO Dibenzocyclooctyne-amine 
DHFR Dihydrofolate reductase 
DIBO Dibenzocyclooctynes 
DIFO Difluorocyclooctyne 
DNA Deoxyribonucleic acid 
DNA-PAINT DNA point accumulation for imaging in nanoscale topography 
DNP Dinitrophenyl 
DOX Doxicicilne 
DRF Diaphanous-related formin  
DTT Dithiothreitol  
E. coli Escherichia coli 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immuno sorbent assay 
EMT Epithelial–mesenchymal transition 
Ena-VASP Enabled vasodilator stimulated phospoprotein 
EtcK Nε-(3-ethynyltetrahydrofuran-2-carbonyl)-L-lysine 
EVH1 Ena-VASP homology 1  
Fab Fragment antigen-binding  
FACS Fluorescence-activated cell sorter 
FAK Focal adhesion kinase  
FGE Formylglycine-generating enzyme  
fGly Formylglycine 
FH1 Formin-homology 1  
FH2 Formin-homology 2 
FRI Fluorescence reflectance imaging 
FWR Frame work region 
GA Glutaraldehyde 
G-actin Monomeric actin 
GBD GTPase binding domain  
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GPCR G protein-coupled receptor 
  VII 
GQD Graphene quantum dots 
GTP Guanosine triphosphate 
HA Hemagglutinin 
HCAb Heavy chain antibody 
HEK293T Human embryonic kidney cells 
HeLa Henrietta Lacks cervix cell line 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER2 Human Epidermal growth factor Receptor 2 
HGF Hepatocyte growth factor  
HIV Human immunodeficiency viruses 
HNSCC61 Head and neck squamous carcinoma cancer cells  
Hpg Homopropargylglycine 
HRP Horseradish peroxidase 
HypE Huntingtin-associated yeast-interacting protein E 
IEDDA Inverse electron-demand Diels–Alder cycloadditions  
IFP Interstitial fluid pressure  
IgG Immunoglobulin G 
IgNAR Immunoglobulin new antigen receptor 
IMAC Immobilized metal affinity chromatography 
JMY Junction-mediating and regulatory protein  
IPL Intein-mediated protein ligation 
IR Infrared 
ITC Isothermal titration calorimetry 
LPETG Sortag consisting of Leu – Pro – Glu – Thr – Gly 
LplA Lipoic acid ligase 
Malf1 Malassezia furfur cell surface protein 
MamC Magnetosome protein MamC of Magnetococcus marinus strain MC-1 
MDA-MB-231 Breast cancer cells 
MESNA 2-Mercaptoethane sulfonate sodium 
MET Mesenchymal to epithelial transition 
MjTyrRS/MjtRNATyr Methanocaldococcus jannaschii Tyr tRNA synthetase/tRNATyr 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
MOM Mitochondrial outer membrane 
MT1-MMP Membrane type I matrix metalloproteinases  
MWCO Molecular weight cut off 
NAD(P)H Nicotinamide adenine dinucleotide phosphate 
Nb Nanobody 
Nck1 Non-catalytic region of tyrosine kinase adaptor protein 1 
NHE1 Sodium hydrogen exchanger  
NHS N-hydroxysuccinimide  
NMR Nuclear magnetic resonance  
NPC Nuclear pore complex 
NPF Nucleation promoting factors  
NSF Nanobody Service Facility  
NTA Amino-terminal acidic region 
 VIII 
N-WASp Neural Wiskott-Aldrich syndrome protein 
o-AzbK Nε-(o-azidobenzyloxycarbonyl)-L-lysine 
PAG Propargylglycine 
PAGE Polyacrylamide gel electrophoresis 
PALM Photo-activated localization microscopy 
pAzF Para-azido phenylalanine 
PBMC Peripheral blood mononuclear cell 
PC-3 Prostate cancer cells 
PCR Polymerase chain reaction  
PDGF Platelet derived growth factor  
PE38 Pseudomonas Exotoxin A  
PEG Polyethyleenglycol 
PET Positron emission tomography  
P-EtF P-ethinylphenylalanine 
PFA Paraformaldehyde 
PH Pleckstrin homology  
PI(3,4)P2  Phosphatidylinositol-(3,4)-biphosphate 
PI(3,4,5)P3  Phosphoinositol-(3,4,5)-triphosphate  
PI(4,5)P2 Phosphatidylinositol-(4,5)-biphosphate 
PI3K Phosphoinositide 3-kinase 
PrgF P-propargyloxy-L-phenylalanine 
Protein-i Protein interference 
Ptk2 Potorous tridactylis epithelial kidney cells  
Rac1 Ras-related C3 botulinum toxin substrate 1 
RFP Red fluorescent protein 
Rho Ras homologous 
RING Really interesting new gene 
RNA Ribonucleic acid 
RNAi RNA interference  
ROS Reactive oxygen species 
SCAR Suppressor of cAR 
scFv Single-chain variable fragment 
SDS Sodium dodecyl sulfate 
SEC Size exclusion chromatography 
SH3 SRC Homology 3 domain 
SHP2 Src homology region 2-containing protein tyrosine phosphatase 2 
shRNA Short hairpin RNA 
SIM Structured illumination microscopy 
siRNA Small interfering RNA 
smFRET Single molecule fluorescence resonance energy transfer 
SMLM Single molecule localization microscopy  
SPAAC Strain-promoted alkyne-azide cycloaddition  
SPECT Single-photon emission computed tomography  
SrtA Sortase A 
STED Stimulated emission depletion microscopy 
  IX 
STORM Stochastic optical reconstruction microscopy 
SYNJ2 Synaptojanin2 
T-ALL T-cell acute lymphoblastic leukemia 
TAM Tumor associated macrophage 
TAMRA Tetramethylrhodamine 
TBTA Tris-(benzyltriazolylmethyl)amine 
TCEP Tris[2-carboxyethyl]phosphine 
TGFβ Transforming growth factor β 
Tgase Transglutaminase 
THPTA Tris-(3-hydroxypropyltriazolylmethyl)-amine 
TIRF Total internal reflection fluorescence 
Tks5 Tyrosine kinase substrate with five SH3 domains 
TMP Trimethoprim 
TOCA1 Transducer of Cdc42-dependent actin assembly protein 1 
tRNA Transfer RNA 
TTL Tubulin tyrosine ligase 
Tub Tubulin‐derived recognition sequence 
VCA Verprolin-homology (V), cofilin-homology or central (C) and acidic (A) region 
VEGF Vascular endothelial growth factor 
VH Variable domain of the heavy chain of a conventional Ab 
VHH Variable domain of the heavy chain of a HCAb 
VHL von Hippel-Lindau  
VL Variable domain of the light chain of a conventional Ab 
VNAR Variable domain of immunoglobulin new antigen receptors 
WAML WASp and missing-in-metastasis like protein  
WAS Wiskott-Aldrich syndrome  
WASH WASp and SCAR homologue protein  
WASp Wiskott-Aldrich syndrome protein 
WAVE WASP family verprolin-homologous protein 
WAWH WASp without WH1 domain protein  
WH1 WASp homology 1  
WH2 WASp homology 2 
WHAMM WASp homologue associated with actin, membranes, and microtubules 
WIP WASp-interacting protein  
XLT X-linked thrombocytopenia  
YFP Yellow fluorescent protein 
 
 
  XI 
List of Tables 
Table 1: Thermodynamic parameters (and respectively standard deviations) of HA-
tagged VCA nanobodies interacting with synthetic VCA peptide, 
determined by ITC.  ...................................................................................... 73 
Table 2: Buffer composition overview. .............................................................................. 95 
Table 3: Quantification of purified nanobody obtained per L of bacterial culture via 
the sortase A labeling method.  ................................................................... 96 
Table 4: Quantification of purified nanobody obtained per L of bacterial culture 
following pAzF incorporation method. ........................................................ 96 
Table 5: Overview of the effects on the invadopodium pathway due to the VCA 
nanobodies. ............................................................................................... 117 
Table 6: The use of labelled nanobodies for super resolution microscopy.  ................... 122 
 
List of Videos 
Video 1: HeLa cells photoporated with β-catenin Nb86-AF488 (labelled through the 
pAzF method).  ........................................................................................... 101 
Video 2: HeLa cells photoporated with fascin Nb2-AF488 (labelled through the pAzF 
method). .................................................................................................... 101 
  
 
  XIII 
List of Figures 
Figure 1: Antibody and antibody fragments.  ....................................................................... 4 
Figure 2: Heavy chain antibodies.  ........................................................................................ 5 
Figure 3: Structure of VH (A) and VHH (B).  .......................................................................... 6 
Figure 4: Schematic representation of the photoporation technique.  ............................. 10 
Figure 5: Protein delivery by esterification.  ...................................................................... 11 
Figure 6: Generation and isolation of nanobodies through phage panning.  .................... 12 
Figure 7: Nanobody-based protein degradation methods.  ............................................... 16 
Figure 8: A nanobody and non-immunoglobulin based molecules.  ................................. 21 
Figure 9: Linkage error.  ...................................................................................................... 25 
Figure 10: An enzymatic labelling method using a tubulin tyrosine ligase (TTL) or 
using a sortase A (SrtA).  .............................................................................. 27 
Figure 11: Enzymatic labelling methods by using a formaylglycine-generating 
enzyme (FGE) or a transglutaminase (Tgase).  ............................................ 28 
Figure 12: Chemical labelling methods.  ............................................................................ 30 
Figure 13: Intein-mediated protein ligation (IPL).  ............................................................. 32 
Figure 14: The incorporation of an unnatural amino acid.  ............................................... 33 
Figure 15: Unnatural amino acids.  ..................................................................................... 35 
Figure 16: Chemical labelling reactions.  ............................................................................ 36 
Figure 17: Raman scattering.  ............................................................................................. 38 
Figure 18: Schematic visualization of metastasis.  ............................................................. 40 
Figure 19: The main components of the cytoskeleton: actin filaments, microtubules 
and intermediate filaments.  ....................................................................... 41 
Figure 20: Lamellipodia and filopodia.  .............................................................................. 43 
Figure 21: Invadosomes (podosomes and invadopodia) and focal adhesions.  ................ 44 
Figure 22: Schematic visualisation of the invadopodium formation pathway: the 
initiation.  ..................................................................................................... 48 
Figure 23: Actin polymerisation via Arp2/3.  ...................................................................... 49 
Figure 24: Schematic visualisation of the invadopodium formation pathway: the 
precursor formation.  ................................................................................... 50 
Figure 25: Schematic visualisation of the invadopodium formation pathway: the 
maturation.  ................................................................................................. 51 
Figure 26: Schematic visualisation of the invadopodium formation pathway: the 
accumulation of MMPs.  .............................................................................. 53 
 XIV 
Figure 27: Schematic representation of the domains of WASp and N-WASp. .................. 56 
Figure 28: Conformations of N-WASp, from auto-inhibited to activated state.  ............... 58 
Figure 29: VCA nanobody - N-WASp binding.  .................................................................... 68 
Figure 30: VCA nanobody—N-WASp binding in EGFP-tagged VCA Nb expressing 
HNSCC61.  .................................................................................................... 69 
Figure 31: Mitochondrial pattern in MDA-MB-231 breast cancer cells which 
transiently express a VCA Nb equipped with a MOM-tag.  ......................... 70 
Figure 32: VCA Nb2, 7, 13 and 14 capture endogenous N-WASp at mitochondria.  ......... 71 
Figure 33: Mitochondrial pattern in MDA-MB-231 breast cancer cells in which 
EGFP-tagged VCA Nbs inducibly are expressed.  ......................................... 72 
Figure 34: Affinity study of VCA Nbs.  ................................................................................. 73 
Figure 35: VCA Nb effect on actin or Arp2/3 binding to N-WASp using a nanobody 
concentration range.  ................................................................................... 74 
Figure 36: N-WASp colocalizes with invadopodia markers.  .............................................. 75 
Figure 37: Expression of VCA Nbs in cancer cells reduces invadopodia number.  ............. 76 
Figure 38: Effects of VCA intrabodies on matrix degradation.  .......................................... 78 
Figure 39: Effects of VCA Nbs on MMP9 secretion and activity levels.  ............................ 79 
Figure 40: Effects of VCA Nbs on MT1-MMP positioning.  ................................................. 79 
Figure 41: Schematic visualization of labelling strategies in this study.  ........................... 93 
Figure 42: Optimization of the labelling of cortactin nanobody 2 - sortag.  ...................... 94 
Figure 43: CuAAC reaction time course after incorporation of a para-azido 
phenylalanine (pAzF).  .................................................................................. 95 
Figure 44: Purifying Alexa Fluor 488-labeled nanobody.  .................................................. 96 
Figure 45: Comparison of cortactin staining in HNSCC61 cells.  ........................................ 98 
Figure 46: Dual staining using a nanobody and a commercial antibody to visualise 
cortactin and β-catenin in 4% PFA fixed HNSCC61 cells, seeded on 
collagen coating.  ......................................................................................... 99 
Figure 47: β-catenin visualization using β-catenin Nb86-AF488 and the commercial 
antibody (a rabbit monoclonal anti-β-catenin antibody (ab32572)). ....... 100 
Figure 48: Cortactin Nb2 photoporation in HNSCC61 cells.  ............................................ 101 
Figure 49: VCA Nbs binding on VCA domain of N-WASp.  ................................................ 117 
Figure 50: GFP nanobodies enable the selective labelling of newly-exocytosed 
vesicle proteins.  ........................................................................................ 126 
Figure 51: Comparison of PFA and glyoxal fixation of a cortactin Nb2-AF488 staining 
in HNSCC61. ............................................................................................... 133 
  XV 
Summary 
Metastasis is a known lethal factor for cancer patients which is still not evident to 
prevent. It is one of the hallmarks of cancer. Metastasis is the process in which cancer 
cells escape from the primary tumor to disseminate through the body and to create a 
secondary tumor. To succeed in the spreading, such cancer cells hijack the normal 
cellular functions to become motile and invasive. Those invasive properties are a result 
of the actin cytoskeleton changes. Invasive cancer cells use specialised actin based 
membrane structures, called invadopodia, to facilitate their escape from a primary 
tumor leading to the dissemination. To study these invadopodia, the nanobody 
technology is utilised. Nanobodies are the smallest antigen binding fragment derived 
from the variable part of Camelidae heavy chain antibodies. Because of the high 
specificity and selectivity of nanobodies, it is possible to target specific invadopodium 
proteins which aid the study of the structure and the regulation of invadopodia as well as 
the contribution to invasion in the metastatic pathway. 
The aim of this study is to reveal the function of neural Wiskott-Aldrich syndrome 
protein, N-WASp, in the invadopodium pathway by using nanobodies. N-WASp is one of 
the key players in the metastatic pathway through invadopodia due to its role in the 
actin polymerisation. The second goal of the study is to create a tool that enables a more 
accurate imaging compared to the existing methods by using the nanobody technology. 
In the first part, nanobodies were generated to target the C-terminal domain of N-WASp, 
the VCA domain. Through its VCA domain, N-WASp is able to bind directly to actin 
monomers and Arp2/3 (actin related protein 2/3). Together they form a complex which 
is the precursor for a fast actin polymerisation. This is required to start the formation of 
an invadopodium. Following immunisation, a series of possible nanobodies were 
generated and had to be characterised first. After the characterisation and the 
measurement of the binding capacities, the nanobodies were implemented to analyse 
the role of N-WASp in the invadopodium pathway. The VCA nanobodies were able to 
 XVI 
create inhibiting effects by reducing the number of invadopodia. However, they exert 
only small influence on the extracellular matrix degradation. Those results lead to the 
hypothesis that N-WASp found its main purpose in the invadopodium formation. Due to 
less invadopodia, the ECM degradation is slightly decreased as well. 
In the second part, the nanobody technology is expanded to create a better imaging tool. 
Since the nanobodies are smaller compared to conventional antibodies, they enable a 
reduction in distance between the target and a dye (also known as linkage error). This 
results in higher resolution properties compared to the existing methods (e.g. 
conventional immunostaining, fusion proteins …). In this part, two ways are presented to 
attach a dye to a recombinant nanobody: by using the sortase A enzyme or by 
incorporating para-azido phenylalanine, an unnatural amino acid. The inclusion of an 
alkyne or azido group, allowed performing Cu(I)-catalyzed Azide-Alkyne Click Chemistry 
(CuAAC) to attach a fluorophore on the nanobody. When such fluorescent nanobodies 
were obtained, they were used for immunocytochemistry to visualise their target. 
However, the nanobodies face the same obstacles as antibodies. Due to fixation, the 
immunoreactivity of proteins can be altered. Further, those fluorescent nanobodies need 
fixed cells since they are not able to breach through the membrane of living cells. 
However, photoporation enables the delivery of fluorescent nanobodies into living cells. 
The combination of fluorescent nanobodies with photoporation creates a new 
instrumental strategy which allows a new and more precise way of doing research. 
Besides, due to the smaller linkage error, the labelled nanobodies are an interesting tool 
for super resolution microscopy to image invadopodia and other small structures more 
precisely. 
Altogether, this study used the nanobody technology to analyse the role of N-WASp in 
the invadopodium pathway and to create a tool that allows better imaging of certain 
cellular structures.  
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Samenvatting 
Van metastase of uitzaaiing is het geweten dat het een lethale factor is voor vele 
kankerpatiënten en dat het nog steeds moeilijk is om dit te voorkomen. Het is dan ook 
één van de gevreesde kenmerken van kanker. Metastase is het proces waarbij 
kankercellen ontsnappen uit de primaire tumor om zich te verspreiden doorheen het 
lichaam en zo een secundaire tumor te vormen. Echter, om in deze uitzaaiing te slagen, 
misbruiken dergelijke kankercellen de normale functies van de cel om beweeglijk en 
invasief te worden. Die invasieve eigenschappen zijn o.a. een resultaat van 
veranderingen in het actine cytoskelet. De invasieve kankercellen gebruiken namelijk 
actine gebaseerde membraan structuren, ook wel invadopodia genoemd, om net hun 
vrijkomen van de primaire tumor en hun verspreiding mogelijk te maken. In deze studie 
wordt er gebruik gemaakt van nanobodies om deze invadopodia te bestuderen. 
Nanobodies zijn het kleinste antigen herkennende domein dat afkomstig is van het 
variabele domein van zware keten antilichamen, die terug gevonden worden in 
kameelachtigen. Door de hoge specificiteit en selectiviteit van nanobodies, is het 
mogelijk om specifieke invadopodium eiwitten te visualiseren en op die manier zowel de 
structuur als de regulatie van een invadopodium te gaan bestuderen, als ook de invloed 
van dergelijke eiwitten op metastasering.  
Het doel van deze studie is om de functie van het neurale Wiskott-Aldrich syndroom 
eiwit (N-WASp) in de invadopodium pathway te achterhalen door gebruik te maken van 
nanobodies. N-WASp is één van de hoofdrolspelers tijdens de invadopodium 
gerelateerde metastase door zijn rol in de actine polymerisatie. In het tweede deel is het 
doel vooral het creëren van een tool die het mogelijk maakt om accuratere 
beeldvorming te verkrijgen in vergelijking met de reeds bestaande methoden. Hierbij ligt 
de nanobody technologie ook aan de basis. 
In het eerste deel worden er nanobodies opgewekt tegen het C-terminale domein van N-
WASp, het VCA domein. Via dit domein kan N-WASp een directe interactie aangaan met 
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actine monomeren en met Arp2/3 (een actine gerelateerd eiwit 2/3). Tezamen vormen 
ze een complex wat uiteindelijk de precursor voor een snelle actine polymerisatie wordt. 
Dit is een vereiste om de invadopodium vorming van start te laten gaan. Door de 
immunisatie, ontstaan er een groot aantal nanobodies die eerst gekarakteriseerd 
moeten worden. Na deze karakterisatie en na het bepalen van de bindingscapaciteiten, 
worden de nanobodies gebruikt om de rol van N-WASp te analyseren in de 
invadopodium pathway. De resultaten tonen aan dat de VCA nanobodies in staat zijn om 
het aantal invadopodia te verminderen en een kleine invloed uit te oefenen op de 
extracellulaire matrix degradatie. Deze resultaten leidden tot de hypothese dat de rol 
van N-WASp hoofdzakelijk terug te vinden is tijdens de vorming van een invadopodium. 
De kleine, niet significante verlaging van de degradatie wordt dan verklaard doordat er 
minder invadopodia zijn en dus ook minder ECM degradatie.  
In het tweede deel wordt de nanobody technologie uitgebreid om een betere 
beeldvormingstool te verkrijgen. Doordat nanobodies kleiner zijn in vergelijking met 
conventionele antilichamen, bezitten ze het voordeel dat de afstand tussen het target 
eiwit en de fluorescente molecule kleiner is. Deze afstand wordt ook wel de ‘linkage 
error’ genoemd. Hierdoor kan er een hogere resolutie verkregen worden dan de reeds 
bestaande methoden (zoals een conventionele immunokleuring, fusie eiwitten …). In dit 
deel worden er twee methoden voorgesteld om een fluorescente molecule te koppelen 
aan een recombinant nanobody: enerzijds door gebruik te maken van het enzym sortase 
A en anderzijds door de inbouw van een para-azido phenylalanine, een onnatuurlijk 
aminozuur. Dit heeft als gevolg dat er een alkyne of azido groep aanwezig is die het 
toelaat om Cu(I)-gekatalyseerde Azide-Alkyne Click Chemie (CuAAC) uit te voeren en op 
die manier een fluorofoor op het nanobody te plaatsen. Eenmaal een dergelijk 
fluorescent nanobody verkregen is, kan dit gebruikt worden in immunocytochemie om 
de target te visualiseren. De nanobodies ondervinden echter dezelfde problemen als 
antilichamen. Door het fixeren is het mogelijk dat de immunoreactiviteit van eiwitten 
gewijzigd wordt. Aangezien (fluorescente) nanobodies niet doorheen het membraan van 
levende cellen geraken, is de fixatie nog steeds nodig. Alhoewel, fotoporatie maakt het 
mogelijk om fluorescente nanobodies binnen te brengen in levende cellen. Door de 
combinatie van fluorescente nanobodies met de fotoporatie techniek, wordt er dan ook 
een nieuwe strategie gecreëerd die het toelaat om onderzoek te doen op een nieuwe en 
preciezere manier in levende cellen. Daarnaast kunnen de fluorescent gemerkte 
nanobodies als een belangrijke tool gezien worden voor super resolutie microscopie net 
doordat ze een kleine ‘linkage error’ hebben. Hierdoor kunnen kleine structuren, zoals 
een invadopodium, met meer precisie in beeld gebracht worden.  
  XIX 
Algemeen kan besloten worden dat de nanobody technologie in deze studie gebruikt is 
om enerzijds de rol van N-WASp in de invadopodium vorming te analyseren en 
anderzijds om een tool te creëren dat een betere beeldvorming van bepaalde cellulaire 
structuren toelaat. 
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  Chapter 1
A nanobody or VHH 
 The discovery of heavy chain antibodies 1.1
The human body makes antibodies to defend itself against infections and harmful 
diseases. These IgG antibodies are 150 kDa in size1, 12-15 nm in dimensions and consist 
of two light and two heavy chains. The heavy chain is composed of three constant (CH1, 
CH2 and CH3) and one variable domain (VH), while the light chain only consists of one 
constant (CL) and one variable domain (VL). Due to the high specificity and affinity 
between an antibody and its target2 and due to the enormous diversity of the antigen 
binding domains2, scientists have been searching for (recombinant) antibody formats 
that are as small as possible and which have applications as therapeutics, research tools 
or diagnostics. Such formats can be seen as next-generation antibody fragments (Figure 
1A)3. The first antibody fragment consisted of four immunoglobulin domains (CH1, VH, 
CL and VL) and is called a ‘fragment antigen-binding’ or Fab (55 kDa)3, 4. Some difficulties 
were found when a Fab fragment is expressed recombinantly. Because two different 
polypeptides are required to associate and have to be linked through a disulfide bond, 
the assembly and folding of Fab fragments became a challenge5, 6. Besides, the light 
chains are likely to form undesired homo-dimers, making the challenge even bigger5, 6. 
Once formed properly, Fabs possess high stability over time5.  
Due to these obstructions, the search was going on to find and to engineer antibody 
fragments which were able to be expressed as a single polypeptide7. A single-chain 
variable fragment (scFv) (25-28 kDa) consists only of the variable domains of an antibody 
(VH and VL) which are linked using a synthetic linker peptide ((Gly)n or [(Gly)n-Ser]p) 
(Figure 1A)3, 4, 6-8. Next to a linker peptide, a disulfide bond can be used as well9. This 
fragment yielded better expression levels in microorganisms4, 10 and could be used for in 
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vivo experiments7, 11. However, the intracellular, cytoplasmic expression of scFvs 
remained challenging as scFvs are unstable over a period of time and some scFvs showed 
a reduced affinity compared to the Fab fragments5, 6, 8. This is because the orientation of 
the paratope is only mediated by hydrophobic interactions of the VH with VL, while Fab 
also has the stability of the disulfide bridge between CH1 and CL6, 8. Both Fab and scFv 
enhance pharmacokinetics for tissue penetration4, but can often suffer from loss of 
antigen binding12. So, the urge to find better antibody fragments was still existing. In the 
late 1980s, a fragment existing of only a variable domain (VH or VL) was generated and 
called a single domain antibody (dAb) (Figure 1A)13. Such a single immunoglobulin 
domain has four framework regions (FWR) and three complementarity determining 
regions (CDRs) (Figure 1B). Because in conventional antibodies the antigen recognition 
site needs six CDRs (three CDRs from the VH and three CDRs from the VL), an dAb could 
be faced with a big ‘recognition problem’ due to the split of the original paratope into 
two4, 14.  
 
Figure 1: Antibody and antibody fragments. (A) Starting from the conventional antibody, different antibody fragments 
were made such as fragment antigen-binding (Fab), single-chain variable fragment (scFv) and the variable domain (VH or 
VL) or single domain antibodies (dAbs). (B) A dAb consists of four frame work regions (FWR) and three complementarity-
determining regions (CDRs). 
A breakthrough in the search is to be situated in the early 1990s. Hamers-Casterman and 
co-workers discovered a different kind of antibodies15, 16. Compared to conventional 
antibodies (150 kDa) (Figure 2A), this new type of antibody was only 90 kDa in size and 
was called heavy chain antibody (HCAb) (Figure 2B)17. HCAbs lack the light chains and are 
composed of a CH3, a CH2 and a variable domain (VHH)17, 18. Those HCAbs are found in 
animals from the Camelidae family such as dromedaries (Camelus dromedaries), camels 
(Camelus bactrianus), llamas (Lama glama) and alpacas (Vicugna pacos)17, 19. A few years 
later in 1995, another variant of the HCAbs was found in cartilaginous fishes 
(Chondrichthyes) such as nurse sharks (Ginglymostoma cirratum), wobbegong sharks 
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(Orectolobus maculates) and dogfish sharks (Squalus acanthias and Mustelus canis)20, 21. 
This variant is called immunoglobulin new antigen receptor or IgNAR and is composed of 
five constant domains and one variable domain (Figure 2D)18, 21. The fact that HCAbs are 
produced by the immune system, is due to a defective splicing site which causes the 
elimination of the CH1 region resulting in the lack of interaction site for the light chain17, 
22. Based on similar interests, the HCAbs were used as a starting point to make antibody 
fragments leading to the VHH or nanobody (Figure 2C). 
 
Figure 2: Heavy chain antibodies. Next to the conventional antibodies (A), Camelidae have a second pool of antibodies. 
Those are lacking the light chain and are called heavy chain antibodies (HCAbs) (B). This discovery resulted in the VHH or 
the nanobody (C), the counterpart of the VH. Next to Camelidae, a variant of the HCAbs is found in some shark species and 
those are called immunoglobulin new antigen receptor or IgNAR (D). 
 Nanobodies  1.2
1.2.1 VH versus VHH 
Structurally, both VH (Figure 3A) and VHH (Figure 3B) are composed of nine β strands 
which are organised in a four-stranded and a five-stranded β sheet17, 19. A VH and a VHH 
are similar in size and both have four FWRs and three CDRs (Figure 1B). However, some 
important differences lead to the preference for VHHs for downstream applications. For 
a VH the distinction between a CDR and a FWR is obvious, but when looking at VHHs the 
difference is far less clear22, 23. It has been suggested that some amino acids in the FWR 
for many nanobodies take part in the binding and hence, co-determine the affinity for 
the antigen22, 23. Besides, there are two main differences between a VH and VHH of 
which the first is found in the frame work region 2 (FWR2). Highly conserved amino acids 
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in the VH are needed to interact with the VL to have a proper orientation of the 
paratope8, 19. Those amino acids are typically hydrophobic (Val42, Gly49, Leu50, Trp52) 
and they may cause undesired aggregation, accounting for their ‘sticky’ properties17, 19, 24, 
25. In case of VHHs, those hydrophobic amino acids are replaced by more hydrophilic 
amino acids (mostly Phe42, Glu49, Arg50, Gly52), making the VHHs more soluble6, 17-19, 25. 
The second difference is found in the length of the CDR1 and CDR3, which is larger in 
case of VHH compared to VH17, 19, 22. The advantage of the extended loops gives a 
nanobody better antigen binding affinities then the VH or VL17, 19, 22. While the CDRs of 
the VH and VL contribute similarly to antibody specificity, the CDR3 in VHHs contributes 
for the most part of the antigen recognition (at least 60-80% of the antigen binding)1, 8, 23. 
This explains why the length of a CDR3 loop in VHHs varies broadly in length (3 – 28 
amino acids) compared to a human VH (8 – 15 amino acids)8, 26. Notably, the CDR3 loop is 
on average shorter in llama than in dromedary17, 27. Furthermore, the extended CDR3 
gives the advantage of binding cryptic epitopes and antigen cavities which are 
unreachable to conventional antibodies15, 17-19, 22. For nanobodies with a long CDR3, the 
CDR3 works as a finger-like structure that is able to reach cavities, such as active sites of 
enzymes8, 18, 28. For nanobodies with a less longer CDR3, the shape of the nanobody 
creates a convex paratope that is able to interact more into concave epitopes15, 18, 22, 28. In 
some cases the long CDR3 is stabilised by an additional disulfide bond between the CDR3 
loop and the CDR1 loop (common in camel and dromedary VHHs) or between CDR3 and 
CDR2 (which is common in llama VHHs)6, 17, 19, 22, 24, 26, 29. This extra disulfide bond favours 
the stability of a VHH in harsh conditions29 and creates higher affinity due to the reduced 
flexibility of the CDR317, 19, 22, 30.  
 
 
 
Figure 3: Structure of VH (A) and VHH (B). Those single domains have four framework regions alternated with three 
complement determine regions (CDR). Both, VH and VHH, are structural build-up of nine β strands, divided in two β sheets 
(a four-stranded and a five-stranded β sheet). Figure is adapted from Wang et al.
19
. 
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1.2.2 Advantages and disadvantages of nanobodies 
Because a nanobody or VHH consists of only one immunoglobulin domain, it makes a 
nanobody the smallest natural antigen binding fragment that retains its binding 
properties and affinity17, 28. The complete antigen binding capacity depends on only three 
CDRs, while a conventional antibody needs six CDRs15, 22. Nanobodies are known to have 
high specificity and high affinities in the nanomolar range, and even picomolar range1, 15, 
17, 31. Because of the properties of this monomeric domain, nanobodies are more stable 
than its counterpart found in conventional antibodies1, 17, 28. Due to the more hydrophilic 
amino acids (compared to the VH), a nanobody is more soluble in aqueous solutions 
than a VH fragment28. Nanobodies possess high conformational stability and are able to 
unfold and refold again without the feared aggregation problems that are found for most 
proteins18, 32. Next to the conformational stability, nanobodies have high thermal 
stability and survive harsh conditions32, 33. They preserve their binding capacities after 
incubation at elevated temperatures and in different pH conditions25, 33-35. This opens 
possibilities as it signifies that nanobodies are still functional in the gut, and they are able 
to resist the acidic environment of the stomach17, 34. Anti-rotavirus Nbs for instance were 
able to reduce the morbidity of rotavirus-induced diarrhea in mice after oral 
administration34. The nanobody stability in high pH or in detergent containing 
environments are also useful: e.g. nanobodies against the Malassezia furfur cell surface 
protein (Malf1) have been used in shampoo to inhibit the growth of M. furfur which 
causes dandruff35. Because of the large sequence similarity and structural homology with 
the human VH gene family, nanobodies have low toxicity and low immunogenity1, 17, 31. 
As the nanobody lacks the Fc domain which is needed to activate the Fc-receptors on 
natural killer cells and macrophages, nanobodies on itself cannot induce antibody-
dependent cell-mediated cytotoxicity (ADCC)8, 29. 
Nanobodies are easy to modulate and to produce in prokaryotic and eukaryotic cells1, 30. 
As mentioned above, nanobodies are able to target challenging epitopes. They are able 
to bind cryptic epitopes, unreachable for four-chain antibodies, which is a result of the 
extended CDR315, 17-19, 22, 28, 36. Next to cryptic antigens, nanobodies have a broader range 
of antigens than antibodies. While the large size of antibodies can sometimes be an 
obstacle for certain epitopes, nanobodies have the advantage of targeting smaller 
biomolecules such as epitopes found on pathogenic agents like toxins, viruses, bacteria, 
or parasites15, 17, 36. This gets special attention for therapeutic purposes17. Nanobodies are 
also able to target flat surfaces in macromolecules18 or small linear peptides19, 37, 38, but 
they prefer binding to clefts39. The size of a nanobody is 2.5 nm in diameter and 4 nm in 
height4, 19, 28. However, this has both advantages and disadvantages. When a nanobody is 
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used to coat substrates e.g. to perform ELISA, the paratopes of the nanobodies are very 
close to the surface, which can obstruct the interaction with the antigen19. This problem 
can easily be undone by adding tags at the C-terminus19.  
The interstitial fluid pressure (IFP) in tumors is elevated compared to the surrounding 
tissues, meaning the transport of large molecules is hindered40. This makes tumor 
penetration difficult for larger proteins such as antibodies. The small size of nanobodies 
has the advantage to overcome this problem. As observed previously, nanobodies show 
a good tumor penetration and a more homogenous distribution through the tumor19, 40. 
If the nanobodies are used in vivo, a fast renal clearing is observed1, 17, 19. This fact can be 
an advantage and disadvantage simultaneously. Because of their small size, a rapid 
extravasation and diffusion into tissues is observed18, 19, 28. As such, the nanobodies give a 
fast renal clearing which is required for a good in vivo imaging agent17. This means that 
nanobodies are able to give high contrast images as early as 1h post-injection in case of 
positron emission tomography (PET) or single-photon emission computed tomography 
(SPECT)17-19. Another advantage is low radiation exposure for the patient, when using 
radionuclides17, 18. A major hurdle however is the accumulation of the radiolabelled 
nanobodies in the proximal tubuli of the kidney18, 19. If a more therapeutic setting is 
desired, a fast renal clearing would be a disadvantage. If a nanobody is coupled to a drug, 
the fast renal clearing could cause renal toxicity40. The easiness of modulating 
nanobodies makes it possible to conjugate a nanobody to another biomolecule, e.g. 
another nanobody, albumin, polyethylene glycol, sugar moieties … 1, 28, 40. This 
conjugation increases the size and enlarges the circulation time of the nanobody1, 28. For 
example, CONAN1, a biparatopic anti-EGFR nanobody, against the epidermal growth 
factor (EGF) receptor (EGFR), when fused to an anti-albumin Nb, increased the 
circulation time from 1-2h to 2-3 days8, 41. Besides the good in vivo tissue penetration, 
nanobodies rarely penetrate the blood-brain-barrier39. 
Probably the biggest disadvantage of nanobodies, as for many other proteins, is the 
problem that they are not able to pass through the (cell) membrane30, 39. This is caused 
by the anionicity and hydrophobicity of the membrane itself42 and explains why studies 
using nanobodies against intracellular targets are routinely performed by transduction or 
transfection28, 43-48. Since antibodies suffer from assembly and folding issues due to the 
reducing environment of the cytoplasm, nanobodies are preferred for intracellular 
targeting6. High glutathione concentrations tend to disrupt the disulfide bonds between 
antibody chains in the cytosol6. If recombinant protein delivery is desired, researchers 
are faced with a challenge. Protein delivery is a problem not only for nanobodies10, 49. 
Many ways have already been investigated, such as electroporation50-52, microinjection53-
55, cell squeezing56, 57 and virus-like particles (delivery of proteins as Gag-fusion protein or 
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on the surface of virus-like particles)58. These are only possible when a small number of 
cells need to be subjected to protein delivery or when the required recipient or device is 
used (e.g. in case of the electroporation). If recombinant nanobodies are used in vivo 
(without any adaptations), they are only able to target extracellular epitopes. Different 
options have already been tried to target the nanobody to the cytoplasm, i.e. by coupling 
cell-penetrating peptides to nanobodies (cyclic arginine-rich peptides59 or penetratin60, 
61), by polycationic resurfacing of a nanobody (done by changing amino acids in the 
frame work region to arginine or lysine)62, 63, by making use of already existing 
internalization proteins on the target cell (e.g. by making use of the folate receptor 
specific uptake process64 or by inducing receptor dimerization using a bivalent 
nanobody39), by transportation of the nanobodies in mesoporous silica nanoparticles65 or 
by using the Escherichia coli (E. coli) type III secretion system39, 66.  
A more recent and more physical procedure is photoporation (Figure 4). This is shown by 
Liu et al.67, 68. In those experiments the nanobody is introduced into a living cell through 
laser light and nanoparticles such as gold nanoparticles (AuNP) or graphene quantum 
dots (GQD)67, 68. The laser light causes thermal energy transfer to the nanoparticle 
making it extremely hot67, 69. Depending on the laser intensity, two options are possible 
of which both result in pore formation of the cell membrane70, 71. This pore formation is a 
reversible process in which cells reseal those pores in a time range of seconds to a few 
minutes depending on the size of the pore69, 70, 72. In case of low intensity laser pulses, 
the pores are formed due to the increase of the temperature70, 71. At the heated 
nanoparticle, the local temperature can rise up to 100 °C70, 71. This causes a local phase 
transition in the lipid bilayer or a thermal denaturation of integral glycoproteins resulting 
in the pore formation70, 71. However, when higher laser energy is used, the heated 
nanoparticle leads to the evaporation of the surrounding water which result in the 
formation of a vapor nanobubble69, 70. Due to this, the mechanical force of this expanding 
and imploding vapour nanobubble perforate the cell membranes locally allowing a free 
diffusion of an external protein into the cell67, 70, 71. A disadvantage of the first options is 
that the local heat increase will diffuse throughout the cell and its environment. This can 
create hyperthermia-induced cell stress and a decreased cell viability70, 71. However, in 
case of the vapour nanobubbles there is no toxicity increase or no decrease in cell 
viability69, 70. This is because the diffusion of heat from the nanoparticles into the 
environment is negligible69, 70. This is the result of the extremely short (<1 μs) lifetime of 
a vapour nanobubble and of the conversion of almost all the energy of the irradiated 
nanoparticles to mechanical energy70. Additionally, Xiong and co-workers showed that 
the vapor nanobubble option was more efficient due to the larger pore size that is 
created compared to direct heating70. Both, AuNP and GQD, can create such pores after 
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irradiation with laser light67. However, while AuNPs are fragmenting after one laser 
pulse, the GQD are more resistant and are able to form repeated vapor nanobubbles67. 
While photoporation is not a commonly used technique, it is functional with different 
agents already such as phalloidin67, 73, siRNA74 and dextran67, 70, 74. It has shown to 
combine a good cell viability with high delivery efficiencies67, 70, 73, 74. Photoporation 
allows high throughput experiments since it is a fast technique and can be used in 
different cell culture substrates and devices67, 68. This technique is not only applicable on 
cultured cell lines, it is also useful for primary cells such as T-cells71, 74. 
 
 
Figure 4: Schematic representation of the photoporation technique. Due to laser light, the gold nanoparticles or graphene 
quantum dots heighten in temperature creating a vapour nanobubble. This makes reversible pores in the cell membrane 
allowing other proteins to enter the cell.  
 
Other options are possible as well; Teng and co-workers have used streptolysin O, a 
bacterial toxin, to create pores into the cell membrane which allows the uptake of 
labelled nanobodies75. Another strategy was used by Leduc and co-workers76. They used 
a GFP nanobody which was coated on gold nanoparticles76. This negatively charged GFP 
Nb - Au nanoparticle complex allows electroporation of the nanobodies into living cells 
and detection by photothermal imaging76. By implementing this, they were able to 
visualise GFP fusion proteins (e.g. GFP-kinesin fusion protein) in living and fixed cells76. 
Additionally, Ressler et al.42 have shown another strategy in which it was possible to 
internalize a ribonuclease 1 into the cytosol of living cells (Figure 5). The esterification of 
the carboxyl groups of the protein (Glu and Asp) with 2-diazo-2-(p-methylphenyl)-N,N-
dimethylacetamide allows the passage through the membrane. Once inside the cell, the 
esterases of the cell will reverse the process42. This means that once intracellular the 
internalized protein is unchanged and is able to carry out its activity as before42. 
However, before having an ideal method for all nanobodies, the search of protein 
delivery still continues. 
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Figure 5: Protein delivery by esterification. The Glu and Asp will be coupled to 2-diazo-2-(p-methylphenyl)-N,N-
dimethylacetamide in order to establish the esterification. This allows internalisation. Once inside the cell, cytosolic 
esterases undo the protein modification and restore the original state of the delivered protein. This figure is adapted from 
Ressler et al.
42
. 
1.2.3 Nanobody generation 
To obtain immunoglobulin derivates such as nanobodies, animals are required to 
perform an immunisation to obtain nanobodies. By immunizing the animal with an 
antigen, the B-cells of the immune system will produce specific antibodies against the 
target. Afterwards, the peripheral blood lymphocytes are isolated from the immunized 
animal and the total RNA will be extracted (Figure 6)4, 15, 19, 39. Next, cDNA is synthesised 
via reverse transcriptase of those collected RNA. Because the nanobodies belong to the 
same gene family, they have homologous border sequences which makes it possible to 
use the cDNA for amplifying specifically only the VHH sequences4. For this, some 
methods with small differences are possible. Pardon and co-workers use two sets of 
primers77. The first set amplify the fragment between a conserved region of the CH2 for 
all IgG isotypes of Camelidae and a well-conserved region of the signal sequence of the 
most abundant V element family in camelids77. After the first polymerase chain reaction 
(PCR), they perform a second nested PCR by using primers at the beginning and end of 
the nanobody77. This method has been shown to be successful for dromedaries, camels, 
llamas and alpacas77. Van der Linden and co-workers used a different set of primers78. 
They amplify the fragment from the N-terminal nanobody sequence to the hinge region 
of each HCAb IgG isotype of all camelid species78. Other options exist as well, but those 
are in most case not applicable for all Camelidae79, 80. 
Once the nanobody cDNA is obtained, this product has to be transferred and cloned into 
a selected plasmid leading to a nanobody library4, 15, 19. Next, the screening can start4. A 
common way is the phage display which is based on the expression of a nanobody fused 
with coat proteins on the phage surface31, 77, 81. For this the used vector is a phage display 
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vector or phagemid, so the selection is performed by panning which allows a selection 
for binders with high affinity and for nanobodies that are expressed well in bacteria4. The 
nanobody is fused in this case with phage coat protein pIII which will bring the nanobody 
at the tip of phage particles39, 81. This is needed for a successful round of panning39. In 
such a round of panning, those phages are added to the coated and immobilised antigen 
followed washing steps in order to remove the unbound phages31. After a few rounds of 
panning, the best binders will remain and become more and more enriched15, 31, 39. The 
immunisation and panning together takes approximately 3 months starting from the first 
injection until the first experiments of the nanobodies15, 31.  
 
Figure 6: Generation and isolation of nanobodies through phage panning. After the immunisation in an animal of the 
Camelidae family, the mRNA is extracted from the lymphocytes. This is converted to cDNA and eventually cloned into a 
vector (here: phagemid) to obtain a nanobody library. The screening is performed via phage display. A nanobody is fused to 
a phage coat protein which allows a selection of binders through a few rounds of panning. In a round of panning, the 
phages are incubated with the immobilised target. The unbound phages are washed away, which leaves only the fraction of 
phages that contain a target-binding nanobody. The latter fraction is eluted and amplified in E. coli which allows another 
round or panning. The figure is adapted and modified from Revets et al.
4
, Desmyter et al.
15
 and Liu et al.
31
. 
However, an immunisation is not always required anymore to obtain nanobodies. 
Sometimes an immunisation is even not possible (in case of toxins4, 31, non-immunogenic 
compounds31, 39, lack of purified proper folded antigens39, bloodstream stability31 …) or 
unwanted, but alternatives are already available. Nanobodies can be obtained from a 
naïve library15, 31. This is a nanobody library starting from blood of non-immunized 
animals15. Once such a library is obtained, it can be used for different targets. This way of 
obtaining nanobodies reduces the time to approximately three weeks15. The only 
problem is found in the lack of somatic hypermutation which increases the chance on 
finding low affinity binders, meaning a large diversity library is needed to find high 
affinity nanobodies15, 19, 31. This requires a substantial amount of blood samples from 
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different individual animals and/or species31. Besides, synthetic or semi-synthetic 
libraries can offer a solution19. As somatic hypermutation is found in nature to obtain 
better affinities, synthetic or semi-synthetic libraries mimic this process to have more 
diversification31. This kind of library is based on engineering an existing library19, 31. While 
the conserved FWRs of a nanobody are kept unchanged, the CDRs are randomly changed 
and especially the CDR319, 31. This can be achieved using different approaches, e.g. by 
introducing length and sequence variations using randomized CDR3 primers19, 82, spiked 
mutagenesis combined with ribosome display17 or error-prone PCR17. This can even lead 
to a library with more variation than found after immunisation19.  
1.2.4 Nanobody interference with protein functions 
Nanobodies bind their target in a non-covalent way. When a nanobody is present, the 
targeted protein or the protein of interest and its interaction partners are likely to be 
disturbed. While both, the nanobody and the interaction partner are competing for the 
same epitope on the protein of interest, the nanobody is most likely going to win the 
battle since nanobodies are known to be high affinity binders. When the nanobody 
occupies a domain of the protein, it will mask or block that domain resulting in a 
disturbance of its functions2, 83. This is a big difference compared to RNAi, nanobodies 
can target and interfere with only the targeted part of the protein of interest, while RNAi 
targets the full-length protein6, 84. Koromyslova and co-workers developed a nanobody 
that targets the capsid protein of noroviruses85. Upon binding, the nanobody targeted an 
epitope that triggered the disassembly of the virus particle85. Rudolph et al. generated a 
nanobody that was able to neutralize the ricin toxin, a ribosome inactivating protein, 
upon binding to its enzymatic subunit86. 
If it is necessary to target the full-length protein, the nanobodies can be used to 
selectively bind proteins and induce protein degradation19, 30. This results in a functional 
knock-out of the protein that is targeted by the nanobodies19, 30. In the next section, this 
will be explained in more detail (1.3.1 Research purposes). However, similar outcomes 
can be obtained by genetically adding a localisation tag to the nanobody2. This results in 
redirecting the antigen to a new cellular compartment which is different from its normal 
site of action2. It is interesting to relocalise the protein of interest knowing that the 
molecular control is missing or that the endogenous modification (e.g. phosphorylation) 
at the redirected location is no longer achievable83. This can disturb its usual interaction, 
function and pathway83. 
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Next to disturbing the proteins, nanobodies can lock the protein of interest in an 
(in)active conformation. Based on this phenomenon, the company Confo Therapeutics 
used intracellular nanobodies to stabilise a G protein-coupled receptor (GPCR) in a 
conformation at which they want to screen for a small molecular drug that can be active 
extracellularly87.  
 Nanobody applications 1.3
1.3.1 Research purposes 
Due to the properties of nanobodies, they have a broad capability to be used in many 
applications such as a research tool in basic research. Because of their high specificity 
and affinity, they can operate as an alternative to conventional antibodies. They can 
replace antibodies in protocols such as ELISA experiments88-90, pull-down assays, 
immunoprecipitations91, 92, affinity purifications93, immunocytochemistry94, 95, flow 
cytometry95, 96 … . For example, Pollithy and colleagues have made a fusion protein of an 
RFP nanobody and the magnetosome protein MamC92. By expressing this construct in 
the magnetite-synthesizing bacterium Magnetospirillum gryphiswaldense, the nanobody 
will be found on the surface of magnetic nanoparticles (magnetosomes), from bacterial 
origin92. By using this in immunoprecipitations, nanobodies facilitate pull down of their 
targets92. BAC BV/Life Technologies has commercialised an anti-CaptureSelect C-tag VHH 
and a CaptureSelect C-tag, a tag of only four amino acids (EPEA or Glu – Pro – Glu – Ala)3. 
This combination leads to an efficient protein purification3. Nanobodies can be used in 
flow cytometry as has been shown by de Bruin et al.97. By staining a Vδ2-T-cell receptor 
specific nanobody for flow cytometry, the mean fluorescence intensity appears to be 
higher compared to the staining with a commercial anti-Vδ2 monoclonal antibody97. 
Sheng et al. made a nanobody-HRP (horseradish peroxidase) fusion protein for an ELISA 
assay to detect Newcastle disease viruses90.  
As mentioned above, nanobodies can be modified easily which increases the possibilities 
for nanobody applications. Nanobodies can be used as fusion protein. They can be fused 
to alkaline phosphatase to reduce the number of steps of the protocol and to made 
sensitivity improvements in immunoassays98, to fluorescent proteins (like green 
fluorescent protein (GFP)) for tracking the antigen inside cells99, to make antibody-drug 
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conjugates36, to albumin for prolonged circulation time in the body17, 40, to HRP as 
detection tool90, 100 … . 
Recently, different techniques to obtain functional knock-outs using nanobodies have 
been developed as alternative to conventional methods. Current methods without 
genomic modification (such as RNA interference (RNAi) and Morpholino antisense 
oligonucleotides (ASOs)) are able to reduce proteins expression levels. However, they 
suffer from off-target effects, are inefficient for depleting of long-lived proteins and 
require long treatments before having an outcome84. Persengiev and co-workers showed 
that one siRNA molecule can alter over a 1000 genes of diverse cellular functions101. 
Besides, RNAi does not obtain a 100% knock-out in most cases. To obtain gene knock-
outs, methods like clustered regularly interspaced short palindromic repeat DNA 
sequences (CRISPR) / CRISPR-associated gene (Cas9) are used. Nevertheless, it is 
irreversible, not possible for proteins which are essential for cell survival and it causes 
off-target effects. Because those methods still have some disadvantages, the search 
continues for new alternative techniques to create specific protein degradation19, 30. 
Targeting proteins directly for degradation can lead to faster outcomes compared to e.g. 
RNAi. Through making adaptations to the Cullin-RING (really interesting new gene) E3 
ubiquitin ligase (CRL) complex, different strategies are already being developed to 
directly degrade proteins (Figure 7)30. Caussinus et al. developed the deGradFP fusion 
protein in which a GFP Nb is fused to an F-box domain, thus recruiting the poly-
ubiquitination machinery and degrading GFP fusion proteins (Figure 7B)102. It is 
functional for nuclear, cytoplasmic and transmembrane GFP-fusion proteins102. Another 
method was developed by Shin and co-workers, termed Protein interference (Protein-
i)103. They replaced the substrate recognition domain of SPOP, an adaptor protein of the 
Cullin-RING E3 ubiquitin ligase complex, by a GFP Nb (Figure 7C)103. Due to the 
interaction between SPOP and the cullin3 E3 ligase complex, the GFP-fusion protein is 
degraded. Their technique was limited to nuclear GFP-fusion proteins103. Fulcher et al. 
created a third method, the affinity-directed protein missile (AdPROM)104, 105. They fused 
the GFP Nb to the von Hippel-Lindau (VHL) adaptor protein which enables the interaction 
of the GFP-fusion protein with the adaptor protein, Elongin B/C, to establish cytoplasmic 
protein degradation (Figure 7D)104, 105. Those three methods were able to cause a specific 
proteasome-dependent degradation of GFP-fusion proteins. However, the later one was 
also able to degrade a protein tyrosine phosphatase (SHP2) and apoptosis-associated 
speck-like protein (ASC) by using nanobodies targeting those two proteins105. Recently a 
fourth method has been established by Daniel et al.106. This degradation method 
requires the ectopic expression of TIR1, a plant F-Box protein, and a GFP Nb fused to an 
auxin-inducible degron (AID)106. A GFP-fusion protein, which is targeted by the GFP Nb - 
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AID fusion protein, will be recruited to the ubiquitin E3 ligases complex by TIR1 in an 
auxin-dependent manner (Figure 7E)106. An advantage of this method is the possibility to 
induce the degradation via auxin106. Daniel and co-workers were able to obtain promising 
results in HeLa cells and in zebrafish106. Since these four models are planning to knock-
out proteins at the post-translational level, they can be a valuable alternative because 
the outcome is obtained faster compared to methods like RNAi, which are focused on 
gene-silencing at the post-transcriptional but pre-translational level84. 
 
Figure 7: Nanobody-based protein degradation methods. (A) The Cullin-RING (really interesting new gene) E3 ubiquitin 
ligase complex consist of an Cullin-RING core, adaptor proteins and/or substrate receptors to enable the E2 ubiquitin-
conjugating enzyme to load the substrate with ubiquitin-molecules (Ub). (B) The deGradFP method of Caussinus et al. in 
which an GFP Nb is fused to an F-box domain
102
. (C) The Protein interference (Protein-i), developed by Shin et al.
103
. They 
replaced the substrate recognition domain of SPOP, an adaptor protein, by an GFP Nb. (D) The affinity-directed protein 
missile (AdPROM) of Fulcher et al.
104, 105
, created by fusing a GFP Nb to the von Hippel-Lindau (VHL) adaptor protein. (E) 
Daniel et al. fused a GFP Nb to an auxin-inducible degron (AID) and binds the E3 ligase complex through TIR1, a plant F-Box 
protein
106
. 
To study intracellular proteins using nanobodies, those nanobodies need to traverse the 
plasma membrane. Such delivery of a nanobody as recombinant protein, is still 
challenging as discussed earlier. Nanobodies are able to fold properly even in a reducing 
environment such as the cytosol26. That is why they can be properly expressed 
intracellularly after transfection or transduction. This is not a new idea as the expression 
of an antibody in Saccharomyces cerevisiae was first reported in 1988 by Carlson et al.107. 
An intracellular nanobody or intrabody can be useful for different goals, such as 
interfering with the protein conformation, with the protein localization with protein 
functioning3. This intrabody can be a fusion protein or the original nanobody26. Because 
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nanobodies can easily be modified, they can be genetically tagged with a localization tag 
(e.g. mitochondrial outer membrane (MOM)-tag45, 47). After intracellular expression, such 
nanobodies can be used to study the function of proteins by translocating or delocalising 
the protein of interest. Van Audenhove et al.45 observed that fascin nanobodies were 
only able to reduce matrix metalloproteinase 9 (MMP9) secretion when fascin was 
delocalised due to a MOM-tag; without MOM-tag MMP9 secretion could not be 
reduced45. Herce et al. studied protein-protein interactions using nanobodies108. They 
used an anti-GFP nanobody to delocalise a GFP-tagged protein to a chosen location (e.g. 
to the nuclear lamina with GFP Nb-laminB1, to the centriole with GFP Nb-centrin or to 
the nucleus with GFP Nb fused to the methyl cytosine-binding domain), and the 
interaction partner is RFP-tagged. After transfection of the constructs, the GFP tagged 
protein of interest will translocate to the location of the GFP Nb. If the interaction 
partner (tagged with RFP) interacts, both GFP and RFP signals will be found at the 
relocated site confirming the interaction108. Because this is done in living cells, they were 
able to study binding interactions and the kinetics108.  
For some techniques, nanobodies can be a helpful tool to make certain experiments 
possible. Since it is difficult to obtain crystal structures of membrane proteins for 
instance, or of large molecular complexes, nanobodies can be and are used as 
chaperones to enable X-ray crystallography109-111. They assist the crystallisation process 
and improve the crystallisation behaviour by accelerating the production of high 
resolution diffraction crystals3, 19, 36. Nanobodies are able to stabilise a protein in a certain 
conformation and to prevent self-oligomerisation3, 19, 36. Next to X-ray crystallography, 
they can also be used as probe in nuclear magnetic resonance (NMR) spectroscopy to 
better understand protein structures and folding112. Nanobodies can offer more than 
only the function of a chaperone. They can modulate or stabilise protein conformations. 
Pardon and co-workers showed that nanobodies against G protein-coupled receptors 
(GPCR) were able to stabilise or lock the receptor in a certain conformation87, 113. Due to 
the intracellular nanobody binding to the GPCR to maintain the locked conformation, 
they were able to identify novel conformation-specific small molecules which bind 
extracellularly87. Kirchhofer et al. have shown that nanobodies can modulate the 
conformation of GFP and by doing so, they enhance the spectral properties114. This 
enables a higher intensity, leading to better visualisation114. Besides, nanobodies can be 
used as imaging tool, but this will be described further (Chapter 2 Labelling and 
microscopy).  
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1.3.2 Therapeutic and diagnostic purposes 
Antibodies have already a long history as therapeutics26. In 1901, Emil von Behring 
received the first Nobel Prize in medicine for the invention of passive immune therapy to 
cure diphtheria, an epidemic disease in those days, while the molecular structure of an 
antibody was discovered nearly 50 years later26, 115. Until today researchers are still 
searching for better, more specific and more efficient therapeutics. As nanobodies are a 
good alternative for classical antibodies, many of the properties for a good therapeutic 
or diagnostic are also found in nanobodies as well. They are low immunogenic, small in 
size, easy to modify, robust against harsh conditions. Because of a broader range of 
epitopes, nanobodies can be an option for example when the large size of antibodies 
interferes with the access to certain epitopes17. This makes nanobodies an ideal tool for 
developing new and better alternatives than the currently available methods.  
As described above, nanobodies can be used as an in vivo imaging agent or biosensor 
because of their small size, high specificity, robustness and the fast renal clearing. 
Nanobodies as in vivo imaging agent opens the opportunity for SPECT116, 117 and PET 
scans118, as some nanobodies are entering clinical phases39, 119. For example, 68Ga-labeled 
anti-HER2 Nb can be used to screen patients using PET imaging leading to a faster 
decision in knowing if a patient would benefit from an anti-HER2 therapeutic 
treatment119. Additionally, a nanobody has also applications as biosensor. For example, 
due to the fusion between HIV-1 p24, an antigen of HIV, and a red blood cell-specific 
nanobody, a simple agglutination test can diagnose HIV in the patient120. As antibodies 
are used for diagnostic purposes in antibody-based slides or arrays, nanobodies can be 
used as well19, 121. 
Next to the imaging application of nanobody-radionuclide conjugates, these conjugates 
can offer therapeutic use as well. Radionuclide therapy requires a targeting moiety 
which causes the accumulation at the tumor, and a radionuclide which delivers the 
cytotoxic load8. Because of the high stability against harsh conditions and homogenous 
tumor penetration, nanobodies are an ideal candidate8. Since nanobodies can locally 
deliver the cytotoxic radiation, there will be a minimal toxicity to surrounding healthy 
tissues compared to conventional radiation treatments8. For example, 177Lu-labeled anti-
HER2 nanobodies were able to prevent tumor growth in HER2-positive xenografts in vivo, 
while radioactivity levels in normal organs remained low122. 
Due to the easiness of modifying nanobodies, a high variety for therapeutic purposes is 
available8. Nanobodies could easily be coupled to toxins by genetic fusion, e.g. the anti-
CD7 nanobody fused to the truncated form of Pseudomonas Exotoxin A (PE38) shows 
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cytotoxicity in T-cell acute lymphoblastic leukaemia in vitro (in CD7-positive cell lines 
such as Jurkat, and primary T-cell acute lymphoblastic leukemia or T-ALL cells) expressing 
and in a preclinical mouse model in vivo123, 124. Unfortunately, this has a big drawback as 
it can induce a strong immune reaction against the foreign protein toxin8. As protein-
toxin fusions have a disadvantage, fusions with non-toxic proteins such as enzymes are 
safer. For example, Cortez-Retamozo et al. were able to cure the established tumor 
xenografts by using nanobodies which target the carcinoembryonic antigen (CEA or 
CD66e)125. CEA is highly expressed on epithelial cancer cells and very low on healthy 
adult cells, making it possible to selectively target cancer cells26, 125. Those nanobodies 
were fused to a β-lactamase enzyme which is able to convert a non-toxic pro-drug into a 
toxic agent125. The combination of the nanobody targeting cancer cells selectively and 
the β-lactamase conversion of the pro-drug, enables the drug to be active in the direct 
environment of the cancer without harming healthy tissue125. Nanobody-targeted 
nanoparticles (<200 nm) offer the advantage to transport encapsulated drugs, that 
otherwise suffer from fast clearance, limited stability and/or poor solubility8. The 
nanobody covering of nanoparticles results in a decreased risk of immunogenic response 
to the nanoparticle, a delayed retention time and a better targeting of the nanoparticle 
to specific locations such as cancer cells8. Polymeric micelles decorated with anti-EGFR 
nanobodies and containing doxorubicin were internalized into the target cell resulting in 
inhibiting tumor growth126. 
There are already therapeutic nanobodies passing phase I and phase II clinical trials127. 
Because of the stability against harsh conditions (pH, temperatures …), nanobodies offer 
the advantage of a patient-friendly administration (oral, topical or inhalation)17, 34. For 
example: nanobodies for treatment of psoriasis, Vobarilizumab (or ALX-0061, an Ablynx 
Nb) targeting interleukin-6Rα128 and ALX-0761 (another Ablynx Nb) targeting interleukin-
17A and IL17A/F. ALX-0761 consist of two nanobodies (one against interleukin-17A and 
one against interleukin-17A/F) and human albumin which increases the half-life128, 129. 
Caplacizumab (or Cablivi) is the first nanobody that is allowed to be used for clinical use 
to treat patients with acute thrombotic thrombocytopenic purpura127, 130. It is a bivalent 
humanised nanobody containing two identical anti-von Willebrand factor nanobodies 
developed by Ablynx127, 130, 131.  
Because nanobodies are a good counterpart of conventional antibodies, they have the 
opportunity to be used as antiserum for toxins and venoms like from scorpions and 
snakes17, 19. Nowadays, blood of venom-immunized horses and sheep are used, but it has 
low potency and is very variable in efficacy26, 39. This is due to the toxin or venom itself 
which is small and low immunogenic26, 39. Nanobodies are able to target a high range of 
biomolecules and without the Fc region, nanobodies only neutralize the toxin. Because 
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of its small size and fast renal clearing, it gave a lot of benefits compared to the practices 
existing today39. First experiments in mice using nanobodies against the most toxic 
venom of scorpions, show better results than the existing antibody therapy132. A 
dromedary VHH against Androctonus australis hector AahI′ toxin, a scorpion toxin, was 
able to neutralize the toxin and even at low Nb doses it showed better results than in 
case of the scFv alternative132. 
Next to medical purposes, nanobodies have their applications in other divisions as well. 
For example, nanobodies against caffeine are able to detect caffeine in hot and cold 
drinks (from coffee to coke)133. This was possible because nanobodies are thermally 
stable133. When developing a “dip-stick” format assay, it gives consumers a qualitative 
determination of caffeine133. 
 Non-immunoglobulin based molecules 1.4
In contrary to nanobodies and antibodies in general, some non-immunoglobulin based 
molecules can be used as counterpart to target biomolecules similar as antibodies do 
(Figure 8). Those antibody alternatives are engineered to have an affinity comparable to 
that of antibodies36. Those proteins they need huge libraries where antibodies use 
immunisation mechanisms to obtain high-affinity binders. In contrast to nanobodies and 
antibody fragments, non-immunoglobulin based antigen-binding proteins benefits from 
the lack of a disulphide bond which allow them to be more resistant in reducing 
environments134. Monobodies, also called adnectins (Figure 8B), (± 10 kDa) are based on 
human fibronectin type III and are such an alternative to conventional immunoglobulin 
based molecules36, 135. Monobodies are structurally very similar to the immunoglobulin 
structure36 and consist of seven β sheets and three CDR-like loops134, 136. Their affinities 
can reach nanomolar and picomolar affinity137. Monobodies also have high thermal (up 
to 80 °C) and conformational stability and are able to reversibly and rapidly unfold and 
refold135, 138. Dineen et al. was able to observe the preventing of tumor growth and 
metastasis by using monobodies targeting the vascular endothelial growth factor 
receptor (VEGFR-2)139, 140. Another possibility are affibodies (Figure 8C) (± 6.5 kDa). Those 
are small synthetic binders consisting of three α-helices and are based on ProteinA, a cell 
wall protein of Staphylococcus aureus36, 141-144. Affibodies prefer interacting with flat 
surfaces and resistant to high temperatures134, 145, 146. Affibodies already showed 
promising results in disturbing protein-protein interactions and as carrier for drug 
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delivery142, 147. Lindborg et al. was able to show specific changes in tumoral angiogenesis 
and not in normal blood vessels by using an affibody against the platelet-derived growth 
factor receptor (PDGFR)148. Next, anticalins (Figure 8D) (± 20 kDa) are another possibility. 
Those are based on lipocalins structurally containing a β-barrel and four loops36, 137, 149. 
Anticalins are low immunogenic and are beneficial binders against small molecules. A 
few anticalins are already in clinical phase, e.g. an anticalin which neutralise vascular 
endothelial growth factor (VEGF) to inhibit angiogenesis in solid tumors137. Last to be 
discussed here, designed ankyrin-repeat proteins or DARPins (Figure 8E) (± 18 kDa). 
Those are based on natural ankyrin repeats36 and have high thermodynamic stability150. 
The ankyrin fold is biological of importance in mediating protein-protein interactions134, 
151. DARPins consist of a β-turn, a pair of antiparallel α-helices and a loop of typically 33 
amino acids150, 152. DARPins are beneficial for flat surfaces146. DARPins are used to 
selectively inhibit the c-Jun N-terminal kinases isoforms in human cells, which is 
important stress-induced signalling153.  
 
Figure 8: A nanobody and non-immunoglobulin based molecules: (A) a nanobody or VHH, (B) a monobody or adnectin, (C) 
an affibody, (D) an anticalin, (E) a DARPin and (F) an aptamer. 
As the above mentioned molecules all are amino acid based and can be easily 
manufactured in E. coli, other alternatives to immunoglobulin molecules based on 
nucleotides are options as well. Aptamers (Figure 8F) were discovered in the same 
period as nanobodies154-156. They are found in nature and are single-stranded 
oligonucleotides which forms complex shapes. Both DNA and RNA aptamers are 
possible157, 158. This allows them to act as a scaffold which enables the targeting of a 
protein159. Aptamers are also able to interfere in the protein-protein interactions159. 
Their affinity range is similar to that of nanobodies157. To find high affinity binders large 
libraries and a selection method (systematic evolution of ligands by exponential 
enrichment or SELEX) are needed157, 160, 161. Since aptamers are nucleotide based, they 
suffer from nuclease activity, but are never immunogenic. Aptamers can denature and 
regenerate easily160. Aptamers also suffer from limited shelf life and are suggested to 
have a production cost similar to antibody production157. Because of the small size, they 
are able to access to many biological compartments36, 159. However, similar to 
nanobodies, they cannot enter the cell by itself157, 162.   
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  Chapter 2
Labelling and microscopy 
Researchers in the field of cell biology make frequently use of microscopic techniques for 
their own experimental setups and purposes, but they all have a similar goal: by imaging 
their research, they try to illustrate their work and findings in a way that is more difficult 
to describe with words163. Not only more intuitively the results are becoming more 
comprehensive, it is also a primary source of data that is available to be analysed and 
interpreted163.  
 Fusion proteins 2.1
To look at an intracellular protein of interest, the protein itself can be modified by 
coupling to a fluorescent protein, e.g. GFP. Such fusion proteins can help in studying the 
protein of interest. Due to the large size of fluorescent proteins (27 kDa for GFP), 
differences between the endogenous protein and the fusion protein in terms of 
functionality can be observed, as well as some unwanted effects such as artificial self-
oligomerization, loss of function and mislocalization163-170. Next, the expression of a 
fusion protein leads to the presence of two pools of the protein of interest (the 
fluorescent fusion protein and the endogenous untagged protein). This latter one results 
in a pool that is not visible for analysing and probably competes with the fluorescent 
pool166, 167. Because one fraction is undetectable for microscopic purposes, this pool is 
undesired in the study.  
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As mentioned above, nanobodies are easily modified and can be used as a fusion 
protein, e.g. after coupling to the green fluorescent protein (GFP). In that way the 
unwanted effects of modifying the protein of interest are overcome and it is possible to 
look directly at the endogenous protein. The company ChromoTek has discovered this as 
well. They sell chromobodies as a plasmid in which a nanobody is genetically engineered 
to GFP99, 171, 172. These chromobodies can help to study proteins on an endogenous level 
in vivo171, 172. Noticeable is the fact that nanobodies have to bind the protein and can 
interfere in the normal binding interactions between the protein of interest and other 
proteins. This is wanted in case of examining the function of the protein, but in 
visualising the native conditions this can be a disadvantage. However, this is not always 
the case. It is previously seen that some nanobodies do not interfere with any interaction 
e.g. a survivin nanobody47. 
While the use of chromobodies or fluobodies are on the rise, a fluorescent protein fusion 
is not always desired depending on the kind of assay. GFP is in diameter 4 nm, but will be 
seen as a 400 nm blur by light microscopy173, 174. Especially when a high resolution is 
required e.g. super resolution, smaller fluorophores are desired above fluorescent 
proteins175. When considering the resolution, the diffraction of light has to be mentioned 
as well. The maximal resolution of a microscope is constrained by the diffraction limit of 
light163. This was found by Ernst Abbe in 1873176. It is the minimal distance between two 
objects in the same plane which are still distinguishable as separated elements163, 174. 
This depends on the wavelength of light and the numerical aperture of the lens that has 
been used163. When using a light microscope, the resolution is 200-250 nm laterally and 
500-700 nm in the axial direction, meaning all signals closer together than this will be 
seen as one signal. This is why a normal light microscope does not always provide an 
accurate representation of the sample that is being visualized174, 177. For this reason, 
super resolution microscopy has been worked out. Depending on the used technique, 
super resolution microscopy made it already possible to gain a resolution from 200 – 250 
nm to approximately 10 nm laterally163, 177. 
As mentioned above, it is preferable to choose a bright small label to increase 
localisation precision instead of a big fluorescent protein which will give a blur178. 
Besides, fluorescent proteins have typically a bigger spectral range compared to small 
chemical dyes and they also suffer from limited photostability170. Because of the better 
resolving power, sizable fluorophores undo the benefits of super resolution, but not only 
the fluorophores have to be taken into account. Nowadays, antibodies are used 
commonly to visualize the protein of interest. A big problem when using antibodies, is 
the ‘localisation error’ or ‘linkage error’ (Figure 9)174, 178. If an accurate location of the 
protein is desired, the size of an antibody increases the distance between the protein 
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and the fluorescent dye. Because one antibody has a size of around 12-15 nm (Figure 
9B), the location of the dye is not entirely the same as the location of the desired 
biomolecule163, 174, 175, 179. Especially not when a secondary antibody is needed (Figure 
9A), the distance between the label and the protein can even reach 24-30 nm175, 179. If an 
accurate location is required, especially when super resolution microscopy is used, this 
distance is of high importance to give accurate information about the location of the 
protein of interest175. As mentioned before, nanobodies are an ideal counterpart to 
antibodies and can represent a better alternative. The ‘linkage error’ of nanobodies will 
be decreased by a factor 4 to 7 compared to the use of the standard antibody staining 
(Figure 9C). In that case nanobodies have to be labelled directly, otherwise the benefits 
of the smaller linkage error are wasted. Indeed, nanobodies have been used before for 
immunostaining. However, the linkage error was not decreased since they used a 
labelled primary antibody targeting the nanobody, or a tag on the nanobody180, or they 
used an unlabelled antibody combined with a labelled secondary antibody94, 97. 
 
Figure 9: Linkage error. (A) When using a primary antibody and a labelled secondary antibody, the linkage error can reach 
24-30 nm. (B) In case of a labelled primary antibody, the distance between the dye and the target decreases to 
approximately 12-15 nm. (C) A labelled nanobody is able to reduce the linkage error even more. 
 Coupling mechanisms for the labelling of nanobodies 2.2
Because of the big size of a fluorescent protein, it also heightens the size of a fusion to a 
nanobody by a factor 2-3 (e.g. GFP is 27 kDa). Therefore, smaller fluorophores have to be 
chosen of which the Alexa fluorophores are the best known. The only challenge is a 
specific addition of a fluorophore onto a nanobody. Many strategies were already tested, 
all with their own advantages and disadvantages.  
2.2.1 Self-labelling enzymes 
To overcome the blur of the big fluorophores and retain the easiness of fusion proteins, 
it is an option to fuse a nanobody to a self-labelling enzyme. Such enzymes can be fused 
to a protein of interest (e.g. a nanobody) with the intention to covalently attach an 
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exogenous synthetic ligand. If such a ligand is fluorescently modified, it enables 
fluorescent labelling181-183. The fusion protein can be expressed in cells but needs in that 
case a dye that is cell permeable and non-toxic (e.g. rhodamin), meaning the labelling 
has to occur before fixation in living cells181. A few self-labelling enzymes are already 
commercially available, such as a HaloTag184, a SNAP-tag182, 185 and a CLIP-tag182, 186. The 
first originated from a haloalkane dehalogenase, which removes a halide from an alkyl 
halide ligand184, 187. The SNAP-tag is from an O6-alkylguanine-DNA-alkyltransferase, a DNA 
repair enzyme, which reacts with benzylguanine derivatives185, 186. The third one, the 
CLIP-tag is derived from an O2-alkylcytosine-DNA-alkyltransferase and uses O2-
benzylcytosine ligands186. This method can be introduced for nanobodies as well. 
However, to image a protein of interest with labelled nanobodies, the cell has to express 
the nanobody fused to the self-labelling enzyme tag. This fusion enlarges the nanobody 
in size by a factor of approximately two (e.g. the SNAP-tag is 20 kDa) which also 
heightens the linkage error compared to a directly labelled nanobody. 
2.2.2 Enzymatic recognition tags 
A nanobody can easily be genetically engineered with a small tag which is recognised by 
an enzyme to obtain an enzymatic labelling. One such effort is performed by Schumacher 
and co-workers (Figure 10)36, 188. A GFP nanobody was provided with a C-terminal 
tubulin‐derived recognition sequence (Tub-tag), existing of 14 amino acids 
(VDSVEGEGEEEGEE)36, 188, 189. This Tub-tag sequence is recognised by tubulin tyrosine 
ligase (TTL) which adds a small unnatural tyrosine to the Tub-tag in an ATP dependent 
reaction189. Schumacher et al. were able to couple a 3‐formyl‐L‐tyrosine to the Tub-
tagged anti-GFP nanobody followed by a chemical hydrazone forming reaction to couple 
it with an Alexa Fluor594-hydrazide dye (Figure 10A)189. Many functional groups can be 
added to the tyrosine which allows a chemical reaction of choice for the coupling of the 
dye. Since this is a two-step process, they further developed a one-step protocol by using 
a coumarin coupled amino acid or β-(1-azulenyl)-l-alanine (Figure 10B)188. However, the 
main disadvantage in this one-step method is the limitation of the fluorescent substrates 
that are compatible with this method188.  
Another possibility is by genetically adding a sortag to the nanobody (Figure 10C). Its 
consensus sequence is LPETG (Leu – Pro – Glu – Thr – Gly)36, 190. By engineering this 
sequence at the C-terminus of a nanobody, it will be recognised by sortase A (SrtA), a 
transpeptidase derived from Staphylococcus aureus36. SrtA cleaves at the sortag and 
coupled the nanobody to peptides starting with GGG (Gly – Gly – Gly) followed by 
molecules of choice191. The nanobody can be engineered to facilitate the purification 
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between a sortase labelled nanobody and an unmodified nanobody191. In that case, the 
C-terminus contains a sortag followed by a His6-tag
191. This allows a purification after 
production via immobilized metal affinity chromatography (IMAC) and an elimination of 
the unmodified nanobodies after SrtA-mediated cleavage191. Massa et al. developed this 
method to add radiolabels onto a HER2 nanobody for SPECT and PET visualization191. 
They conjugate a Cy5 fluorophore to the HER2 nanobody as well for use in fluorescence 
reflectance imaging (FRI)191. Truttmann and co-workers have conjugated a GGG-AF647 
peptide onto an anti-HypE nanobody (Huntingtin-associated yeast-interacting protein E) 
using the SrtA method192. Fabricius et al. made use of SrtA as well193. They enzymatically 
couple a dibenzocyclooctyne-amine (DBCO) moiety on the nanobody which allows to 
perform a strain-promoted alkyne-azide cycloaddition (SPAAC) with an azide-modified 
oligonucleotide193. Through a DNA-PAINT method based on labelled single strand DNA 
oligonucleotides which are complementary to the oligonucleotide on the nanobody, they 
were able to visualise endogenous tubulin proteins193. Further, Witte and colleagues 
used a TAMRA labelled peptide (GGGK(N3)K-TAMRA) to attach the dye onto a nanobody 
(targeting class II MHC products) through sortase194. As those TAMRA labelled 
nanobodies had their application in FACS, Witte et al. introduced alkyne and azide 
bearing peptides to obtain bivalent nanobodies through SPAAC194. Since those bivalent 
nanobodies had their application in microscopy, they were chemically labelled194.  
 
Figure 10: An enzymatic labelling method using a tubulin tyrosine ligase (TTL) or using a sortase A (SrtA). (A) In a two-step 
process, TTL added a tyrosine derivate with a reactive chemical group (such as 3‐formyl‐L‐tyrosine) to a Tub-tag followed by 
a chemical coupling of the dye to the nanobody. (B) In the one-step process, the TTL is able to ligate dyes to the Tub-tag of 
the nanobody. However, the substrates for this process are rather limited. (C) In case of a sortase labelling, the nanobody 
must be engineered with the sortag (LPETG) followed by a His6-tag. Through SrtA, the His6-tag is cleaved and a labelled 
peptide (Gly-Gly-Gly-dye) is linked to the nanobody. If the SrtA enzyme is His6-tag, the unreacted nanobody and SrtA can 
easily be removed from the end result. 
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Other enzymatic methods are published as well, but none of them have as goal to make 
nanobodies fluorescent. Besides, those techniques can be complementary methods. 
Such an alternative is found by Hudak et al. (Figure 11A)195. By incorporating a tag into a 
protein consisting of 5 amino acids (CxPxR or Cys – x – Pro – x – Arg), this sequence will 
be recognised by formylglycine-generating enzyme (FGE)187, 195. FGE changes the cysteine 
into an aldehyde-bearing residue, a formylglycine (fGly), during the protein expression187, 
195. The aldehyde allows modification to hydrazide or aminooxy which bears e.g. an 
alkyne/azido functional group allowing a SPAAC reaction afterwards195. Again this is a 
multi-step process195. Another enzymatic option could be via transglutaminases (Figure 
11B)196. Transglutaminases are able to site-specifically modify proteins on a glutamine 
residue in a highly flexible region196, which is not common on a nanobody36. By genetic 
engineering a glutamine-containing tag at the C-terminus (e.g. myc-tag (EQKLISEEDL)), a 
transglutaminase will be able to modify the glutamine by coupling it to a primary amine 
group196-198. However, the separation between labelled and unlabelled nanobodies will 
not be that easy, because there is no cleavage of a His6-tag as in case of sortase. Dennler 
et al. have used this to label Fabs with an ATTO-488 or TAMRA dye for microscopic 
purposes198.  
 
Figure 11: Enzymatic labelling methods by using a formaylglycine-generating enzyme (FGE) or a transglutaminase (Tgase). 
(A) The labelling via FGE transforms a cysteine in a short sequence (Cys – x – Pro – x – Arg) to a formylglycine. This can react 
with an aminooxy moiety that allows to attach a functional group to allow a chemical labelling afterwards. (B) The method 
via Tgase requires a glutamine-contacting tag (e.g. myc-tag). Tgase couples a primary amine group to the glutamine which 
leads to the labelling. 
As these are all enzymatic processes, it has to be noticed that the reaction can be 
reversible, as has been shown for sortase, which is a drawback for enzymatic 
attachments36. 
2.2.3 Chemical ways for labelling nanobodies 
Since enzymatic strategies can be reversible, chemical ways have been executed as 
complementary method. One of the first was the N-hydroxysuccinimide (NHS) 
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chemistry. This is based on a simple chemical reaction in which a NHS ester dye is 
coupled to a solvent exposed lysine onto the nanobody (Figure 12A). However, it caused 
some unwanted results because the abundant occurrence of lysine residues and 
accessibility represented a major disadvantage, because it creates a heterogeneous 
mixture of dense and less dense labelled nanobodies36, 179, 191, 199. Besides, the labelling 
can occur at different positions leading to a more random and unselective labelling36, 179, 
191, 199. This could be solved by adding a poly-lysine stretch at the C-terminus which 
resulted in a less heterogeneous mixture179, 200. Additionally, a bigger problem rises 
because lysines are also present in the CDR regions and when these are modified, the 
affinity and specificity of the nanobody could be altered28, 36, 191. Pleiner and co-workers 
experienced even total loss of antigen recognition capacity after NHS labelling179. Ries 
and co-workers used the NHS chemistry to label anti-GFP nanobodies with Alexa Fluor 
647 (AF647)178. They stained tubulin-YFP in Potorous tridactylis epithelial kidney cells 
(Ptk2) and tried to resolve the diameter of a microtubule using PALM178. The diameter of 
a microtubule is known to be 25 nm. After fixation, they found that a nanobody staining 
was able to resolve the diameter of the microtubule to 26.9 nm (± 3.7 nm) while a 
(primary and secondary) antibody staining showed a diameter of 45 nm (± 5.8 nm)178. 
This immediately shows the significant reduction in linkage error when using 
nanobodies178. Similar results were found by Mikhaylova et al. when using nanobodies 
targeting tubulin directly201. 
This C-terminal addition of a poly-lysine stretch led to further thinking. Cysteines are 
much less abundant than lysines36. When an unpaired cysteine was engineered at the C-
terminus, another way of labelling could be performed. This site-specific conjugation was 
following the maleimide chemistry (Figure 12B)199. The free thiol group of the cysteine 
needs to be reduced to react with a maleimide dye36, 190. Because free thiol is robust, it is 
often difficult to achieve high conjugation efficiency202. The protocol is a bit challenging 
since the conditions and timing are important202. First, the cysteines have to be reduced 
by a strong reducing agent such as dithiothreitol (DTT)202, 203, 2-mercaptoethylamine (2-
MEA)199 or tris[2-carboxyethyl]phosphine (TCEP)179, 204-206. During this reduction step, the 
reducing agent has to be titrated carefully to the unpaired cysteine because only the 
chosen cysteine residue is desired to be reduced and not the intradomain disulfide 
bonds30, 179. If this happens the stability of the nanobody will be altered and unwanted 
side products will be created199. After the reduction step and just before the labelling 
reaction, the reducing agent had to be removed since it can react with the maleimides 
itself202. To remove the reducing agent, a desalting is required, followed by a 
quantification to obtain the right stoichiometric amount for the reaction202. However, 
this has to be fast because the longer it takes, the more reoxidation of those free thiol 
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residues will occur resulting in a less efficient labelling202. However, compared to the NHS 
ester method, the maleimide method is more quantitative as the reaction follows more 
in stoichiometric fashion179. Besides, this strategy showed an enhanced homogeneity 
compared to the heterogeneous mixture when targeting lysines36. On the one hand the 
presence of an unpaired cysteine is desired, while on the other hand it is a disadvantage 
at the same time. An unpaired cysteine can cause dimerization and irreversible unfolding 
of the nanobodies, which in that case results in the lower yield after bacterial expression 
or even toxicity for the bacteria30, 179, 199. Nevertheless, Pleiner and colleagues labelled 
nanobodies against the nuclear pore complex with an AF647 via the NHS and the 
maleimide strategy, and they preferred the maleimide method as they observed a much 
lower background compared to the NHS ester method (using STORM microscopy)30, 179. 
Besides, they also conclude that the maleimide-labelled nanobodies recognize their 
target better and more consistently than in case of the NHS labelling strategy30, 179. 
 
Figure 12: Chemical labelling methods. (A) Labelling via N-hydroxysuccinimide (NHS) chemistry needs a NHS ester dye 
which will be coupled onto the nanobody via a solvent exposed lysine residue. (B) The maleimide labelling strategy couples 
a maleimide linked dye to a Cys residue on a nanobody. 
2.2.4 Other strategies 
Finally, other ways to fluorescently label nanobodies have been performed for other 
purposes. Ramos-Gomes et al. coupled nanobodies to quantum dots207. This coupling 
ensued due to sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
which cross-links the C-terminal Cys at the nanobody to an amino group at the quantum 
dots207, 208. Quantum dots are highly fluorescent homogeneous semiconductor 
nanocrystals. They were able to selectively conjugate four nanobodies onto one 
quantum dot207. Quantum dots are capable of emitting enough signal to be detected 
deeper into tissues compared to Alexa fluorophores. For this purpose, quantum dots are 
more preferable than Alexa fluorophores. Ramos-Gomes et al. showed the possibility of 
detecting disseminating cancer cells and micrometastasis inside tissues and organs207.  
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Next, a few strategies of intracellular labelling were devised to cell-free labelling. Chen 
and colleagues have worked out a ‘tagging-then-labelling’ method to label proteins in 
living cells209. For this, they transfected the cells with a fusion protein, consisting of their 
protein of interest fused with an E. coli dihydrofolate reductase (DHFR)209. The latter one 
is a protein of 18 kDa and has a high affinity for the antibiotic trimethoprim (TMP)209. By 
chemically incorporating an azido group onto this antibiotic and adding this to the cell 
culture medium, they were able to tag the fusion protein with an azide209. Once tagged, 
the labelling could be performed through a strain-promoted alkyne-azide cycloaddition 
(SPAAC) afterwards. This method could be implemented for nanobodies as well, but this 
would lead to a bigger linkage error compared to a labelled nanobody since the DHFR 
alone is 18 kDa in size209.  
Recently, Graulus and co-workers used another mechanism to couple a peptide or 
molecule to a nanobody which is called intein-mediated protein ligation (IPL)210. Inteins 
are natural occurring bacterial proteins and have a protein splicing activity210. In this 
strategy, the nanobody is recombinantly expressed as fusion to intein and the chitin 
binding domain (CBD)210-213. This allows an easy purification using a chitin substrate (e.g. 
on column)214. To allow the intein-mediated protein ligation, a genetically engineered 
cysteine between the nanobody (or protein of choice) and intein is required. This enables 
the initial step, which is an N-S acyl shift leading to a thioester linkage between the 
nanobody and intein (Figure 13A)210, 212, 214. Next, a nucleophilic attack on the thioester 
occurs by a small chemical thiol compound (e.g. 2-mercaptoethane sulfonate sodium 
(MESNA) or thiophenol)210, 211, 213, 214. This cleaves between the nanobody and the intein 
(Figure 13B) and creates a new thioester at the C-terminus of the nanobody which is 
reactive to attack a cysteine at the N-terminus on the peptide (Figure 13C)214. This results 
in a thioester bond between the nanobody and the peptide followed by an S-N acyl shift 
(Figure 13D) making it a normal peptide bond (Figure 13E)212, 214. Besides the reaction 
using the small thiol compound, the peptide can also directly attack the thioester bond 
between the nanobody and intein210, 214. Graulus et al. used this method to add an alkyne 
containing peptide to the nanobody210. Additionally, the use of intein is found in protein 
purification with an inducible autocatalytic cleavage activity in presence of e.g. DTT and a 
chitin substrate (e.g. chitin resins)210, 214, 215. 
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Figure 13: Intein-mediated protein ligation (IPL). By equipping the nanobody with a cysteine between the nanobody and 
chitin binding domain (CBD) of intein, this cysteine enables an N-S acyl shift resulting in a thioester linkage between the 
nanobody and intein. Next, a small thiol compound attacks the thioester in order to cleave the nanobody and the intein. 
This creates a new thioester at the C-terminus of the nanobody which reacts with a cysteine at the N-terminus on the 
peptide. This results in a thioester bond between the nanobody and the peptide followed by an S-N acyl shift. The figure is 
adapted and modified from Evans et al.
214
 and Graulus et al.
210
. 
2.2.5 An alternative method: the genetic incorporation of unnatural 
amino acids 
During translation from RNA to amino acids, 20 conical or natural amino acids are the 
building block to obtain a protein. With these 20 amino acids, a huge range of proteins 
can be created216. On top of the 20 canonical amino acids, biological modifications 
expand the range of protein functions such as glycosylation, phosphorylation and metal 
ions216. However, some archaea and eubacteria have a natural genetic code expansion 
since they encode for some non-canonical amino acids as well183, 216. Those are seleno-
cysteine and pyrrolysine which can be seen as the 21st and 22nd amino acid216, 217.  
Inspired by this phenomenon, researchers have developed an expansion of the genetic 
code or a technique which allows site-specific unnatural amino acid incorporation (Figure 
14)217. Their intention was to modify proteins in a way in order to gain novel chemical 
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and physical properties183. However, this requires some important needs. First, an amino 
acid with the desired bio-orthogonal group in its side chain has to be cell permeable and 
metabolically stable216. Secondly, the codon has to be unique, so it is only recognised by 
the newly engineered tRNA183, 216. Since only three out of 64 different triplet codons do 
not encode for an amino acid, these three nonsense codons or stop codons are typically 
used218: the amber stop codon (TAG), the ochre stop codon (TAA) or opal stop codon 
(TGA)216-220. The amber stop codon is most preferred since it is least found nonsense 
codon in an E. coli and it rarely terminates essential genes218-220. Though, these codons 
demand the complementary anti-codon, meaning the right corresponding tRNA183, 216. 
For instance the amber stop codon requires the corresponding amber suppressor 
tRNA221. This tRNA is found in nature in the archaea Methanococcus jannaschii. It does 
not use the amber codon as stop codon, but it actually encodes for a tyrosine218, 222. The 
last requirement is the specificity of the aminoacyl-tRNA synthetase for the chosen non-
canonical amino acid183, 216, 218, 220. 
 
Figure 14: The incorporation of an unnatural amino acid. To efficiently incorporate an unnatural amino acid, an orthogonal 
tRNA/tRNA synthetase is required. The tRNA synthetase couples the non-canonical amino acid to the tRNA. Next, the tRNA 
will recognise the amber codon and allow the site-specific incorporation of the amino acid in the protein. The figure is 
adapted and modified from Chin et al.
221
. 
The most straightforward method to encode an unnatural amino acid in E. coli is by 
introducing a heterologous aminoacyl-tRNA synthetase and its tRNA pair from another 
species such as from archaea216. Based on mutagenesis, the chosen amino acid, with the 
desired functional side chain, and the anti-codon can be selected. The most successful 
combination is using the amber (TAG) codon together with the heterologous Tyr tRNA 
synthetase/tRNATyr (MjTyrRS/MjtRNATyr) pair form Methanocaldococcus jannaschii. 
There are already more than 35 derivates available of this orthogonal tRNA/tRNA 
synthetase pair for unnatural amino acids with different bio-orthogonal groups183, 216, 223. 
Another frequently used orthogonal pair is found in the archaea Methanosarcina mazei 
in which the tRNA synthetase incorporates a pyrrolysine, the 22nd amino acid224.  
Today, many unnatural amino acids are available with different chemical functional 
groups such as an azide225, an alkyne, a furan moiety226-228, fluorescent groups223, 
fluorinated residues220, 229 … . The incorporation of such amino acids widen the processes 
in which a protein can participate; e.g. oxime condensation reactions230, 231, click 
chemistry225, Michael addition reactions and as redox-activereagents232. The 
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incorporation of unnatural amino acids has some interesting perspectives and a huge 
range of applications183, 216, 218, 220. For instance, this allows the incorporation of amino 
acids that are useful for infrared (IR)233 and/or NMR spectroscopy234 or the incorporation 
of amino acids containing heavy atoms for X-ray structure determination235, 236. 
The incorporation of unnatural amino acids is not yet used to fluorescently label 
nanobodies. Nevertheless, labelling of proteins by using the genetic expansion has been 
previously performed. Brustad and co-workers were able to incorporate a ketone 
bearing amino acid into a T4 lysozyme237. Next, they coupled it to an Alexa Fluor to use it 
in a single molecule fluorescence resonance energy transfer (smFRET) experiment237. 
Yanagisawa et al. incorporated an Nε-(o-azidobenzyloxycarbonyl)-L-lysine (o-AzbK)238 into 
a glutathione transferase and labelled it with a fluorescein derivative through a 
Staudinger ligation. Lang and co-workers used dienophile bearing amino acids to label 
the epidermal growth factor receptor (EGFR) with a fluorescent tetrazine conjugate239. 
Antonatou et al. showed promising results of coupling a furan containing amino acid to 
Fluorescein-5-thiosemicarbazide or to Alexa Fluor 488 hydrazide227. As these are only a 
few examples, it immediately shows the variety of options that can be created using 
unnatural amino acid incorporation.  
2.2.5.1 Non-canonical amino acid options 
To obtain fluorescent labelled nanobodies, it is possible to use fluorescent amino acids 
(Figure 15A), e.g. 3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (Anap)223, 240, 
(S)-1-carboxy-3-(7-hydroxy-2-oxo-2H-chromen-4-yl)propan-1-aminium (CouAA)241, 242 and 
2-amino-3-(5-(dimethylamino)naphthalene-1-sulfonamide)propanoic acid (dansyl-
alanine)243. Those amino acids have been incorporated previously in prokaryotic223, 241, 242 
and eukaryotic proteins240, 243. The direct incorporation of a fluorescent amino acid 
means a low linkage error and is unlikely to interfere with the functionality of the protein 
because it introduces only minimal perturbations to the protein structure183. While the 
amino acid is already fluorescent, it minimises the risks of functional disruptions in case a 
chemical labelling was needed217. However, the incorporation of fluorescent amino acids 
suffers from low production yields217, as has been observed for dansylalanin243 and 
CouAA244. Additionally, those fluorescent amino acids require only short wavelengths 
which is not ideal for in vivo imaging183. To enlarge the fluorescent amino acid derivates, 
the limiting factor is to find or to engineer a good working orthogonal aminoacyl-tRNA 
synthetase217, as this is the same for any other non-canonical amino acid. 
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Figure 15: Unnatural amino acids. (A) Fluorescent amino acids. Anap, 3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic 
acid; CouAA, (S)-1-carboxy-3-(7-hydroxy-2-oxo-2H-chromen-4-yl)propan-1-aminium; Dansyl Ala, dansylalanine or 2-amino-
3-(5-(dimethylamino)naphthalene-1-sulfonamide)propanoic acid. (B) Amino acids containing an azido group: pAzF, para-
azido phenylalanine; AhA, azidohomoalanine; o-AzbK, N
ε
-(o-azidobenzyloxycarbonyl)-L-lysine; AzK, N
ε
-(2-azidoethoxy) 
carbonyl-L-lysine. (C) Alkyne bearing amino acids: Hpg, homopropargylglycine; PrgF, p-propargyloxy-L-phenylalanine; p-EtF, 
p-ethinylphenylalanine; EtcK, N
ε
-(3-ethynyltetrahydrofuran-2-carbonyl)-L-lysine.  
To obtain fluorescent nanobodies, the nanobody would benefit to use other amino acids 
than those fluorescent amino acids. Although the incorporation of a fluorescent amino 
acid will reduce the linkage error, a non-fluorescent amino acid will require some 
additional steps after nanobody production to make the nanobody fluorescent. As 
mentioned before, many unnatural amino acids with different functional groups are 
already available. Importantly, a labelling method has to be chosen in which the risks of 
functional disruptions and additional side reactions is minimised. Here, only a few azido 
and alkyne bearing amino acids are mentioned. An azide is a chemical group that is 
reactive to an alkyne and for those are already many complementary fluorescent dyes 
commercially available. Such non-canonical amino acids that bears an azide (Figure 15) 
are para-azido phenylalanine (pAzF)225, azidohomoalanine (AhA)183, Nε-(ortho-azido 
benzyloxycarbonyl)-L-lysine (o-AzbK)183, 238 and Nε-(2-azidoethoxy) carbonyl-L-lysine 
(AzK)183. Since alkyne is more stable than azide, it would be convenient to use an alkyne 
bearing amino acid. Regarding such amino acids, a few are already known (Figure 15): a 
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tyrosine analogue homopropargylglycine (Hpg)183, p-propargyloxy-L-phenylalanine 
(PrgF)245, p-ethinyl phenyl alanine (p-EtF)183 and Nε-(3-ethynyltetrahydrofuran-2-
carbonyl)-L-lysine (EtcK)183. There is only one big issue: the water solubility of such alkyne 
bearing amino acids is limited which results in a lower cellular uptake making the 
incorporation more challenging245. 
2.2.5.2 Optional chemical reactions after the incorporation of an unnatural 
amino acid 
As mentioned above, an azido or alkyne bearing amino acid can be incorporated. When 
this is the case, a copper catalysed azido-alkyne click chemistry or CuAAC reaction can be 
performed. The copper ions enhance the region-selectivity of the reaction, since it 
predominantly creates 1,4-disubstitued 1,2,3-triazoles (Figure 16A)183. Next, a Cu-
independent alternative of CuAAC is already known as well and is called strain promoted 
azide–alkyne click reaction (SPAAC) (Figure 16B). This reaction is based on strained 
cyclooctynes, which are highly strained alkynes246. This means that the alkyne is located 
in a ring structure, while in case of CuAAC the alkyne is a terminal group. Since the 
SPAAC reaction does not require a catalysing metal, the reaction (± 2 x 10-3 M–1 s–1) is a 
factor 10 – 100 times slower compared to CuAAC (± 3 M–1 s–1)217, 247.  
 
Figure 16: Chemical labelling reactions. (A) The CuAAC reaction which requires an azido and alkyne group. This reaction is 
copper dependent. (B) The strain promoted azide–alkyne click reaction (SPAAC) is a Cu-independent alternative of CuAAC 
and is a reaction between an azide and strained cyclooctynes. (C) The Cu-independent the photoclick reaction is and photo-
dependent chemical reaction between an alkene and a nitrile imine. (D) The inverse electron-demand Diels–Alder 
cycloadditions (IEDDA) is a fast chemical reaction in which a dienophile reacts with a diene. This figure is adapted and 
modified from Lee et al.
217
. 
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Another alternative is a photo-inducible dipolar cycloaddition or photoclick reaction. This 
reaction requires a low-power UV lamp, LED or laser beam which is less harmless 
compared to metal ligands217, 248. Yu et al. showed that this photoclick reaction could be 
executed by using a nitrile imine and an alkene in a mammalian cell (Figure 16C)217, 248. 
They incorporated an alkene bearing amino acid into a protein with a tRNA/tRNA 
synthetase orthologous pair and after using the photoclick reaction they were able to 
obtain a fluorescent signal onto that protein248.  
Next, the inverse electron-demand Diels–Alder cycloadditions (IEDDA) can be an 
interesting alternative to CuAAC since no catalyst or reagent is required for the 
conjugation and is highly specific217. IEDDA causes a cycloaddition between a dienophile 
and a diene (Figure 16D)217, 249. Additionally, this reaction is very fast (± 106 M–1 s–1) 
compared to a CuAAC reaction217. 
2.2.6 A label-free strategy 
The above mentioned methods introduce a fluorophore onto the nanobody which will 
eventually require fluorescent light microscopy. However, the use of fluorescent signal 
goes together with photobleaching, phototoxicity, blinking and saturation which all have 
an influence on the brightness250. Additionally, when using fluorescent microscopy, 
researchers image the fluorescent dye or fluorophore as projection of their protein of 
interest. Nevertheless, some microscopic techniques already allow label-free imaging to 
visualise the protein directly. A label-free method has the advantage that the cell does 
not need any pre-treatments since no label had to be added251. This also ensures no 
modulation of protein functions because no dye or fluorescent molecule is needed in 
close proximity of the protein of interest251. Another benefit is that a label-free method is 
a non-destructive strategy that allows to image living cells and after, those cells can be 
used in further experiments252. The downside of looking label-free is that the resolution 
is similar to a normal light microscopy (around 200 nm)253. 
A way to look label-free at cells, is by imaging the cellular autofluorescence via using the 
blue and UV spectrum253, 254. This allows to observe changes in the morphological and the 
physiological state of the cell254. The majority of the autofluorescence is originated from 
the mitochondria and lysosomes254. Most of the time, the autofluorescent signal is 
caused by the aromatic amino acids in proteins254, the reduced form of pyridine 
nucleotides (nicotinamide adenine dinucleotide phosphate or NAD(P)H)254, 255, flavin 
coenzymes254, 256 and lipopigments257. Fuerst and co-workers were able to visualise 
eosinophils based on autofluorescence258. 
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Raman spectroscopy is another example to image in a label-free manner. Raman 
spectroscopy operates by laser light and detects Raman scattering light252, 259, 260. This 
Raman scattering light is inelastic scattering light and is originated from a wavelength 
shift that corresponds to the energy of a molecular vibration (Figure 17)251. During this 
process, the photons from the laser transfer their energy to molecules as vibrational 
energy which depends on the chemical composition of the sample259. This creates a 
vibrational fingerprint of the cell and is generated from the functional groups of proteins, 
nucleic acids, lipids, phospholipids, and carbohydrates259, 261. The vibrational spectra is 
obtained by using infrared or laser light261. However, the efficiency of the Raman 
scattering is very low251, 259. Approximately only one in 108 incident photons will be 
inelastic scattering251, 259. This requires a high concentration of the biomolecules inside 
living cells which is ideal for RNA, DNA and proteins259. A challenge for Raman 
spectroscopy is to study proteins in the intracellular environment because of the strong 
background of other proteins that are present in the close neighbourhood of the protein 
of interest259. Since the strongest Raman signal of a protein is derived from the protein 
backbone, it is very difficult to discriminate between proteins with similar secondary 
structures259. Similar to the autofluorescence method, Raman is ideal to use when 
looking at the biochemical changes of the cell251, 261. Raman spectroscopy is a good 
technique to visualise cell organelles such as the nucleus, chromatin, mitochondria and 
lipid bodies252, 261, 262. Puppels and co-workers were the first to describe Raman 
microscopy in living cells to visualise the nucleus262. Klein et al. was able to clearly 
visualise Golgi apparatus and mitochondria252. Complementary to Raman spectroscopy is 
the label-free method via infra-red microscopy. However, it is not recommended using it 
in aqueous environments251, 263. 
 
Figure 17: Raman scattering. Raman or inelastic scattering light is the result of a wavelength shift that corresponds to the 
energy of a molecular vibration. The figure is adapted and modified from Kumamoto et al.
251
.  
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  Chapter 3
Cancer, metastasis and cellular protrusions 
 Cancer and metastasis 3.1
Cancer is one of the main causes of death in developed countries. A few cancers are 
already treatable, particularly when the cancer is diagnosed in the early stages (e.g. 
breast cancer). If it is detected in later stages, the probability of surviving decreases 
dramatically. In those later stages metastasis is found in many cases. Once metastasis 
has started, the perspectives for cure and recovery diminish exponentially because 
metastasis is the most common cause of cancer-associated mortality264. The process of 
metastasis is linked to a series of steps (Figure 18). In order to establish metastasis, some 
cells of a primary tumor acquire malignant properties (e.g. formation of protrusions and 
extracellular matrix (ECM) degradation). However, not all cancer cells will metastasize, 
only the most malignant ones. Those cells undergo an epithelial–mesenchymal transition 
(EMT) which is a biological process that converts the cancer cell into a more motile 
cell265, 266. Once this happens, such a malignant cancer cell interrupts its contact with 
other cells and becomes resistant to apoptosis264, 267-269. Additionally, it starts to degrade 
the extracellular matrix in order to break through the basement membrane, the physical 
barrier that keep tissues separated, leading to the invasion of the surrounding tissues264, 
267-269. Once escaped from the primary tumor, that cell is able to degrade the 
extracellular matrix to make their path and to enable the dissemination throughout the 
body267. This can be via different potential routes. On the one hand the haematogenous 
or lymphogenous route is an option. It starts with an intravasation, meaning that the 
cancer cell goes through the blood/lymphatic vessels into the lumina where it is free to 
flow through the whole body264, 267, 268. Another option is through transcoelomic spread 
such as dissemination across the peritoneal cavity267. At a certain point, extravasation 
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takes place and the cancer cell locally leaves the vessel in order to colonize new sites to 
form a secondary tumor264, 268, 269. However, fewer than 1 in 10 000 cells that survive the 
escape from the primary tumor, is able to form a secondary tumor270. When such cells 
arrive at a new site, it still must be able to multiply without any surrounding identical cell 
and be able to adhere to the new cell types. This process is the opposite process of EMT 
and is called mesenchymal to epithelial transition (MET)266. Once a cell establishes this, it 
has to supply itself for nutrients by recruiting new blood vessels, as well as the other 
requirements similar to the growth of a primary tumor. 
Cellular migration and invasion is not only found in cancer development, they both are 
dynamic and complex processes which play a vital role in different other cell mechanisms 
such as embryonic development, wound healing and immune response269, 271. Cancer 
cells will mimic those innocent processes and hijack certain molecular components which 
enables them to degrade the extracellular matrix (ECM) and disseminate throughout the 
body269. For instance, the metastasis is enhanced due to cancer cells that mimic actin rich 
protrusions found in immune cells which will be discussed in the next paragraphs. 
 
Figure 18: Schematic visualization of metastasis. When cells from a primary tumor are getting more malignant and 
undergo the epithelial–mesenchymal transition, those cells will degrade the surrounding extracellular matrix and basal 
membranes. This results in an escape of the cancer cell and in the invasion of the surrounding tissue. Eventually, 
intravasation of the cancer cell takes place through the blood vessel. Once the cell is found in the blood stream, it can easily 
disseminate throughout the body until extravasation occurs. This can lead to the formation of a secondary tumor at a new 
site in the body at which the cell becomes less motile via the mesenchymal to epithelial transition.  
 The actin cytoskeleton 3.2
The cytoskeleton is the key to control the mechanical properties of the cell, to transport 
cargo molecules and to maintain cell shape272, 273. The basic structure of the cytoskeleton 
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is composed of three main components (Figure 19): microtubules, intermediate 
filaments and actin filaments, each of them with their own function and purpose272, 274.  
 
Figure 19: The main components of the cytoskeleton: actin filaments, microtubules and intermediate filaments. Actin 
filaments are composed of actin monomers which forms a structure of two helices. The microtubules are a polymer of α 
and β tubulin, which forms a hollow cylinder. The intermediate filaments are rods constructed with two parallel α-helices. 
The figure is adapted from Finkenstaedt-Quinn et al.
272
. 
The microtubule structure consists of a polymer of α and β tubulin and is organized as a 
hollow cylinder272, 273, 275. They play an important role in intracellular transport, 
positioning of organelles and in the formation of the mitotic spindle272, 273. The 
intermediate filaments are a family of about 70 different proteins with vimentin as the 
most common one273. The composition of the intermediate filaments is much more 
variable depending on the tissue and cellular environment272. However, it concerns 
similar structures: a rod, composed of two parallel α-helices, with variable head and tail 
domains272. This part of the cytoskeleton functions in maintaining the cellular shape and 
acting on cellular stress272, 273. The intermediate filaments are more stable than the other 
two cytoskeleton components273.  
The third part is the actin cytoskeleton. It plays a role in maintaining the cell morphology, 
in assembling protrusions, in cellular movement, in endocytosis and exocytosis, in 
facilitating transport in cells, in cell-cell and cell-matrix junctions, in cell signalling, in cell 
contractility, in tension and in motility of the cell272-274, 276. Its basic structure is the 
monomeric actin (G-actin), a globular protein of 42 kDa in size272, 276-278. The actin protein 
can be the product of different genes located on different chromosomes273, 274. This 
results in six different mammalian actin isoforms of which four are predominant in 
muscle cells (α-cardiac, α-skeletal, α-smooth muscle and γ-smooth muscle actin) and two 
non-muscle isoforms (β- and γ-actin)274, 276, 279. Based on small differences in isoelectric 
points (5.40, 5.42 and 5.44), they are divided in three groups (α-, β- and γ-actin)273, 274, 276. 
The actin monomers form filaments (F-actin) which are polar structures existing of two 
helices of ADP-Pi- and ADP-bound actin
272, 275, 277, 280-282. The actin structures are very 
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dynamic and undergo constant remodelling283. The filaments have a ‘plus’ or ‘barbed’ 
end which is important for assembling, while their ‘minus’ or ‘pointed’ end has its 
importance in disassembly271. Not only actin filaments, but also microtubules have a 
polarity275. At both structures the polymerization takes place at the plus end, while 
depolymerisation occurs at their minus end275. During the actin polymerisation, ATP is 
required281. ATP-bound actin leads to the polymerisation. After assembly, ATP is 
hydrolysed and an ADP-Pi-actin remains in the actin filaments. Structurally ATP-actin and 
ADP-Pi-actin are very similar
284. Once the Pi is released, a conformation change occurs 
which destabilise the actin filament and trigger its disassembly284, 285. In presence of ATP, 
G-actin is able to polymerize to more complex actin structures such as a branched, a 
cross-linked, a parallel bundled and an antiparallel bundled actin network277, 278. Two 
types of the actin cytoskeleton are abundant in protrusions: a branched, diagonal or 
dendritic actin network and a parallel bundled network286. The actin structure is a 
complex network that is assembled into a complex, three-dimensional structure by more 
than 100 different actin associated proteins283. 
As the actin cytoskeleton is involved in a wide range of processes, it is associated with a 
variety of diseases in case of malfunction, ranging from muscle diseases, over 
Alzheimer’s disease278, 287, 288 and atherosclerosis278, 289 to immune diseases273, 290, 291. The 
cytoskeleton is also hijacked to stimulate cancer malignancy286, 288, 292. In this case, the 
cancer cells appropriate actin cytoskeleton proteins for migration and invasion286, 288, 292. 
Moreover, different pathogens are also able to hijack the actin cytoskeleton to move 
through the cytoplasm and to increase their infectivity and virulence278. This is observed 
for bacteria such as Listeria monocytogenes, Shigella flexneri and Ricketssia coronii, as 
well as for viruses like Vaccinia virus278. 
 Actin-based protrusions, a way to move the cell 3.3
Dynamic cells make use of specialised structures to enable them to be motile and to 
degrade the surrounding area (e.g. in the case of immune cells). Usually, these structures 
are actin based protrusions which can be found at different places and in different 
formats throughout the cell. The protrusions are grouped depending on their function 
and occurrence. This will be described in the next paragraph.  
  43 
3.3.1 Lamellipodia and filopodia  
Lamellipodia and filopodia are the main components that drive migration (Figure 20)283. 
They also command the direction of migration283. Lamellipodia are flat, sheet-like plasma 
membrane extensions which give protrusive force to the two-dimensional cell motility 
(Figure 20)269, 293, 294. The cytoskeleton inside a lamellipodium is a branched actin 
network269, 294, which is established by actin polymerisation factors like actin-related 
protein 2/3 (Arp2/3)292, 294 and mDia2292, 295. mDia2, a formin protein, creates ‘mother’ 
filaments, whereas Arp2/3 creates a branched network starting on those existing 
filaments292, 294, 295. The combination of both branched and filamentous actin generates a 
force that is able to drive the cell migration283, 292, 295. Other important proteins for actin 
polymerisation in lamellipodium formation are WAVE1-2 and Rac1292-294. 
Filopodia differ from lamellipodia in size and shape as they are thinner, needle-like 
protrusions (Figure 20)269, 292, 293. Filopodia are not the major force behind the cell 
motility, but their role is found mostly in sensing the chemical and physical composition 
and properties of the environment, making them a guide in forming protrusions and 
showing the direction to migrate269, 283, 292-294. They are often found extending from the 
actin network of a lamellipodium269. The actin cytoskeleton consists of long parallel 
bundles of F-actin giving a high stiffness to a filopodium269, 292, 294, 295. The actin associated 
proteins that are important in the filopodium formation are Neural Wiskott-Aldrich 
syndrome protein (N-WASp), cell division cycle 42 (Cdc42), Arp2/3 and formins292-294. 
 
Figure 20: Lamellipodia and filopodia. Lamellipodia are flat, sheet-like plasma membrane protrusions that causes the force 
for cell movements, while filopodia are thinner and needle-like protrusions that are important for the direction of the 
movement. This figure is adapted and modified from Matilla et al.
296
. 
3.3.2 Invadosomes: podosomes and invadopodia 
Invadosomes is a term compromising podosomes and invadopodia without making a 
distinction (Figure 21)297. Podosome comes from the Greek words “podos” (ποδος), 
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meaning feet, and “soma” (σομα), meaning body, making podosomes the ‘bodies’ or 
structures that works as ‘cellular feet’289, 298. This immediately clarifies their function. In 
1989, Chen et al. described for the first time invadopodia which were formed by Rous 
sarcoma virus transformed chicken embryonic fibroblasts267, 299. Those cells were seeded 
on a degradable ECM substrate and were termed as ‘invading podosomes’ which later on 
became the word ‘invadopodium’299. A podosome and an invadopodium are quite 
similar, but a distinction is sometimes made. While invadopodia are used to name those 
protrusions in invasive cancer cells, podosomes refer to the structures in non-cancer cells 
such as typically monocytic cells (e.g. monocytes, macrophages, dendritic cells and 
osteoclasts), endothelial cells and smooth muscle cells300. Invadosomes, so both 
podosomes and invadopodia, make use of physical and chemical mechanisms for cell 
movement through actin polymerization and ECM degradation289, 301. Invadosomes act as 
micro sensors by sensing the extracellular environment to determine the best direction 
to invade followed by a degradation of the ECM298. 
 
Figure 21: Invadosomes (podosomes and invadopodia) and focal adhesions. Podosomes (A) are found in monocytes, 
endothelial and smooth muscle cells. Invadopodia (B) are the counterpart of podosomes and are typically found in 
malignant cancer cells. Invadosomes are known to be the ‘feet’ of the cell that are able to degrade the extracellular matrix 
in order to enhance migration of the cell. Podosomes are usually found in higher numbers per cell compared to the amount 
of invadopodia. Focal adhesions are visible as green dots (B) and are streak-like protrusions that are able to degrade the 
ECM in only low amounts. This figure is adapted and modified from Spuul et al.
298
. 
The formation of invadopodia is suggested to be one of the first steps in tumor 
dissemination271. It could be said that cancer cells hijack the process of podosome 
formation to generate invadopodia269. However, some distinctions can be observed. In 
case of podosomes, cells form a great number of podosomes (often more than 100 per 
cell), while only relatively few invadopodia are found in cancer cells (approximately 10 
per cell depending on cell type)300, 301. Invadopodia typically have a longer protrusive 
length (> 2 µm) compared to podosomes (0.5 - 2 µm), which make them able to protrude 
deeper into the ECM300-303. Besides, invadopodia are more persistent as they can be 
stable for over an hour, while podosomes are more dynamic and have a lifetime of 
several minutes300-302, 304. This makes the degradation pattern of an invadopodium 
deeper and more focused than in case of a podosome269, 301.  
The metastasis of malignant cancer cells has a striking similarity to some extent to 
embryonic development where similar protrusive cytoskeletal structures are previously 
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observed in e.g. Drosophila, Caenorhabditis elegans and Danio rerio (zebrafish)301. 
Altogether, invadosomes play a part in physiological or pathological processes such as 
development, inflammation and cancer.  
3.3.3 Focal adhesions 
Other actin based protrusions have been found that show more similarity to 
invadosomes than expected, while their nanoarchitecture is very different304. Those 
structures are called focal adhesions and are streak-like adhesion structures which link 
the actin cytoskeleton to the ECM (Figure 21B)292, 305. Focal adhesions are found at the 
end of stress fibres where they are connected to adhesion molecules such as integrins278, 
305. They function as signalling and attachment sites to the ECM269 and they are able to 
degrade the ECM to some degree300, 305. Focal adhesions have been suggested to be a 
precursor of invadosomes298, 304, 306.  
The focal adhesion kinase (FAK) is a cytoplasmic cytoskeleton-associated tyrosine kinase 
and it is mostly found at focal adhesions300, 301, 307. Although FAK does not localize to 
invadopodia, it still has an important role in its formation301, 308. FAK keeps the tyrosine 
phosphorylation in balance between invadopodia and focal adhesions301, 308. The 
depletion of FAK in focal adhesions acts as a switch from focal adhesion to invadopodium 
initiation by causing an increase of the phosphorylation levels of invadopodium-
associated proteins (such as tyrosine kinase substrate with five SH3 domains (Tks5))289, 
301, 308. Due to the depletion of FAK and to the change in phosphorylation levels, 
adjustments in the membrane will occur leading to the accumulation of 
phosphatidylinositol-(3,4)-biphosphate (PI(3,4)P2) which is found to recruit the N-
WASp:Arp2/3 invadosome precursor293, 298. 
3.3.4 Formation of an invadopodium 
Invadopodia are estimated to contain approximately 129 different invadopodium key 
proteins283, 309, 310. These are all necessary in a proper formation of invadopodia, including 
signalling proteins, membrane remodelling proteins, actin and actin-regulatory proteins, 
adhesion proteins and matrix degrading proteins303, 310, 311. Some of those proteins and 
the formation of an invadopodium will be discussed in the next paragraphs. 
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3.3.4.1 Initiation  
Invadopodia can be induced through different stimuli which rely on the activation of the 
GTPases of the Rho family298. Mostly it does not depend on only one stimulus, but a 
combination of the below described stimuli. The origin of the stimuli can be extracellular 
and/or intracellular. 
3.3.4.1.1 Growth factors 
Soluble growth factors are an important extracellular factor that can initiate the 
invadopodium formation. Once a growth factor is sensed, a signal cascade will be 
triggered as this is the case for epidermal growth factor (EGF) and its receptor (EGFR)312, 
313. This pathway will recruit Src, leading to the phosphorylation of Arg (Abl-related 
gene), an Abl-family kinase, resulting in the initiation of the cascade314. Other growth 
factors are possible as well, e.g. transforming growth factor β (TGFβ), hepatocyte growth 
factor (HGF), platelet derived growth factor (PDGF)269, 315, 316 and vascular endothelial 
growth factor (VEGF)269. 
3.3.4.1.2 Oncogene expression  
Oncogene expression can also play a role in the initiation, such as proteins of the Src 
family kinases293. The primary role of cellular Src kinase (c-Src) is believed to regulate cell 
adhesion, invasion, and motility306. Scientists already concluded that c-Src is a possible 
master switch for invadosome formation for three reasons298, 300. First, the Src family 
kinases are activated by PDGF and EGF289, 315. Second, they are able to mediate integrin 
signals to the actin cytoskeleton289 and lastly, they phosphorylate important proteins 
that are necessary for the formation of invadosomes (e.g. cortactin and Tks5)289, 317. 
3.3.4.1.3 Extracellular matrix properties 
The extracellular matrix (ECM) consists of different components such as collagen, laminin 
and fibronectin271. The amount of matrix cross-linking, which is related to matrix rigidity, 
is supposed to regulate the formation of an invadopodium269, 271. In addition, a lower 
pH269, 271 (caused by cortactin and the sodium hydrogen exchanger NHE1) and the 
presence of matrix metalloproteinase (MMP) activity315 can further induce 
invadopodium formation318. Next, integrins are adhesion receptors for ECM 
components271, 315, 319. They function as a bridging molecule as they are able to translate 
an extracellular signal to an intracellular one and vice versa289, 300. When a surface 
integrin interacts with substrate components, this results in the initiation of 
invadopodium formation312. The kind of integrins responsible for the start depends on 
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the cell type312. Mostly, a β1 integrin is responsible for the initiation of the invadopodium 
formation pathway316, 320.  
3.3.4.1.4 Focal adhesion kinases 
While FAK is mostly found in focal adhesions, it binds to β1 and β3 integrins as well as to 
Src300. FAK is known to be an important regulator of Src301. As mentioned before, FAK 
does not localize to an invadopodium but it has an important role in invadopodium 
formation301, 308. Phosphorylated FAK (Y397) recruits active Src to focal adhesions to 
mediate localized tyrosine phosphorylation289, 301, 308. This limits the invadopodium 
formation308. However, when FAK is depleted, active Src is released which increases the 
phosphorylation of invadopodium-associated proteins (such as Tks5) and enhances the 
invadopodium formation289, 301, 308, 321. The depletion of FAK induces a switch from focal 
adhesion to invadopodium initiation308. 
3.3.4.1.5 Phosphoinositides 
Phosphoinositides are phospholipids found in the cell membrane. Depending on an 
extracellular signal, they are able to initiate the invadopodium formation pathway306. It is 
known that phosphoinositide(3)-kinase (PI3K) is activated through the Src-FAK 
pathway306. This PI3K creates products such as phosphoinositol-(3,4,5)-triphosphate 
(PI(3,4,5)P3) which is available in negligible amounts under normal circumstances
293, 306. 
Due to its increase in concentration, several cytosolic proteins are recruited to the 
membrane306. The newly formed PI(3,4,5)P3 will bind to the pleckstrin homology (PH) 
domain of guanine nucleotide exchange factors (GEFs)306. Through those GEFs, 
PI(3,4,5)P3 is able to modulate the functions of GTPases of the Rho family (such as 
Cdc42), which takes part in the invadopodium formation precursor306. 
The higher amount of PI(3,4,5)P3 results also in higher amounts of PI(3,4)P2, which is also 
rarely present in normal circumstances293, 306. This is due to the dephosphorylation of 
PI(3,4,5)P3 by PI(3,4,5)P3 5-phosphatases (such as synaptojanin2)
306. PI(3,4)P2 recruits 
Tks5 to the membrane which is important to form the invadopodium formation 
precursor293, 306. 
3.3.4.2 Overview of the initiation  
As mentioned above, there are different options to begin the cascade of the 
invadopodium formation. Mostly it is a combination. A possible pathway is described 
here as an overview (Figure 22).  
 48 
Due to ECM components and their properties, the cytoplasmic tail of β1 integrin will bind 
to the non-receptor tyrosine kinase Arg289, 315. This interaction unmasks the Y272 of Arg 
leading to Arg autophosphorylation and activation320, 322. Once EGF is sensed by its 
receptor EGFR, it can recruit the oncogene c-Src by its SH2 domain289, 313. Next, the 
recruited c-Src will perform a last phosphorylation on Arg Y439, leading to a fully 
activated Arg314, 320. In its turn, the fully active Arg will phosphorylate cortactin on Y421 
and Y466314.  
 
Figure 22: Schematic visualisation of the invadopodium formation pathway: the initiation. Extracellular signals, such as 
ECM and EGF, can trigger the start of the invadopodium formation by interacting respectively with integrins (αβ) and EGFR. 
While integrin binds Arg causing autophosphorylation, EGFR recruit c-Src. Next, c-Src will initiate different responses. c-Src 
phosphorylates Arg which eventually leads to cortactin phosphorylation. It also recruits PI3K which increase the PI(3,4,5)P3 
levels and triggers synaptojanin2 to creates more PI(3,4)P2. The later leads to recruitment of Tks5 which will be 
phosphorylated by c-Src as well. Additionally, c-Src activates GEFs which creates activated GTPases such as Cdc42. Cdc42 
interacts on its turn with TOCA1 that is able to cause membrane curvature. (Arg, Abl-related gene; αβ, α unit and β unit of 
an integrin; Cdc42, cell division cycle 42; Cort, cortactin; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, 
epidermal growth factor receptor; GEF, guanine nucleotide exchange factor; PI3K, phosphoinositide 3-kinase; PIP2, 
phosphatidylinositol-(3,4)-biphosphate; PI(4,5)P2, phosphatidylinositol-(4,5)-biphosphate; PIP3, phosphoinositol-(3,4,5)- 
triphosphate; c-Src, cellular Src kinase; SYNJ2, synaptojanin2; Tks5, tyrosine kinase substrate with five SH3 domains; TOCA1, 
transducer of Cdc42-dependent actin assembly protein 1) 
Src also activates guanine nucleotide exchange factors (GEFs), which stabilize the active 
state or the GTP-bound state of GTPases315, 323. At the same time, activated c-Src recruits 
PI3K which creates an increased PI(3,4,5)P3 level. PI(3,4,5)P3 binds GEFs
306. In their turn, 
these GEFs bind to and activate GTPase Cdc42298, 306. This locates Cdc42 at the membrane 
which will cause a recruitment of the transducer of Cdc42-dependent actin assembly 
protein 1 (TOCA1), an F-BAR protein323, 324. TOCA1 binds to phosphatidylinositol-(4,5)-
biphosphate (PI(4,5)P2) and Cdc42
324. TOCA1 is known to cause the membrane 
curvature325. 
Because of the elevated levels of PI(3,4,5)P3 and because of Src phosphorylation of the 
phosphatase synaptojanin2, dephosphorylation of PI(3,4,5)P3 will occur, thus creating 
PI(3,4)P2 which leads to the recruitment of Tks5
306, 326. The activated c-Src phosphorylates 
Tks5 at Y558317. 
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3.3.4.3 The initiation leads to the invadopodium precursor  
For the formation of an invadopodium, a nucleation complex or precursor must be 
formed. This precursor will contain actin nucleators to perform the actual actin 
polymerization, and actin nucleation promoting factors (NPF) which are required to aid 
the actin nucleator to create a more efficient actin polymerisation301. In this first 
polymerization step, a branched actin network is generated. The actin nucleator 
responsible here is the actin related protein 2/3 (Arp2/3). Arp2/3 consists of seven 
subunits of which only two are actin associated, Arp2 and Arp3327. The branched actin 
network is created by adding actin polymers at a 70° angle to the existing mother 
filament (Figure 23)273. Arp2/3 in itself is not able to cause rapid actin polymerisation, it 
needs the aid of NPFs. Those NPFs trigger a conformational change in the Arp2/3 
complex to reposition the Arp2 and Arp3 subunits into a filament-like conformation327. 
This change enables the Arp2/3:NPF complex to induce actin polymerisation at the 
barbed ends of actin filaments327. NPFs promote also the binding of the Arp2/3:NPF 
complex and the newly formed filament branch to the pre-existing mother filament327. A 
known nucleation promoting factor for invadopodia is N-WASp due to its important VCA 
domain (verprolin-homology (V), cofilin-homology or central (C) and acidic (A) region). It 
contains even a duplication of the V part, also known as WASp homology (WH2) domain, 
which binds directly to actin monomers and delivers it to Arp2 and Arp3327. The second 
part of the VCA domain, the CA part, interacts directly to Arp2/3 which is needed to fully 
activate Arp2/3328. 
 
Figure 23: Actin polymerisation via Arp2/3. The actin nucleator Arp2/3 creates a branched actin network by adding actin 
polymers at a 70° angle to the existing mother filament. Actin nucleation promoting factors (NPF) are required for 
enhancing the actin polymerisation. While they trigger a conformational change of Arp2/3 causing a more active Arp2/3, 
they also promote the binding of the Arp2/3:NPF complex and of the newly formed filament branch to the pre-existing 
mother filament. A known nucleation promoting factor for invadopodia is N-WASp. Figure is adapted and modified from 
mechanobio.info. 
Since cortactin is phosphorylated (see 3.3.4.2 Overview of the initiation), the activated 
cortactin will recruit Nck1, an adapter protein (Figure 24, left panel)314, 329. Besides, the 
phosphorylated Tks5 is also able to recruit Nck1 to the membrane317, 329. Due to the 
interaction between WASp-interacting protein (WIP) and Nck1, N-WASp is recruited to 
the invadopodium site268, 317, 329, 330. Nck1 binds N-WASp to facilitate Arp2/3 activation330. 
Once N-WASp is located at the invadopodial site, a WIP release and TOCA1 binding will 
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happen simultaneously323, 324. TOCA1 increases the affinity of N-WASp for Cdc42 which 
leads to the interaction of the GTP-bound Cdc42 to N-WASp causing a conformational 
change of N-WASp (Figure 24, left panel)271, 298, 323, 324, 331. This change leads to the 
activation of N-WASp298, 323. In the open conformation, N-WASp activates Arp2/3 by 
binding to the CA part of its VCA domain301. This process is enhanced by cortactin 
because cortactin acts as a scaffold to bring Arp2/3 and N-WASp together329. The N-
WASp binding to Arp2/3 causes a conformational change in the Arp2/3 complex332. In 
that case, Arp2 and Arp3 are in closer proximity and form a ‘pseudo actin dimer’ which is 
necessary to enable the rapid actin polymerisation332. Now that the precursor consists of 
cortactin:N-WASp:Arp2/3, cofilin will interact with cortactin as well (Figure 24, middle 
panel)329. Cofilin is also called an actin depolymerizing factor (ADF) and severs actin 
filaments in order to create a pool of actin monomers and free barbed ends301. However, 
when cofilin is bound to the precursor, it inhibits its severing function329. Due to a 
phosphorylation on cortactin, cofilin can be released329, 333 which allows cofilin to sever 
actin filaments resulting in the creation of free barbed ends (Figure 24, right panel)313, 334, 
335. Arp2/3 is able to occupy these free barbed sites on which actin polymerization will 
start leading to the creation of a branched actin network301. Because the actin 
polymerisation must happen at the membrane of the invadopodial site, many proteins 
try to ensure this by anchoring the precursor at the membrane such as Tks5, TOCA1, 
Cdc42 and PI(4,5)P2
326, 336, 337. 
 
Figure 24: Schematic visualisation of the invadopodium formation pathway: the precursor formation. Phosphorylated 
cortactin and phosphorylated Tks5 recruit Nck1 (left panel). Due to the interaction between WIP, Nck1 and N-WASp, N-
WASp will be activated. This results in the formation of the precursor in which N-WASp, Arp2/3, actin, cortactin, TOCA1, 
Cdc42 and cofilin participate (middle panel). Due to a phosphorylation on cortactin, the cofilin interaction is interrupted. 
This results in the severing activity of cofilin which creates actin monomers and free barbed ends on which the precursor 
will start the actin polymerisation leading to a branched network (right panel). (Arp2/3, actin-related protein 2/3; Cdc42, 
cell division cycle 42; Cof, cofilin; Cort, cortactin; ECM, extracellular matrix; G-actin, globular actin or actin monomers; GTP, 
guanosine triphosphate; PIP2, phosphatidylinositol-(3,4)-biphosphate; PI(4,5)P2, phosphatidylinositol-(4,5)-biphosphate; 
Tks5, tyrosine kinase substrate with five SH3 domains; TOCA1, transducer of Cdc42-dependent actin assembly protein 1; 
Nck1, non-catalytic region of tyrosine kinase adaptor protein 1; N-WASp, neural Wiskott-Aldrich syndrome protein; WIP, 
WASp-interacting protein)  
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3.3.4.4 Maturation and ECM degradation 
Active N-WASp is found at the base of invadopodia which implies that the                        
N-WASp:Arp2/3 complex is creating a dense branched actin network at the base of the 
invadopodium298, 338. However, to push the membrane deeper into the ECM, maturation 
of the invadopodium has to occur. This happens by elongating the invadopodium which 
requires the stabilisation of the branched actin network and the creation of a 
filamentous structure295, 298. Steadying the branched network is established by stabilising 
the precursor through restoring the binding between cofilin to cortactin (Figure 25, left 
panel)301. This inhibits the severing capacity of cofilin resulting in a lower concentration 
of actin monomers which stops the fast actin polymerisation301. Starting from the 
branched actin network, actin filaments will grow to create an actin filamentous actin 
structure that forces the membrane deeper into the ECM (Figure 25, right panel)295, 298. 
The proteins responsible for this actin polymerisation are the actin nucleators of the 
Diaphanous-related formin (DRF) / mDia family298, 316. To strengthen this actin 
filamentous core structure, cross-linking or F-actin bundling proteins such as α-actinin 
and fascin are found to be important in this stage (Figure 25, right panel)293, 298. 
 
Figure 25: Schematic visualisation of the invadopodium formation pathway: the maturation. Once a branched network is 
formed, the invadopodium needs to be pushed deeper into the ECM. At this point the precursor stabilise by rebinding of 
cofilin (left panel). From the branched network, formins create a filamentous actin structure to elongate the invadopodium 
(right panel). F-actin bundling proteins, actinin and fascin, stabilise and strengthen this filamentous bundled actin structure. 
Next to the elongation, the ECM degradation is occurring as well through membrane bound (e.g. MT1-MMP) and soluble 
proteases (e.g. MMP2, MMP9 and ADAM). (Actn, actinin; ADAM, a disintegrin and metalloprotease; Arp2/3, actin-related 
protein 2/3; Cdc42, cell division cycle 42; Cof, cofilin; Cort, cortactin; ECM, extracellular matrix; Fas, Fascin; G-actin, globular 
actin or actin monomers; GTP, guanosine triphosphate; MMP, matrix metalloproteinase; MT1-MMP, membrane type I 
matrix metalloproteinase; N-WASp, neural Wiskott-Aldrich syndrome protein). 
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The maturation also includes a recruitment of proteases which will be released 
extracellularly to enable the ECM degradation (Figure 25, right panel). Three main classes 
of proteases were detected around invadosomes269. The first are zinc-regulated metallo-
proteases such as matrix metalloproteinases (MMPs)339, 340 and ‘a disintegrin and 
metalloprotease’ (ADAM) family proteases341. The other two classes are cysteine 
proteases (e.g. cathepsin) and serine proteases (e.g. seprase)269, 289, 316. Besides, the most 
prominent proteases at invadosomal sites are the MMPs. The membrane type I matrix 
metalloproteinases (MT1-MMP, also known as MMP14) is seen as master switch since 
MT1-MMP activates other soluble MMPs269, 339. MT1-MMP is capable of cleaving an        
N-terminal pro-domain from pro-MMP2 to gain the activated MMP2, while pro-MMP9 
needs MT1-MMP, MMP2 and MMP3 to be activated342, 343. 
At the invadopodium, the MT1-MMP is anchored through its 20 amino acid cytoplasmic 
tail by a dense actin network limiting its mobility (Figure 26E), while high dynamics and 
high internalisation rates were detected when it is found at non-invadosome 
membranes316. The fixed positioning of MT1-MMP in invadopodia allows a more 
optimised ECM degradation functioning344. The actin network that stabilise the MT1-
MMP at its cytoplasmic tail is mediated by e.g. N-WASp:Arp2/3344, 345. An accumulation of 
MT1-MMP at the membrane is important for the invasive character of the 
invadopodium316. This occurs through different ways. It was previously observed that 
invadopodia are formed proximal to the Golgi apparatus299, 346. One of the ways to 
accumulate MT1-MMPs is through newly synthesized MT1-MMPs transported from Golgi 
to the plasma membrane (Figure 26A). This is controlled by exocyst complex347, 348 which 
is an octameric complex consisting of six vesicle-associated proteins and of two plasma 
membrane-associated proteins302, 316. Once arrived at the membrane, this complex 
functions as tethering complex which enhances the exocytosis by keeping the vesicle 
close to the membrane until the SNARE-fusion machinery acts349, 350. This is also 
controlled by Cdc42 and RhoA298, 347. Additionally, soluble MMPs are mainly secreted via 
secretory vesicles from Golgi to the membrane (Figure 26B)351, 352. However, the exocyst 
complex is not suggested causing the MMP2/9 transport, but Rab40b is supposed to 
achieve this351. Next, another way to have an accumulation of MT1-MMP is through 
recycling processes like clathrin- and caveolae-mediated endocytosis (Figure 26C)344, 353, 
354. Through the cytoplasmic tail of MT1-MMP, a direct interaction takes place with the 
clathrin adaptor complex344. The Cdc42-interacting protein 4 (CIP4) is an F-BAR protein 
that helps in the formation of endocytic vesicles, while it also interacts with N-WASp, 
Cdc42 and dynamin331. In this way, CIP4 promotes the curvature and the scission of the 
budding vesicles and it forms a link between the membrane curvature and the localised 
actin remodelling331. Because of the interaction with N-WASp, it is possible to activate 
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the actin polymerisation process (cortactin:N-WASp:Arp2/3) in proximity of the 
endocytic vesicles and to form a branched actin network331, 353. This creates a driving 
force to reshape the membrane and to facilitate the pinching off of the endosome331, 353, 
355. 
The vesicular transport is important to recruit MMPs to the invadopodial site. It is 
previously observed that the vesicular transport is enhanced by actin comet tails (Figure 
26D)356, 357. Those comet tails give a propelling force to enhance the movement of the 
vesicles through e.g. an invadopodium357, 358. Also here, an association of the MMP 
pathway and N-WASp:Arp2/3 actin polymerisation pathway is found to create those 
actin comet tails359-361. 
 
 
 
 
 
Figure 26: Schematic visualisation of the invadopodium formation pathway: the accumulation of MMPs. At the Golgi, 
vesicles with newly synthesized MMPs are transported to the membrane at invadopodial sites. This depends on two 
systems; the exocyst complex for MT1-MMP (A) and Rab40b for the soluble MMP2 and MMP9 (B). (C) The recycling process 
(e.g. clathrin- and caveolae-mediated endocytosis) helps in the accumulation of MT1-MMP as well. The actin cytoskeleton 
facilitates the budding of vesicles. (D) The transport of MMP containing vesicles through the invadopodium is enhanced by 
the actin polymerisation by creating comet tails. (E) A branched actin network at the intracellular tail of MT1-MMP 
promotes a better ECM degradation. (MMP, matrix metalloproteinase; MT1-MMP, membrane type I matrix 
metalloproteinase) 
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 Neural Wiskott-Aldrich syndrome protein or N-WASp 3.4
3.4.1 Wiskott-Aldrich syndrome 
In 1937, Alfred Wiskott described three brothers who were affected by an innate 
thrombocytopenia (a decreased number of small platelets)362, 363. They all suffered from 
bloody diarrhea, eczema and recurrent infections which led to their death363. In that 
time, the cause was still not known. These patients were the first to be described to have 
the Wiskott-Aldrich syndrome (WAS)362. In 1954, Robert Aldrich studied a family which 
suffered from an X-linked recessive thrombocytopenic purpura364. Later on, the discovery 
of the WAS gene clarified that the mutants of its corresponding Wiskott-Aldrich 
syndrome protein (WASp) seemed to be responsible for those phenotypes which were a 
result from defected podosome formation in macrophages298, 365. Since then, those 
patients were identified to have the WAS disease362. WAS is a rare X-linked recessive 
immunodeficiency disorder which affects approximately 1 out of 250 000 Europeans298, 
366. It is characterised by immunodeficiency, eczema, autoimmunity and/or micro-
thrombocytopenia366. The syndrome is caused by gene mutations which can be highly 
variable, going from nonsense to missense mutations269, 366. This can result in the 
expression of the full-length WASp with changes in the amino acid sequence, a 
shortened protein or even no expression366. The cause of suffering for WAS patients, is 
found in the loss of podosomes in the cells of the hematopoietic lineage269. Early studies 
clearly show a defective podosome formation in macrophages of WAS patients269. The 
severity of the syndrome depends on the kind of mutation and the residual expression 
that is left362, 366. The worst scenario is the one of the classical WAS patients. They suffer 
from a loss-of-function mutation meaning the WASp expression is fully disabled362. 
Another group with a milder form of WAS are the X-linked thrombocytopenia (XLT) 
patients357, 362. These patients have a partial WASp expression and suffer from low 
platelets and minimal immunodeficiency362. In those patients the mutations is mostly 
found in the VCA domain367. When the mutations lead to a constitutively active form of 
WASp, this causes X-linked neutropenia357.  
3.4.2 Wiskott-Aldrich syndrome protein family 
The discovery of the syndrome introduced a new protein family as well, the Wiskott-
Aldrich syndrome (WAS) protein family. The WAS protein family proteins are known to 
be effectors of the Rho family GTPases and are able to induce rapid actin polymerisation 
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underneath the membrane293. This protein family has a wide variety of functions of this 
family, from physiological to pathological processes. They play a role in the immune 
response, tissue morphogenesis, synaptogenesis, pathogen infection, cancer invasion 
and metastasis293. Members of this family can either enhance or suppress cancer 
malignancies depending on the cell type and pathological state of the cancer293. 
Proteins of the WAS protein family are all characterized by two important domains. The 
first is a proline rich or poly-proline region293, 357. The second is a VCA domain which can 
be divided into three subdomains. The first is a V or verprolin-homology region which is 
able to directly bind to actin294, 357. The other two are a C and an A region which stands 
for cofilin-homology or central region and acidic region, respectively293, 357. This CA region 
directly binds to Arp2/3294.  
The WASp protein was the first member of the WAS protein family. It is a protein of 502 
amino acids362. N-WASp or neural Wiskott-Aldrich syndrome protein has the highest 
homology with WASp (approximately 50% of the overall identity)368. Next to WASp and 
N-WASp, this protein family contains ‘WASP family verprolin-homologous’ protein 
(WAVE) or ‘suppressor of cAR’ (SCAR), ‘WASp and SCAR homologue’ protein (WASH), 
‘WASp homologue associated with actin, membranes, and microtubules’ protein 
(WHAMM), ‘junction-mediating and regulatory’ protein (JMY), ‘WASP and missing-in-
metastasis like’ protein (WAML) and ‘WASp without WH1 domain’ protein (WAWH)293, 
357, 369. 
3.4.3 N-WASp 
N-WASp or neural Wiskott-Aldrich syndrome protein is the expressed product from the 
WASL gene370. It is a scaffold protein consisting of 505 amino acids370. N-WASp is an actin 
nucleation promoting factor. By binding actin nucleation factors such as Arp2/3, N-WASp 
enhances the formation of a branched actin network. It is an important factor in 
enhancing the metastasis by assisting in the formation of invadopodia in cancer cells.  
Since migration is also found in embryonic development, it is suggested that N-WASp 
plays a role in it as well291. Next to migration and degradation processes, N-WASp is 
supposed to stabilize podocyte foot processes in kidneys by maintaining the actin 
cytoskeleton371, 372. When making an N-WASp knock-out mouse model, total loss of          
N-WASp caused embryonic lethality291. While conditional knock-outs in brain or muscle 
cells were lethal, mice with a knock-out in epidermal keratinocytes of the skin are viable, 
but result in complications such as growth defects291. Gligorijevic et al., who showed the 
first invadopodia in vivo, used a xenograft model containing N-WASp knockdown cells373. 
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They observed a significant decrease of invadopodium formation, intravasation and 
metastasis using intravital imaging301, 373. When performing RNAi or expression of 
dominant negative N-WASp, it is observed that the ability to invade decreases344, 374 and 
a nearly complete disruption of invadopodia is detected293, 316. Contrary, overexpression 
of N-WASp stimulates migration and invasion while the cell apoptosis is decreased375. 
WASp and N-WASp are very similar and show almost 50% sequence identity362. While 
WASp is expressed in only non-erythroid hematopoietic cells, N-WASp is ubiquitously 
expressed357, 368. Podosome formation is ascribed to WASp activity, but Isaac and 
colleagues observed that in WASp-deficient macrophages N-WASp could functionally 
compensate for WASp loss283, 376. After the activation of WASp-deficient macrophages, 
they detected an increased N-WASp level and an increase in the macrophage 
functionality376. However, the matrix degradation capability was less efficient compared 
to when WASp is available376. Still, this leads to the acceptation that N-WASp could 
partially replace WASp283, 376.  
3.4.3.1 The domains of WASp and N-WASp 
Starting at the N-terminus, the first domain is the WASp homology 1 (WH1) domain, also 
known as the Ena-VASP homology 1 (EVH1) domain (Figure 27)357. This domain is 
important in keeping the (N-)WASp in an auto-inhibited state by interacting with the 
WASp-interacting protein (WIP)377, 378. Once (N-)WASp is activated, the WH1/EVH1 
domain assists in the recruitment of (N-)WASp via Nck to the membrane379. 
 
Figure 27: Schematic representation of the domains of WASp and N-WASp. Starting from the N-terminus, the WASp 
homology 1/Ena-VASP homology 1 (WH1/EVH1) domain is the first domain, followed by a basic domain. The third domain is 
a Cdc42- and Rac-interactive binding region or GTPase binding domain (CRIB/GBD). Next a proline-rich domain is found. At 
last, the VCA domain is most important in de actin polymerisation and is divided in three sub domains: the verprolin-
homology (V) region, the C (cofilin-homology or central) region and the A (acidic) region. 
The following domain is the basic region as there are multiple lysine and arginine 
residues357, 380. This domain can directly bind to PI(4,5)P2 which partially activates           
(N-)WASp380. The C-terminal neighbouring domain of this basic region is the Cdc42- and 
Rac-interactive binding region (CRIB) or GTPase binding domain (GBD) (Figure 27). This 
CRIB/GBD domain binds the active form of the GTPase Cdc42 which also activates         
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(N-)WASp293. By the cooperation of the basic and the CRIB/GBD region, the (N-)WASp 
protein will be activated synergistically362, 367.  
As mentioned before, the next domains are typical for the WAS family: a proline-rich 
domain and a VCA domain (Figure 27). The proline-rich or poly-proline domain interacts 
with SH3 containing proteins and has a localisation and signalling function357. It is able to 
interact with the non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1), Cdc42-
interacting protein 4 (CIP4), profilin and others366. The poly-proline domain is able to 
accelerate the polymerisation activity by providing a pool of monomeric actin367, 381. This 
is caused by the binding with profilin-actin complexes which shuttles the actin 
monomers to the following domain, the V region of the VCA domain367, 381. This part of 
the VCA domain is also called verprolin-homology or WASP homology 2 (WH2) region 
and is able to bind actin327, 357, 381. The other two regions of the VCA domain are the C 
(cofilin-homology or central) and A (acidic) region. They interact directly with Arp2/3294, 
382. The VCA domain is the most important part for actin polymerisation. A noticeable 
difference between WASp and N-WASp is found in the VCA domain. N-WASp contains a 
duplication of the V region, while WASp only has one V region357. This tandem array of 
the V region is supposed to promote the actin nucleation, due to a more efficient actin 
delivery to Arp2/3, and to localize N-WASp between the membrane and the barbed ends 
more efficiently compared to a single V region357. 
3.4.3.2 From an auto-inhibition state to an activated protein 
N-WASp and WASp are found in two conformations (Figure 28). In normal cells they are 
found in the cytosol in an auto-inhibited resting state (Figure 28A)293, 362. In this 
conformation, the VCA domain is shielded and is unable to bind actin or Arp2/3. The 
basic domain and the CRIB/GBD domain are causing the inactive closed conformation by 
interacting with the A region and the VC region respectively366, 383, 384. To maintain the 
inhibited state, the WH1/EVH1 domain is bound to WIP362, 366. 
When WIP is released, the F-BAR protein TOCA1 binds to N-WASp323, 324. This protein is 
important for increasing affinity of N-WASp for Cdc42 and is important for the curvature 
of the membrane in the invadopodium initiation324. While WIP helps in maintaining the 
closed conformation, guanosine triphosphate (GTP)-bound Cdc42 disrupts the inactive 
state362. When GTP-bound Cdc42 binds to the CRIB/GBD domain of N-WASp, it will open 
its conformation (Figure 28B)362, 366. Besides, the basic domain participates also in the 
activation by binding to phosphatidylinositol-4,5-biphosphate (PI(4,5)P2)
362, 366. Together, 
they have a synergetic effect on the activation of (N-)WASp362. Once in the open 
conformation, the proline-rich region is available for binding SH3 domain containing 
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proteins362. It even can bind Src, which can phosphorylate WASp on Y291 or N-WASp on 
Y256293, 331, 362. This phosphorylation will only happen when (N-)WASp is in the open 
conformation and creates a kind of ‘memory’ mechanism that reminds (N-)WASp of its 
activated state even long after the initiating signals were present331. Not only the poly-
proline region is accessible, also the VCA domain is available. After the activation, the V 
region can bind monomeric actin, where the CA region will bind Arp2/3 leading to the 
initiation of actin polymerisation to create a branched actin network293, 362. 
 
Figure 28: Conformations of N-WASp, from auto-inhibited to activated state. (A) Due to the auto-inhibition state, VCA is 
not available to induce the actin polymerisation. The basic domain and the CRIB/GBD domain are bound to the A region and 
the VC region respectively. The WASp-interacting protein (WIP) interacts with WH1/EVH1 to maintain the inhibited state. 
(B) In the active conformation, the WIP interaction is replaced by TOCA1, leading to an increased affinity of the CRIB/GBD 
domain for GTP-bound Cdc42. While the VCA domain is no longer shielded, it interacts with actin monomers and Arp2/3. 
The basic domain will interact with PI(4,5)P2 at the plasma membrane and the proline-rich domain is available for binding 
SH3 domain containing proteins such as Src, cortactin … . 
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  Chapter 4
Scope 
One of the hallmarks of cancer is metastasis264. It is known that this is the most common 
cause of cancer deaths. Patients suffering from metastasis are likely to experience 
cancer-treatment failure which indicates the importance to search for new and better 
therapies to suppress the metastatic process385, 386. During metastasis and invasion, 
cancer cells gain more motility by hijacking normal cellular functions for their own 
purposes. For instance, they mimic the actin-based protrusions which are found in 
macrophages, to promote their invasiveness. These invadopodia are also known to 
enhance the spreading of such malignant cancer cells. However, it is only recently 
observed in vivo and accepted that invadopodia are important in this pathway373, 387. 
Buccione et al. were previously convinced that the disruption of invadopodia results in 
information which can lead to a better therapeutic development than the existing 
therapies312. Inside an invadopodium, many proteins are present and most of them are 
scaffold proteins, which makes it more challenging investigating since they lack an 
enzymatic activity. In the first part of this thesis, the VCA domain of the scaffold protein 
N-WASp is studied, since it is a suggested key domain to enhance the actin 
polymerisation during the invadopodium pathway. Our goal is to examine the role of this 
domain by using nanobodies and to unravel the mechanism of an invadopodium. The 
nanobody technology is used here as an alternative method to study intracellular 
proteins. An advantage of using this technology here, is that only a part of the protein is 
targeted, while methods like RNAi and CRISPR/Cas deplete the full length protein6, 84, 388. 
This allows us to study the importance of only a small part or a domain of a protein 
without altering its other interactions much. This way is ideal to examine only the VCA 
domain. 
In the second part, the goal was to establish an efficient and broadly applicable protocol 
to create nanobodies bearing a fluorophore. Current methods to visualise biomolecules 
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in a microscope are susceptible to improvement and suffer from a problem known as 
linkage error. Frequently, a primary and a labelled secondary antibody or a directly 
labelled primary antibody are used. These large antibodies introduce a space between 
the dye and the protein, leading to an inaccurate visualisation of the localisation of the 
protein of interest. Another commonly used method is by using fluorescent protein-
fusion proteins. This potentially alters the normal functioning of the protein or can 
trigger the same drawbacks as seen by overexpressed proteins. As nanobodies are a 
good equivalent of antibodies, they can be utilised to target endogenous proteins and 
visualise them, causing the linkage error to decrease. Next to the linkage error, a small 
size of the dye has beneficial effects on the imaging. The combination of a dye that is 
smaller compared to fluorescent proteins, and a nanobody that is smaller than an 
immunoglobulin, results in a higher resolution when used in fluorescence imaging. Due 
to these benefits, nanobodies can be a complementary tool to the existing visualisation 
methods. Different strategies to label nanobodies have been tested before, and they all 
have their own complications. We chose to incorporate an alkyne/azide moiety which 
allows chemical addition of a dye to the nanobody through the copper catalysed azido-
alkyne click chemistry (CuAAC) reaction. Two strategies were expounded in the second 
part of this thesis. In the first strategy an enzymatic coupling of a nanobody with an 
alkyne bearing peptide was used, while the second strategy incorporates a non-canonical 
amino acid in the nanobody sequence itself. For this project, nanobodies were selected 
which already were characterised before. Those nanobodies can be used for further 
analysing the architecture of an invadopodium by using super resolution microscopy 
thereby providing higher precision.  
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  Chapter 5
VCA nanobodies target N-WASp to reduce 
invadopodium formation and functioning 
Tim Hebbrecht
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, Adriaan Verhelle
a
 and Jan Gettemans
a
 
 Introduction  5.1
In this chapter, our goal was to characterize N-WASp nanobodies and to investigate the 
function of N-WASp in the invadopodium pathway. The nanobodies were generated in 
alpacas against the C-terminal domain of N-WASp, the VCA domain (verprolin-homology, 
cofilin-like and acidic region). It is known that N-WASp participates in invadopodium 
precursor formation to enhance the actin polymerization. Invadopodia are degrading 
structures formed by cancer cells, which promote cancer cell metastasis. The VCA 
domain of N-WASp is able to directly interact with actin and Arp2/3294, 381, 382, making it 
an important domain for actin polymerization. By using nanobody technology, we seek 
to determine the contribution of the VCA domain to actin polymerization and 
invadopodium formation.  
 
                                                   
a
 Department of Biomolecular Medicine (former department of Biochemistry), Faculty of Medicine and Health Sciences, 
Ghent University, B-9000 Ghent, Belgium 
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The N-WASp nanobodies highlight the importance of the VCA domain because the 
number of invadopodia is significantly reduced in cancer cells expressing one of these 
VCA nanobodies. Extracellular matrix degradation by cancer cells is also countered in the 
study. The results of this study lead to the conclusion that VCA nanobodies perturb the 
functioning of endogenous N-WASp in the cancer cells. However, the effect of the VCA 
nanobodies shows that the role of the VCA domain during the invadopodium formation 
is more prominent than during the ECM degradation process.  
 Research paper 5.2
The paper389 is published in PlosOne after a peer revision on September 22nd, 2017. 
5.2.1 Abstract 
Invasive cancer cells develop small actin-based protrusions called invadopodia, which 
perform a primordial role in metastasis and extracellular matrix remodelling. Neural 
Wiskott-Aldrich syndrome protein (N-WASp) is a scaffold protein which can directly bind 
to actin monomers and Arp2/3 and is a crucial player in the formation of an 
invadopodium precursor. Expression modulation has pointed to an important role for N-
WASp in invadopodium formation but the role of its C-terminal VCA domain in this 
process remains unknown. In this study, we generated alpaca nanobodies against the N-
WASp VCA domain and investigated if these nanobodies affect invadopodium formation. 
By using this approach, we were able to study functions of a selected 
functional/structural N-WASp protein domain in living cells, without requiring 
overexpression, dominant negative mutants or siRNAs which target the gene, and hence 
the entire protein. When expressed as intrabodies, the VCA nanobodies significantly 
reduced invadopodium formation in both MDA-MB-231 breast cancer and HNSCC61 
head and neck squamous cancer cells. Furthermore, expression of distinct VCA Nbs (VCA 
Nb7 and VCA Nb14) in PC-3 prostate cancer cells resulted in reduced overall matrix 
degradation without affecting MMP9 secretion/activation or MT1-MMP localisation at 
invadopodial membranes. From these results, we conclude that we have generated 
nanobodies targeting N-WASp which reduce invadopodium formation and functioning, 
most likely via regulation of N-WASp – Arp2/3 complex interaction, indicating that this 
region of N-WASp plays an important role in these processes. 
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5.2.2 Introduction  
Metastasis is the primary cause of cancer associated deaths. In this process cancer cells 
leave a primary tumour to disseminate through the entire body390. In doing so, these 
cancer cells are able to create secondary tumours throughout the body, a lethal process 
for the cancer patient in almost all cases390. In order to leave the primary tumour, cancer 
cells create small actin-based protrusions to facilitate their spreading391. Invadopodia are 
such malignant specialized structures known to enable cancer cells to invade through 
natural barriers387, 391. Invadopodium formation is found in highly invasive cancer cell 
lines374 and has been evinced in vivo387. A mature invadopodium displays considerable 
proteolytic activity. More specifically, invadopodium-related degradation of the 
extracellular matrix (ECM) has been linked to extravasation and metastasis in vivo392. 
Inside an invadopodium, approximately 129 different proteins can be found310. They 
contribute to the aggressive nature of invadopodia in cancer. Before an invadopodium 
can be formed, assembly of a precursor is required. This precursor will kick-start actin 
polymerisation towards the plasma membrane and invadopodia will arise329, 337, 344, 393.  
Activation of the Arp2/3 – N-WASp pathway, found to be important in invadopodium 
formation, has been observed in a broad spectrum of cancers394. Arp2/3 (actin related 
protein) is a protein complex existing of seven subunits, of which Arp2 and Arp3 are the 
only two proteins of the complex that are actin-related395. Once Arp2/3 is activated, 
those two subproteins will mimic two actin monomers to boost the actin 
polymerisation332, 395.  
The neural variant of WASp (N-WASp) is a ubiquitously expressed member of the 
Wiskott-Aldrich syndrome protein (WASP) family344, 396, 397. This family is known as 
nucleation-promoting factors of the Arp2/3 complex357 and fills the gap between 
reorganisation of the actin cytoskeleton and signalling molecules373, 398. Because N-WASp 
is a scaffold protein, it has several domains through which it interacts with interaction 
partners344, 396, 397. Using its C-terminal VCA domain, N-WASp can directly interact with 
actin monomers and the Arp2/3 complex. The VCA domain consists of a verprolin-
homology (V) domain (a.k.a. WASp homology 2 (WH2) domain), a cofilin-like or central 
(C) domain and an acidic (A) domain399. While the V domain is a binding site for actin 
monomers, the Arp2/3 complex binds the latter two parts (C and A domains)357, 397, 399-401. 
It has been shown in vitro that N-WASps VCA domain is needed during the formation of 
the invadopodium precursor336, 337, 373, 402. Moreover, by bringing actin monomers and 
Arp2/3 closer together, N-WASp stimulates and enhances the actin polymerisation383.  
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We generated alpaca nanobodies against the VCA domain of N-WASp (VCA Nb) to 
investigate the role of this region in formation of cancer cell invadopodia. Nanobodies 
are single-domain antibody fragments or, more specifically, the variable part of the 
heavy chain of Camelid heavy chain antibodies16. A nanobody is the smallest, natural, 
antigen binding fragment that completely retains its original binding affinity and 
specificity. Contrary to RNAi, intracellularly expressed nanobodies or so-called 
intrabodies can interfere with protein functions without silencing the whole protein. 
Moreover, intracellular nanobodies render the need for overexpression, siRNA or 
dominant negative mutants superfluous, which makes it able to study functions of 
endogenous proteins. By using VCA Nbs, we study the influence of N-WASps VCA domain 
in invadopodium formation and extracellular matrix degradation. Using breast, prostate 
and head and neck cancer cell lines that inducibly express these VCA nanobodies, we 
show that this N-WASp region indeed contributes to invadopodium formation and 
extracellular matrix remodelling, suggesting that it is involved in invadopodium based 
spreading of cancer cells. 
5.2.3 Results  
5.2.3.1 N-WASp recognising of VCA nanobodies 
Initially, 16 different nanobodies were identified through phage display following 
immunization with chemically synthesized N-WASp VCA domain (human N-WASp K420-
D505), lymphocyte collection and library construction. Based on their amino acid 
sequence, 10 different groups could be discerned. One nanobody was chosen from each 
group for biochemical characterisation. To detect antigen-nanobody binding in vitro, 
recombinant HA-tagged nanobodies were used in a pull down assay. MDA-MB-231 
breast cancer cell lysate was used as a source of endogenous N-WASp. Seven nanobodies 
out of 10 bound with the endogenous N-WASp (Figure 29).  
 
Figure 29: VCA nanobody - N-WASp binding. Pull down assay of endogenous N-WASp from MDA-MB-231 breast cancer cell 
lysate with HA-tagged VCA Nb (1, 2, 5, 6, 7 and 12, 13, 14, 15, 16) by means of anti-HA agarose beads. Two negative 
controls were included, anti-HA agarose beads were incubated with no nanobody (C1) or with a cortactin NTA nanobody 
against the N-terminal acidic (NTA) region of cortactin (C2). N-WASp was blotted and detected by anti-N-WASp antibody. To 
see the pull down of the 4 selected VCA Nbs using HNSCC61 cancer cells, which express EGFP-tagged VCA Nbs, see Figure 
30. 
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Figure 30: VCA nanobody—N-WASp binding in EGFP-tagged VCA Nb expressing HNSCC61. The EGFP-tagged VCA Nbs were 
pulled down using a GFP Ab and Protein G Sepharose beads. N-WASp is detected by N-WASp antibody and the VCA-Nbs by 
GFP Ab. 
5.2.3.2 Mitochondrial outer membrane anchoring and intracellular 
displacement of N-WASp 
To investigate whether the nanobodies would still bind their target in the reducing 
environment of the cytosol, we performed a MOM (mitochondrial outer membrane) 
delocalisation assay. In this experiment, the nanobodies were equipped with a MOM- 
and V5-tag at their N-terminus. The MOM-tag originates from yeast TOM70403 and 
redirects the tagged nanobodies to the mitochondrial outer membrane, which can 
confirm the intracellular binding capacity of VCA Nb to endogenous N-WASp. If N-WASp 
binds to the VCA Nbs, N-WASp will be found at the mitochondrial outer membrane 
which does not correspond with its natural subcellular localization. The effectiveness of 
the MOM-tag is first analysed by performing immunofluorescent assays visualising the 
mitochondria with MitoTracker Orange (Figure 31). This confirmed that the MOM-tagged 
nanobody patterns are similar to the mitochondrial patterns. Further, we will only look 
at the nanobody patterns as it stands for the mitochondrial patterns. Secondly, the        
N-WASp co-localisation is performed by visualising the VCA Nbs and N-WASp at the same 
time. In MOM-tagged EGFP Nb expressing control cells, no mitochondria-like pattern for 
N-WASp could be found (Figure 32, upper panel). The same was observed in MOM-VCA 
Nb1, 5 and 15 expressing cells. These are the same 3 nanobodies which did not bind N-
WASp in pull down experiments. All other MOM-VCA nanobodies resulted in a 
mitochondrial-like N-WASp distribution pattern. This was most obvious in MOM-VCA 
Nb2, 7, 13 and 14 expressing cells (Figure 32, lower panels). The intensity plots were 
determined as well to quantify the co-localisation (Figure 32, at the right). In conclusion, 
the nanobodies which were able to bind N-WASp in vitro (Figure 29) are also able to 
efficiently capture endogenous N-WASp in the dense intracellular environment, 
demonstrating their in vivo interaction with the target. 
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Figure 31: Mitochondrial pattern in MDA-MB-231 breast cancer cells which transiently express a VCA Nb equipped with a 
MOM-tag. Representative epifluorescence images showing the mitochondrial patterns indicating that the MOM-tag directs 
the nanobody to the mitochondrial outer membrane (compare with the MitoTracker channel). MOM-tagged EGFP 
nanobody was used as a negative control (upper panel). Nuclei were visualized with DAPI (blue), nanobodies with anti-V5 
antibody (green) and the mitochondria with MitoTracker Orange (red). (Scale bar = 10 μm) 
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The mitochondrial patterns of the MOM-tagged VCA Nb13 and VCA Nb14 show a 
dissimilar pattern compared to the control and the other VCA Nb conditions (VCA Nb2 
and VCA Nb7) (Figure 31 and Figure 32). These patterns were only found with the MOM-
tag which is used here to demonstrate binding. In all subsequent experiments this tag 
was not included and under these conditions the mitochondrial pattern looks the same 
for all nanobodies (Figure 33).  
 
 
 
 
Figure 32: VCA Nb2, 7, 13 and 14 capture endogenous N-WASp at mitochondria. Representative epifluorescence images of 
MDA-MB-231 breast cancer cells transiently expressing VCA Nbs equipped with a MOM-tag. MOM-tagged EGFP nanobody 
was used as a negative control (upper panel). Nuclei were visualized with DAPI (blue), nanobodies with anti-V5 antibody 
(green) and N-WASp with anti-N-WASp antibody (red). Right: the intensity profiles for N-WASp (red) and MOM-tagged 
nanobodies (green) are very similar, indicative of co-localisation, except for the EGFP nanobody (negative control). (Scale 
bar = 10 µm)  
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Figure 33: Mitochondrial pattern in MDA-MB-231 breast cancer cells in which EGFP-tagged VCA Nbs inducibly are 
expressed. Representative epifluorescence images showing the mitochondrial patterns. Nuclei were visualized with DAPI 
(blue) and the mitochondria with MitoTracker Orange (red). (Scale bar = 10 μm) 
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5.2.3.3  Affinity and stoichiometry of 4 selected VCA Nbs 
Based on the pull down and MOM delocalisation criteria, we determined the binding 
affinity and stoichiometric properties of 4 nanobodies; VCA Nb2, 7, 13 and 14. 
Isothermal titration calorimetry (ITC) was performed at physiological pH by using 
recombinant VCA Nbs (Figure 34). As these nanobodies were generated against a domain 
of N-WASp, we used chemically synthesized pure VCA peptide. The Kd values were 
determined at 0.699 ± 0.154 µM for VCA Nb2, 0.820 ± 0.201 µM for VCA Nb7, 0.685 ± 
0.133 µM for VCA Nb13 and 1.597 ± 0.249 µM for VCA Nb14 (Table 1 and Figure 34). 
These results showed that VCA Nb2, 7, 13 and 14 have a submicromolar affinity for the 
VCA peptide. This submicromolar affinity proved to be sufficient as the VCA nanobodies 
were able to relocate N-WASp to the outer membrane of mitochondria (Figure 32).  
 
Figure 34: Affinity study of VCA Nbs. ITC profiles of recombinant HA-tagged VCA Nbs with synthetic VCA peptide of human 
N-WASp. VCA peptide was titrated once with VCA Nb7 and once with VCA Nb14. VCA Nb2 and VCA Nb13 were titrated with 
VCA peptide. The upper panel shows the raw data of heat release in function of time, while the lower panel shows the 
fitted binding curve of total heat release per injection as a function of the molar ratio. 
 
 
Table 1: Thermodynamic parameters (and respectively standard deviations) of HA-tagged VCA nanobodies interacting 
with synthetic VCA peptide, determined by ITC. (
#
, molar ratio or stoichiometry; 
*
, ΔG = ΔH – T * ΔS with T = 303.15 K) 
Parameters VCA Nb2 VCA Nb7 VCA Nb13 VCA Nb14 
N
# 
0.912 ± 0.037 0.905 ± 0.037 0.757 ± 0.035 0.780 ± 0.031 
ΔH (cal/mol) -4657 ± 254 -4686 ± 258 -6967 ± 433 -3194 ± 165 
ΔS (cal/mol) 12.8 12.4 5.2 16.0 
ΔG (cal/mol)
*
 -8537.45 -8445.18 -8551.53 -8044.56 
Kd (µM) 0.699 ± 0.154 0.820 ± 0.201 0.685 ± 0.133 1.597 ± 0.249 
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5.2.3.4 The VCA Nbs interfere in the binding between N-WASp and its direct 
interaction partner Arp2/3, but not actin 
N-WASps VCA domain can directly interact with actin monomers via its V region and with 
Arp2/3 via its CA regions. To analyse if the VCA Nbs are able to interfere with the binding 
between N-WASp and either actin or Arp2/3, a pull down assay was performed by adding 
a concentration range of VCA Nb2, 7, 13 or 14 together with biotinylated VCA peptide 
and STREPTactin beads. As an Arp2/3 and actin source, we used MDA-MB-231 cell lysate 
(Figure 35). Via Western blotting, the amount of bound Arp2/3 and actin was quantified. 
A quadruplicate of this experiment was analysed with a Kruskal-Wallis test and Dunns 
post tests. Four different concentrations of each VCA Nb were added, based on the 
stoichiometry of VCA Nb to the VCA domain. The results show a dose dependent 
decrease of Arp2/3 binding with increasing concentrations of VCA Nb. While only VCA 
Nb2 and VCA Nb13 were able to show significant differences, the decreasing trend was 
found in all four VCA Nbs. This reduction in binding was not observed for actin, meaning 
that VCA Nbs do not disturb the interaction between N-WASp and actin and VCA Nbs do 
not interfere at the V region of the VCA domain.  
 
 
Figure 35: VCA Nb effect on actin or Arp2/3 binding to N-WASp using a nanobody concentration range. Pull down was 
performed by using biotin-tagged VCA peptide, MDA-MB-231 breast cancer cell lysate, recombinant VCA Nbs and 
STREPTactin beads. The two controls (no nanobody (No Nb) or EGFP Nb) show maximal Arp2/3 binding. A concentration 
range was used (VCA Nb : VCA domain stoichiometry of 0.5x, 1x, 2x, 4x). For each repeat, actin as well as Arp2/3 were 
analysed on western blot and quantification was done using ImageJ (bars represent mean and SEM, n=3). Kruskal-Wallis 
and Duns post test was performed. On top the influence of each VCA Nb on actin – N-WASp binding (A-D) is shown and at 
the bottom the effect of each VCA Nb on Arp2/3 – N-WASp binding (E-H) is shown.  
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5.2.3.5 VCA nanobodies reduce cancer cell invadopodium formation 
Before a fully mature invadopodium can be formed, an invadopodium precursor has to 
be created. N-WASp plays an important role in the latter344, 393, 394. The VCA domain of   
N-WASp brings Arp2/3 and actin monomers in close proximity to enhance actin 
polymerisation. This polymerisation creates actin-based protrusions, which in cancer 
cells may develop into invadopodia. To visualise N-WASp in invadopodia, a staining was 
performed of invadopodia markers (actin and cortactin) (Figure 36). Our findings clearly 
revealed N-WASp concentrated at invadopodium sites, which confirms previous 
research383, 394.  
 
 
 
Figure 36: N-WASp colocalizes with invadopodia markers. Representative epifluorescence images of HNSCC61 head and 
neck squamous cancer cells. Nuclei were visualized with DAPI (blue) and N-WASp (green) with anti-N-WASp antibody. 
Invadopodia were visualized by using an invadopodium marker; (A) actin (red) with Alexa Fluor labelled phalloidin and (B) 
cortactin (red) with anti-cortactin antibody. (Scale bar = 10 µm) 
 
To analyse if the VCA Nbs could influence invadopodium formation in different cancer 
cells, lentiviral, stable doxycycline-inducible MDA-MB-231 breast and HNSCC61 head and 
neck squamous cancer cell lines were made in which EGFP-tagged VCA Nbs are 
expressed as intrabodies. As a control, an EGFP-only expressing stable cell line was 
made. After nanobody induction overnight, the cells were fixed with paraformaldehyde 
and stained with phalloidin. When VCA Nb2, 7, 13 and 14 were expressed a significant 
reduction in invadopodia numbers was observed in both MDA-MB-231 and HNSCC61 
cancer cells (Figure 37).   
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Figure 37: Expression of VCA Nbs in cancer cells reduces invadopodia number. Representative epifluorescence images of 
HNSCC61 head and neck squamous cancer cells which express EGFP-tagged VCA Nbs (green) (A). Nuclei were visualized 
with DAPI (blue) and actin (red) with phalloidin. Bar plots of MDA-MB-231 breast (B) and HNSCC61 head and neck 
squamous (C) cancer cells, which inducible express EGFP- tagged VCA Nbs, were used to count invadopodia per cell. 
Quantification was done using ImageJ and Kruskal-Wallis and Dunns post tests were performed. As negative control EGFP-
only expressing stable cells were used. (* p < 5%, ** p < 1%, *** p < 0.01%)  
  77 
5.2.3.6 The VCA Nbs reduce overall matrix degradation 
A conspicuous and important link to metastasis is the proteolytic activity of a mature 
invadopodium392. Once this structure is formed, matrix remodelling follows, underlining 
the importance of matrix metalloproteinases (MMPs). MMPs are zinc-containing 
endopeptidases296, 309, 344, 391. The gelatinases MMP2 and MMP9 and the membrane 
bound collagenase MT1-MMP (also known as MMP14) are the most abundant MMPs. 
The latter is important since it acts as a master switch to activate other MMPs296, 309, 391, 
404. To analyse the effect of N-WASp nanobodies on matrix degradation, stable 
doxycycline-inducible PC-3 prostate cancer cell lines were constructed in which the 
EGFP-tagged VCA Nbs are expressed as an intrabody after adding doxycycline. As a 
control, an EGFP-only expressing stable cell line was made. In earlier studies we have 
used a similar approach45, 46, 48, 405-407. The cells were seeded on a Cy3-gelatin matrix and 
overnight induced with doxycycline (Figure 38A). Analysis was done with ImageJ45, 408 and 
a Kruskal-Wallis test and Dunns post tests were performed. First, the degradation index 
was determined. This parameter can be interpreted as the normalised difference 
between the mean grey value of the background (here the red fluorescent labelled 
gelatin matrix) and of the cell area. For two out of four VCA Nbs (VCA Nb7 and Nb14), 
significant less degradation was found (Figure 38B). The second parameter ‘degradation 
area per cell’ revealed significantly less degradation per cell for the same two VCA Nbs 
(Figure 38C). Thirdly, the ratio of ‘degradation area to total cell area’ was determined. 
This parameter gives only for VCA Nb14 a significant reduction in degradation per cell 
area (Figure 38D). In conclusion, only expression of VCA Nb7 and Nb14 in PC-3 cells 
resulted in reduced matrix degradation. 
Matrix remodelling is caused by proteolytic activity of invadopodia344, 392. The MMPs 
need to be transported through the invadopodia before they can perform their function 
extracellularly. N-WASp is suggested to form actin comet tails at vesicles, which brings 
the MMPs to the membrane356. These actin tails will give the vesicles a propelling force 
to help their movement. To study this, the secretion and activity in the medium of the 
most abundant MMP was analysed by zymography experiments with PC-3 prostate 
cancer cells. Initially, the purpose was to study either MMP2 and MMP9, but no MMP2 
activity was observed after 20 h of incubation, not even in the control experiment. We 
could observe a small decrease of MMP9 secretion/activity between the induced and the 
non-induced VCA Nb-EGFP expressing cell lines but these proved to be not statistically 
significant (Figure 39). Furthermore, another proposed function of N-WASp involves 
proper localisation of MT1-MMP344. The potential effect of the VCA Nbs on MT1-MMP 
positioning was analysed in HNSCC61 cells by counting MT1-MMP containing 
invadopodia when MT1-MMP positive dots overlapped with F-actin dots. However, no 
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difference in MT1-MMP localisation was observed (Figure 40). In conclusion, VCA Nb7 
and VCA Nb14 reduce the degrading properties of PC-3 cells, but without significant 
effects on MMP9 secretion/activity or on MT1-MMP localisation.  
 
 
 
 
 
 
Figure 38: Effects of VCA intrabodies on matrix degradation. (A) Representative epifluorescence images of PC-3 prostate 
cancer cells, which inducibly express EGFP-tagged VCA Nbs, were seeded on Cy3-gelatin matrix (scale bar = 10 µm). As 
negative control EGFP-only expressing stable cells were used. Quantification was done using ImageJ and Kruskal-Wallis test 
and Dunns post tests were performed. Degrading capacity of PC-3 cells was analyzed by 3 parameters. For the first 
parameter ‘degradation index’ (B) and the second parameter ‘degradation area per cell’ (C), a comparison between ‘not 
induced’ and ‘doxycycline induced’ was made for each stable cell line. The third parameter ‘degradation area per total cell 
area’ (D) was compared to the EGFP-only cell line. (ns = not significant, * p < 5%, ** p < 1%, *** p < 0.01%) 
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Figure 39: Effects of VCA Nbs on MMP9 secretion and activity levels. (A) Quantification of MMP9 levels in medium was 
determined using ImageJ after SDS-PAGE and Western blotting. As control the uninduced cell line was used. (B) Activity was 
obtained after digestion in 0.1% gelatin gel. Quantification was performed using ImageJ and a Kruskal-Wallis and Dunns 
post tests were performed. The bars represent mean and SEM (n = 3). (ns, not significant) 
 
 
 
Figure 40: Effects of VCA Nbs on MT1-MMP positioning. MT1-MMP containing invadopodia were counted when MT1-
MMP dots were overlapping with F-actin dots in HNSCC61 cells, in which VCA Nbs expression could be induced. The number 
of MT1-MMP containing invadopodia was divided by the total amount of invadopodia for each cell and Kruskal-Wallis and 
Dunns post tests were used. The bar plot represents mean and SEM (n = 3). (ns, not significant) 
5.2.4 Discussion  
In this study, nanobodies were generated against the VCA domain of N-WASp, an actin 
and Arp2/3 interaction partner. Out of all binders, four VCA nanobodies (VCA Nb2, 7, 13 
and 14) were selected and expressed in 3 different cancer cell lines. Pull down 
experiments and immunofluorescence revealed their ability to bind endogenous            
N-WASp. Their submicromolar affinity for the VCA peptide was determined with ITC. 
Previous studies found actin binding affinities to the VCA domain of WASP family 
proteins ranging from 50 to 250 nM, also using ITC409, 410. The affinity between VCA and 
Arp2/3 complex is more difficult to determine and expected to be lower382, 411-414. 
Depending on the techniques used, previous research suggested a binding of one Arp2/3 
complex to two N-WASp molecules411-413. These previously determined affinities cover a 
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broad range, but almost all conclude that the affinity differences between those two 
binding sites differs by one or two order of magnitude411-413. As we observed a 
delocalization of N-WASp using the MOM-tagged VCA nanobodies (Figure 32), a 
decreased binding of Arp2/3 to VCA in the presence of the VCA Nbs (Figure 35), a 
significant disturbance of invadopodium formation (Figure 37) and a decrease in the 
overall matrix degradation (Figure 38), we conclude that VCA nanobodies indeed perturb 
several functions of endogenous N-WASp in these cancer cells.  
N-WASp participates in the formation of an invadopodium precursor which activates the 
actin polymerisation process. It was previously demonstrated that N-WASp is a key 
player in invadopodium genesis289. The cancer cell receives a signal (i.e. EGF) which 
activates a cascade leading to invadopodium formation. In this cascade, the RhoGTPase 
Cdc42 is activated and will change the conformation of N-WASp from the inactive to the 
active state384, 397. Only in the active state will the VCA domain of N-WASp bind Arp2/3 
and actin and stimulate actin polymerisation at the pre-invadopodium site. Next, Arp3 
binds to cortactin and after the activated N-WASp comes in, the Arp2/3 complex will 
interact with N-WASp, leading to a higher activation of Arp2/3 and initiation of actin 
polymerisation395. N-WASp interacts with Arp2/3 through the central or cofilin-like (C) 
and acidic (A) regions of the VCA domain. Of the seven subunits of the Arp2/3 complex, 
only Arp2 and Arp3 bind to the VCA domain of N-WASp332, 395. This double interaction 
differs in properties and functions402, 415. The first interaction occurs at the acidic (A) 
region of the VCA domain and is important for the affinity between N-WASp and the 
Arp2/3 complex, but is not essential for Arp2/3 activation. The second interaction 
involves the central (C) region, which binds Arp2/3 with lower affinity, but it is 
indispensable for Arp2/3 activation. Our observations show that the VCA nanobodies are 
able to interfere with this process. The Arp2/3 and actin binding experiments reveal that 
the VCA Nbs have no effect on actin binding, but the VCA Nbs all show a reduction in 
Arp2/3 interaction with VCA. Moreover, we observed a significant reduction in the 
number of invadopodia, both in MDA-MB-231 and HNSCC61 cells, when VCA Nbs were 
expressed as intrabody (Figure 37), highlighting the importance of the VCA domain of N-
WASp in invadopodium formation336, 337, 373, 402. Because VCA Nb2 and VCA Nb13 show a 
significant reduction in Arp2/3 interaction, we suggest that these nanobodies interrupt 
the interactions via binding to the acidic (A) region of the VCA domain. In contrast, VCA 
Nb7 and VCA Nb14 elicit only a slight reduction in Arp2/3 interaction, but display a 
significant effect in the degradation properties of PC-3 cells. We suggest that VCA Nb7 
and VCA Nb14 bind the central (C) region of the VCA domain, where they do not disturb 
the Arp2/3 interaction that much, but more specifically affect Arp2/3 activation. Because 
VCA Nb2 and VCA Nb13 do not show an effect on overall degradation, we hypothesize 
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that the interference with the acidic (A) part of the VCA domain is enough to significantly 
reduce the number of invadopodia but not sufficient to show effects in the following 
degradation step. 
After invadopodium maturation, matrix remodelling will follow. Our results revealed that 
VCA Nb7 and 14 were able to significantly reduce the overall degradation (Figure 38). 
Presumably, these nanobodies lead to invadopodia that are defective in protrusion 
through interfering with N-WASp - Arp2/3 interaction. When there are less protrusive 
invadopodia, the overall degrading properties of cells will decrease because actin 
polymerisation is what drives invadopodium growth through the matrix, followed by 
matrix degradation. 
The properties of N-WASp in this pathway may also be related to the transportation of 
vesicles356-358. To elicit matrix degradation, the MMPs must traverse the invadopodium to 
the extracellular space, where they can exert their function358. N-WASp is expected to 
activate actin polymerisation via Arp2/3 to form actin comet tails at vesicles356, 358. This 
will give a propelling force to enhance the movement of these vesicles through an 
invadopodium357, 358. To study this further, we analysed MMP9 secretion and activity in 
VCA nanobody expressing cancer cells. However, in PC-3 cells no effects were found 
(Figure 39). This is contrary to what we observed for cortactin48. Indeed, cortactin 
nanobodies targeting its C-terminal SH3 or the N-terminal NTA domains significantly 
reduced MMP9 secretion and activity. FasNb5 however, which blocks the actin bundling 
activity of the actin bundling protein fascin that is also present in invadopodia, did not45, 
48. Alternatively, the degrading properties of N-WASp can be attributed to MT1-MMP as 
suggested previously344. Yu et al. concluded that N-WASp plays a role in matrix 
degradation by optimising the organisation and positioning of MT1-MMP, the master 
switch of other MMPs. At the cytoplasmic tail of MT1-MMP, N-WASp creates an actin 
network to specifically stabilize MT1-MMP to increase the effectiveness of 
degradation344. Moreover, no difference in MT1-MMP localisation was observed in 
HNSCC61 cells (Figure 40). Currently, we suggest that the reduction in overall matrix 
degradation is due to the reduction in Arp2/3 complex binding to N-WASp leading to 
defective invadopodia. When the VCA Nbs reduce the number of invadopodia per cell, 
the overall degradation properties will also be lower per cell. Less invadopodia implies 
less available MT1-MMP (enriched in invadopodia) for degradation. We therefore 
propose that the effect of N-WASp in matrix remodelling is caused by its regulation of 
invadopodium formation.  
Recently, Fulcher et al. succeeded in eradicating endogenous proteins via the 
proteasome degradation pathway using nanobodies and monobodies105. If this approach 
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proves to be efficient for a broad variety of targets (providing that a nano/monobody can 
be generated or is available), it would be an important new tool to study protein 
function, one that parallels the advent of RNAi in mammalian cells nearly two decades 
ago416. In this respect, Shaefer et al. very recently demonstrated that CRISPR/Cas9 
genome editing can trigger hundreds of unintended mutations and deletions in the 
genome417. It is therefore incumbent to continue developing new methodologies aimed 
at studying protein function in cells and organisms and we expect that proteasome-
induced protein knock out represents a valuable and important new technological 
approach towards this end.  
In conclusion, nanobodies against the VCA domain of N-WASp affect invadopodium 
formation and overall matrix degradation, most likely via regulation of N-WASp – Arp2/3 
complex interaction, indicating that this region of N-WASp critically contributes to these 
processes.  
5.2.5 Materials and methods  
5.2.5.1 Antibodies and reagents 
Rabbit polyclonal anti-N-WASp (H100) was obtained from Sigma (St. Louis, MO, USA) and 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-actin clone C4 
(0869100) was obtained from MP Biomedicals (Santa Ana, CA, USA). Rabbit monoclonal 
anti-ARPC2 antibody (ab133315) and anti-MMP14 (ab51074) were obtained from Abcam 
(Cambridge, UK). Rabbit monoclonal anti-MMP9 was obtained from Epitomics 
(Burlingame, CA, USA). Alexa Fluor-labeled secondary goat anti-rabbit or anti-mouse IgG 
antibodies were obtained from Molecular Probes (Eugene, OR, USA). Mouse monoclonal 
anti-V5 antibody, Alexa Fluor labeled phalloidin and MitoTracker Orange were purchased 
from Invitrogen (Merelbeke, Belgium). The synthetic VCA – hN-WASp peptide biotin-Ahx-
420KKVEQNSRPVSCSGRDALLDQIRQGIQLKSVADGQESTPPTPAPTSGIVGALMEVMQKRSKAIHS
SDEDEDEDDEEDFEDDDEWED505-NH2, used for raising nanobodies (see further), was 
chemically synthesized by Caslo (Denmark). 
5.2.5.2 Generation of VCA Nbs 
Nbs were obtained in collaboration with the Vlaams Instituut voor Biotechnologie (VIB) 
Nanobody Service Facility (NSF). All animal work was performed by the VIB NSF and has 
PHS approved animal welfare assurance from OLAW (F16-00131(A5593-01)). Briefly, two 
alpacas were immunized by a subcutaneous injection of human VCA-N-WASp peptide on 
days 0, 7, 14, 21, 28 and 35. On day 39, anticoagulated blood was collected for 
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lymphocyte preparation. A nanobody library was constructed by extracting total RNA 
from peripheral blood lymphocytes and screened for the presence of antigen-specific 
nanobodies. The obtained Nbs were subcloned into the phagemid vector pMECS. In 
order to isolate N-WASp nanobodies, several rounds of phage panning were performed. 
These experiments suggested that the phage population was enriched for antigen-
specific phages from round 3 panning onwards. In total, 380 colonies from 3rd and 4th 
rounds were randomly selected and analyzed by ELISA for the presence of antigen-
specific nanobodies in their periplasmic extracts. The positives ones were sequenced. 
Based on those sequence data, the positive colonies represented 5 different groups of 
nanobodies in each of the two alpacas. 
5.2.5.3 cDNA cloning 
Nbs were cloned into mitochondrial outer membrane (MOM) V5 pcDNA3.1 His6 and 
pEGFP-N1 vectors (Clontech, Mountain View, CA, USA), as described before45, 406, 418. The 
nanobodies were subcloned by means of a Cold Fusion Cloning Kit (System Biosciences, 
Mountain View, CA, USA). The first subcloning was performed into V5 pcDNA3.1 His6 
vector by using the following primers: forward 5’-TCGATTCTACGCGTACCGGTGCCCAGGT 
GCAGCTGCAGGAG-3’ and reverse 5’-GGTGATGATGACCGGCTAGCTGGAGACGGTGACCTG-
3’. Cloning of the Nbs in the pEGFP-N1 vector was done using the following primers: 
forward 5’-CGAGCTCAAGCTTCGGCCACCATGCAGGTGCAGCTGCAGGAG-3’ and reverse 5’-
GGCGACCGGTGGATCCTTGCTGGAGACGGTGACCTG-3’. 
To obtain inducible Nb expressing cells, a third cloning of the EGFP-tagged VCA Nbs into 
the pLVX-TP vector (Clontech) was done using following primers: Forward 5’-TGGAGAAG 
GATCCGCGGCCGCGCCACCATGGCCCAGGTGCAGCTGCAGGAGTCTGGG-3’ and reverse 5’-
CTACCCGGTAGAATTCTTACTTGTACAGCTCGTCCATGCC-3’. 
5.2.5.4 Recombinant nanobody and N-WASp production 
BL21 cells were transformed with VCA Nbs in pMECS vector or N-WASp in pTrcHis TOPO. 
They were grown in TB (with 100 μg/ml ampicillin) at 37 °C. After induction with 1 mM 
IPTG, incubation was performed at 28 °C (overnight for nanobody production or 4 h for 
N-WASp production).  
Nanobodies were extracted from the periplasm, where they are located due to an N-
terminal PelB signal, by means of an osmotic burst of the outer membrane using TES 
buffer (0.2 M Tris, 0.5 mM EDTA, 0.5 M sucrose, pH 8.0). Next an IMAC and/or gel 
filtration was performed for a higher purification, as described before47.  
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To extract recombinant N-WASp, pelleted cells were dissolved in lysis buffer (1% Triton, 
20 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF and 1 mM protease inhibitor, pH 7.5) 
supplemented with 200 μg/ml lysozyme and incubated during 30 min at room 
temperature. After sonication and pelleting, IMAC purification was performed. 
5.2.5.5 Cell culture, transfection and transduction 
MDA-MB-231 (ATCC HTB-26), PC-3 (ATCC CRL-1435) and HEK293T (ATCC CRL-11268) cells 
were maintained at 37 °C in a humidified 10% CO2 incubator, HNSCC61 cells were grown 
at 5% CO2. All cells (except PC-3) were grown in DMEM. We obtained the HNSCC61 cells 
from Prof. Dr. Weaver419 (Vanderbilt University) in August 2011, who obtained the cells 
from Prof. Dr. Yarbrough420-422. PC-3 cells were grown in RPMI. All media (from Gibco Life 
Technologies (Grand Island, NY, USA) were supplemented with 10% foetal bovine serum, 
10 µg/mL streptomycin and 10 IU/mL penicillin. As an exception, HNSCC61 required 20% 
fetal bovine serum and an extra addition of 0.4 µg/mL hydrocortisone (Sigma-Aldrich, St. 
Louis, MO, USA).  
JetPrime (Polyplus Transfection Inc., New York, NY, USA) was used to perform transient 
expression according to the manufacturer’s protocol. For virus production HEK293T cells 
were transfected using the calcium phosphate method as described before45. Inducible 
stable cell lines were obtained by transduction of the VCA Nbs in the pLVXTP vector, 
making use of the Lenti-X Tet-On advanced system (Clontech, Mountain View, CA, USA) 
according to the manufacturer’s protocol. Expression was induced by addition of 500 
ng/mL doxycycline.  
5.2.5.6 Pull down assays, immunoprecipitations and binding assay 
Cells were lysed with ice-cold lysis buffer (1% Triton, 20 mM Tris-HCl, 150 mM NaCl, 1 
mM PMSF and 1 mM protease inhibitor, pH 7.5)406. Protein concentrations were 
determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).  
In the pull down assays to analyse binding between N-WASp and the 10 VCA Nbs, 
recombinant HA-tagged nanobodies were immobilized onto HA-agarose beads (Sigma-
Aldrich, St. Louis, MO, USA) (1.5 h at 4 °C). Next, 650 µg crude cell lysate was added and 
followed by incubation (1.5 h at 4 °C). 
In the pull down to analyse binding between N-WASp and VCA Nbs using EGFP-tagged 
VCA Nb expressing cancer cells, we performed overnight incubation of cell lysate with 
anti-GFP antibody (at 4 °C), followed by an incubation with Protein G Sepharose beads 
(GE Healthcare) (1.5 h at 4 °C). 
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In the binding assay, recombinant HA-tagged VCA Nbs, in a concentration range, were 
incubated with the synthetic biotin-tagged VCA domain (1.5 h at 4 °C). Next, 550 µg 
crude MDA-MB-231 cell lysate was added, as source for Arp2/3 and actin, and an 
incubation was followed (1.5 h at 4 °C). Last, an immobilization on STREPTactin beads 
(IBA, Göttingen, Germany) was performed (1h at 4 °C). 
After washing steps, elution of the beads was obtained by boiling for 5 minutes in 
Laemmli SDS sample buffer (65 mM Tris-HCl, 20% glycerol, 5% SDS, 0.2% bromophenol 
blue, 5% β-mercaptoethanol in Milli-Q, pH 6.8). This was followed by SDS-PAGE and 
Western blot analysis. The H100 N-WASp antibody from Santa Cruz Biotechnology was 
used to detect N-WASp on blot.  
5.2.5.7 Isothermal titration calorimetry  
Isothermal titration calorimetry (ITC) was performed as described before45, 47, 406. Binding 
of VCA Nbs to VCA peptide was measured by ITC using a MicroCal VP-ITC 
MicroCalorimeter and MICROCAL ORIGIN software (Malvern Instruments Ltd, Malvern, 
UK). The recombinant VCA Nbs were dialyzed against 20 mM Tris buffer and 150 mM 
NaCl at pH 7,5. Briefly, 8,6 μM biotinylated VCA peptide was titrated once with 108 μM 
VCA Nb7 and once with 88 μM VCA Nb14. 46,91 μM VCA Nb2 and 5,6 μM VCA Nb13 was 
titrated with 46,91 μM and 56 μM biotinylated VCA peptide, respectively. The obtained 
values are expressed with the standard deviation.  
5.2.5.8 Immunofluorescence and microscopy 
Cells were seeded on a 100 µg/ml gelatin (Sigma-Aldrich, St. Louis, MO, USA) or 50 µg/ml 
rat tail type I collagen (BD Biosciences, Franklin Lakes, NJ, USA) coated coverslip. Cells 
were fixed using 3% paraformaldehyde, permeabilized using 0.1% Triton for 5 min and 
neutralized in 0.75% glycin for 20 min. Next, a blocking step was performed using 1% 
bovine serum albumin (Sigma-Aldrich), followed by an incubation with primary 
antibodies (1 h at 37 °C) and Alexa Fluor-conjugated secondary antibodies (30 min at 
room temperature). DAPI (0.4 µg/ml; Sigma) and Alexa Fluor labeled phalloidin 
(Invitrogen) were used to stain nuclei and actin filaments, respectively. Cells were 
mounted using VectaShield (Vector Laboratories, Burlingame, CA, USA). For imaging, a 
Zeiss Axiovert 200 M Apotome epifluorescence microscope equipped with a cooled CCD 
Axiocam camera (Zeiss x63 1.4-NA Oil Plan-Apochromat objective; Carl Zeiss, 
Oberkochen, Germany) and Axiovision 4.5 software (Zeiss) was used at room 
temperature. 
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5.2.5.9 Matrix degradation  
In matrix degradation assays, coverslips were coated with Cy3-labeled gelatin according 
to the manufacturer’s protocol (QCM Gelatin Invadopodia Kit, Millipore, Billerica, MA, 
USA). 24h after induction with doxycycline, cells were seeded and allowed to degrade 
the matrix for another 24h. Degradation is found on the places where black holes were 
present in the matrix underneath the cells. Two parameters were used to analyze the 
degradation. The parameter ‘degraded area per cell area’ was obtained by dividing the 
total degraded area by the total cell area per picture. The second parameter 
‘degradation area per cell’ is determined by the total degradation area divided by the 
amount of cells per picture. 
5.2.5.10 Gelatin zymography 
24 h after induction with 500 ng/ml doxycycline, cells were seeded in a 1 mg/ml collagen 
matrix which was allowed to polymerize for 1 h at 37 °C. After approximately 20 h 
incubation in serum-free medium, equal amounts of conditioned medium proteins were 
analyzed on 10% SDS-PAGE without (for secretion levels) or with 0.1% gelatin (for 
activity). In the SDS-PAGE containing 0.1% gelatin, proteins were enabled to renature by 
removing SDS with 2% Triton X-100 washing buffer. To analyse the activity, digestion was 
allowed during an overnight incubation in MMP buffer (50 mM Tris and 10 mM CaCl2, pH 
7.5). Band intensities were analyzed with ImageJ. 
5.2.5.11 MT1-MMP localization 
Nanobody expression was induced 24 h before cells were seeded on a 100 µg/ml gelatin 
matrix. They were fixed, stained and imaged as described above. MT1-MMP containing 
invadopodia were count when MT1-MMP dots were overlapping F-actin dots. To analyse 
MT1-MMP, the amount MT1-MMP containing invadopodia was divided by the total 
amount of invadopodia for each cell.  
5.2.5.12 Image and statistical analysis  
Image analysis (protein intensities, intensity profiles, quantifications) was performed 
with ImageJ (National Institutes of Health, Bethesda, MD, USA). Statistical analysis was 
performed with GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) using 
Kruskal-Wallis test and Dunns post tests with p=0.05. Bar plots were made using mean 
and SEM. 
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 Introduction  6.1
In this chapter, we intended to obtain fluorescent and site specifically labelled 
nanobodies for microscopic use. The strategy uses the Cu-dependent chemical reaction, 
the Cu(I)-catalyzed Azide-Alkyne Click Chemistry (CuAAC) or click chemistry. This reaction 
requires an alkyne and an azide moiety423-425. However, these are not naturally occurring 
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in a nanobody or any other protein. To incorporate such a chemically reactive group, two 
methods were used. While in the first strategy an alkyne bearing peptide was ligated to 
the nanobody through an enzymatic sortase reaction, the second method was based on 
genetic engineering of the nanobody to allow incorporating of a non-canonical amino 
acid which contains an azide moiety. Afterwards, the CuAAC reaction covalently coupled 
an AlexaFluor488 to the nanobody.  
Once fluorescent labelled nanobodies (or fluobodies) were obtained, they could be used 
to visualize their target. The original goal was to use those fluorescent nanobodies in a 
conventional immunocytochemistry protocol. Because the nanobodies contain a 
fluorophore, such a staining procedure is reduced to a single-step immunocytochemistry. 
In this study, two nanobodies were used. The first is a nanobody against the SH3 domain 
of cortactin45. Cortactin assists the actin polymerisation process, plays a role in the 
invadopodium dynamics and stabilizes actin filaments48, 329. The second nanobody targets 
the C-terminal part of β-catenin. β-Catenin is a structural protein in adherens junctions 
and has a role as transcriptional activator in the Wnt signal transduction pathway426, 427.  
Special attention has to go to the fixation and/or permeabilisation of cells, since this can 
cause loss of antibody (here: nanobody) immunoreactivity to its target163. In this study, a 
solution is proposed by using the photoporation technique to deliver recombinant 
fluorescent nanobodies in living cells69, 73. This allows the nanobody to bind its target in 
its native conditions prior to fixation and permeabilisation. The positive effect of this 
approach is clearly shown using β-catenin Nb86.  
 Research paper 6.2
The paper428 is published in New Biotechnology after a peer revision on June, 2020. 
6.2.1 Abstract 
While conventional antibodies have been an instrument of choice in 
immunocytochemistry for some time, their small counterparts known as nanobodies 
have been much less frequently used for this purpose. In this study we took advantage of 
the availability of nanobody cDNAs to site-specifically introduce a non-standard amino 
acid carrying an azide/alkyne moiety, allowing subsequent Cu(I)-catalyzed Azide-Alkyne 
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Click Chemistry (CuAAC). This generated a fluorescently labelled nanobody that can be 
used in single step immunocytochemistry as compared to conventional two step 
immunocytochemistry. Two strategies were explored to fluorescently label nanobodies 
with Alexa Fluor 488. The first method involved enzymatic addition of an alkyne 
containing peptide to nanobodies using sortase A, while the second consisted of 
incorporating para-azido phenylalanine at the nanobody C-terminus. Through these 
approaches, the fluorophore was covalently and site-specifically attached. It was 
demonstrated that cortactin and β-catenin, cytoskeletal and adherens junction proteins 
respectively, can be imaged in cells in this manner through single step 
immunocytochemistry. However, fixation and permeabilisation of cells can alter native 
protein structure and form a dense cross-linked protein network, encumbering antibody 
binding. It is shown that photoporation prior to fixation not only allows delivery of 
nanobodies into living cells, but also facilitates β-catenin Nb86 imaging of its target, 
which was not possible in fixed cells. Pharmacological inhibitors are lacking for many 
non-enzymatic proteins, and it is therefore expected that new biological information will 
be obtained through photoporation of fluorescent nanobodies which allows the study of 
short term effects, independent of gene-dependent (intrabody) expression. 
6.2.2 Introduction 
An important aspect of cell biology is visualization of proteins of interest at high 
resolution. Not only does visualization help in comprehending results more intuitively, it 
also results in a primary source of data available for analysis and interpretation163. The 
most commonly used techniques for imaging of biomolecules are immunofluorescence 
assays using a primary and secondary antibody or fusions with a fluorescent protein. 
Nanobodies can simplify this process. They are single-domain antibody fragments 
originating from the variable part of the heavy chain of camelid heavy chain antibodies 
(VHH)16. A nanobody is the smallest, natural antigen-binding fragment that retains its 
original affinity and specificity16, 17. Because of its small size (2.5 nm diameter and 4 nm 
height429), the ‘linkage error’ (space between the dye and the protein) will be reduced 4-
7-fold compared to the use of conventional antibodies. Nanobodies are easier to 
manipulate because their cDNAs are available, allowing site-specific derivatization. 
REFERENCE Previously, different routes to link small fluorophores to nanobodies have 
been tested, e.g. N-hydroxysuccinimide (NHS) chemistry has been used to covalently link 
a small fluorophore to a nanobody178. However, random labelling of lysine residues is 
difficult to avoid (including in CDR regions), resulting in heterogeneously labelled 
nanobodies430. Alternatively, the use of maleimide chemistry requires unpaired 
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cysteines, with problems of dimerization or irreversible unfolding of the nanobody due 
to harsh reaction conditions179. 
In this study, we present an alternative nanobody labelling approach that circumvents 
these problems. We here demonstrate site specific covalent labelling of nanobodies with 
a fluorophore through click chemistry reaction. The reactive alkyne or azido group is 
introduced at the C-terminus of a nanobody in a sortase A mediated manner (enzymatic) 
(Figure 41A) or by modifying the nanobody cDNA sequence at the 3’ end (non-
enzymatic), thus encoding a non-standard para-azido phenylalanine (pAzF) residue at the 
carboxy terminus of the nanobody primary structure (Figure 41B). 
Nanobodies labelled in this fashion can be used for immunocytochemistry, as 
demonstrated here by specifically targeting cortactin and β-catenin in cells with 
nanobodies raised against the respective proteins. Because the nanobodies contain a 
dye, such a staining procedure is time beneficial since it is reduced to a single step. It is 
further shown that photoporation is an efficient and convenient way to circumvent 
problems related with immunocytochemistry when the epitope is occluded in a dense 
and inaccessible cross-linked protein network, due to chemical permeabilization and 
fixation. Photoporation is a laser-induced transfection-type approach to overcome the 
cell membrane barrier for delivery of biomolecules (including nanobodies) into living 
cells67, 431. Since nanobodies are the small counterpart of antibodies, it is easier to insert 
them through the membrane barrier. This photoporation strategy allows live cell 
labelling with exogenous labels that can be used for microscopic analysis and in vivo 
imaging67, 431. Through this approach, the nanobody can bind its target under native 
conditions before the cells are fixed. In addition, direct delivery of a (fluorescent) 
nanobody into the cytoplasm creates the possibility of studying short term effects on 
target perturbation, whereas intrabody expression is dependent on a relatively slow 
process of gene expression after transfection or transduction of DNA. 
6.2.3 Results 
Prior to subsequent derivatization with organic compounds or larger moieties, 
introduction of new functional groups into a nanobody is preferably at the C-terminus, to 
avoid interference with the binding capacity of the nanobody to its target432. Two 
different strategies leading to a nanobody carrying a C-terminal azido or alkyne group 
were exploited: an enzymatic sortase ligation procedure (Figure 41A) or incorporation of 
a non-canonical amino acid directly into the encoding sequence of the nanobody (Figure 
41B). (For more experimental detail, see 6.2.6 Supplementary information.) Once the 
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nanobody contains such a group, it can be used in a CuAAC click reaction to covalently 
add a moiety of interest to the nanobody.  
 
Figure 41: Schematic visualization of labelling strategies in this study. (A) Schematic visualization of the enzymatic SrtA 
labelling process, a recombinant nanobody containing the sortag (LPETG), is coupled to a peptide with an alkyne. Then, 
CuAAC can be completed to obtain a labelled nanobody. (B) Schematic visualization of the labelling process via a pAzF 
incorporation into the recombinant nanobody by using CuAAC. 
6.2.3.1 CuAAC reaction 
The test CuAAC reaction was performed on cortactin Nb245, 46, 48, 433, a nanobody that 
interacts with the cortactin SH3 domain. (For additional information about the test 
experiment, see 6.2.6 Supplementary information). Alexa Fluor 488 (AF488) was chosen 
in these test experiments, as a bright and commonly used fluorophore known to be 
stable for longer time periods and available with both the azide or alkyne reactive 
moieties. Figure 42A shows the result of the CuAAC reaction when the purified alkyne-
nanobody was used directly after the sortase reaction. Because the sortase reaction 
buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl2) contained a high concentration of 
Cl- ions, it was possible that the CuAAC reaction was suboptimal424. By changing the 
buffer to 10 mM HEPES, the reaction proved to be more efficient (Figure 42B), 
confirming previous observations that a lower concentration or absence of Cl- ions is 
preferable for the CuAAC reaction434, 435, since high Cl- ion concentrations compete for 
copper, leading to lower efficiency434. Regarding the buffer effect, the range of THPTA 
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and sodium ascorbate can be adjusted according to436. The experiment was further 
optimized by comparing the effect of both compounds on the click reaction. The CuAAC 
reaction was performed once with the initial concentrations (Buffer 1 in Table 2), once 
with elevated THPTA (Buffer 2 in Table 2) and once with elevated sodium ascorbate 
(Buffer 3 in Table 2). The addition of sodium ascorbate showed the greatest impact on 
the CuAAC reaction as shown in Figure 42C. From these experiments, a low 
concentration of THPTA and increased sodium ascorbate was the best choice. Since 
sodium ascorbate reduces the Cu(II) to Cu(I), using a higher concentration of sodium 
ascorbate and lower concentrations of THPTA created a higher risk of hydrolysis due to 
radicals and/or peroxides as noted in437, 438. The selected concentrations for the CuAAC 
were set at 0.1 mM CuSO4, 1 mM THTPA and 7.5 mM sodium ascorbate.  
 
Figure 42: Optimization of the labelling of cortactin nanobody 2 - sortag. CuAAC labelling was less efficient when the 
sortase reaction mixture was used directly for CuAAC (A) compared to dialysis into HEPES buffer before the CuAAC reaction 
(B). These results were obtained by using the buffer 1 composition (Table 2). Each lane corresponds to 6 µl of the CuAAC 
reaction mixture. The lowest fluorescent band is free labelled peptide/free fluorophore. (C) Elevated levels of THPTA (Buffer 
2 (Table 2)) or Na Ascorbate (Buffer 3 (Table 2)): only an elevated Na Ascorbate concentration showed better labelling 
efficiency compared to the initial test reaction (Buffer 1 (Table 2)). Each lane corresponds to 6 µl of the CuAAC reaction 
mixture.  
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Table 2: Buffer composition overview. Buffer 1-3 were used to determine optimal buffer concentrations for the CuAAC 
reaction for nanobody labelling.  
Buffer 1 Buffer 2 Buffer 3 
10 mM HEPES-NaOH 10 mM HEPES-NaOH 10 mM HEPES-NaOH 
0.1 mM CuSO4 0.1 mM CuSO4 0.1 mM CuSO4 
0.5 mM THPTA 2.5 mM THPTA 0.5 mM THPTA 
5 mM sodium ascorbate 5 mM sodium ascorbate 10 mM sodium ascorbate 
pH 7.4 pH 7.4 pH 7.4 
 
To monitor the optimal duration of the CuAAC reaction, a sample was taken after 0, 5, 
15, 20, 30, 45, 60 and 75 min. As show in Figure 43, the reaction proceeded very rapidly, 
with a fluorescent band being observed within a few minutes and most of the reaction 
completed after 1h.  
 
Figure 43: CuAAC reaction time course after incorporation of a para-azido phenylalanine (pAzF). After nanobody 
production, the nanobodies were dialysed against a HEPES buffer to remove imidazole. This was followed directly by the 
CuAAC reaction resulting in fluorescently labelled nanobodies. CuAAC reaction time course using cortactin Nb2-pAzF (Nb-
pAzF). Coomassie stained gel on the left and corresponding fluorescent signal on the right. The reaction proceeded fast and 
at 45-60 minutes, saturation was reached. Each lane corresponds to 3 µl of the reaction mixture. 
 
Eluting the nanobodies with the incorporated C-terminal pAzF directly into a compatible 
buffer can speed up the protocol. The standard buffer used for nanobody purifications215, 
389 contains too high a level of Cl- ions to be followed by the CuAAC reaction; therefore 
others used a potassium phosphate buffer434, or preferred a HEPES buffer436. Both are 
compatible as elution buffers and as buffers for CuAAC434, 438. For the elutions, there is 
almost no difference using those two buffers as they gave similar yield. When 
performing CuAAC using these two buffers, similar results were found as shown in Figure 
44. As precipitate was observed in some cases after the CuAAC using the potassium 
phosphate buffer, HEPES was preferred as elution buffer during IMAC purification and as 
buffer in CuAAC reaction. After CuAAC, an Amicon Ultra-0.5 Centrifugal Filter Unit was 
used to remove copper ions. This step decreases free AF488, as can be observed in 
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Figure 44. In a final step, free fluorophore was removed by size exclusion 
chromatography (SEC) using a PD Spintrap™ G-25.  
 
Figure 44: Purifying Alexa Fluor 488-labeled nanobody. Comparison between CuAAC after using different elution buffers 
for β-catenin Nb77 (K Phos BFF = potassium phosphate elution buffer, HEPES BFF = HEPES elution buffer). CuAAC was 
performed for 1h (0h = before CuAAC reaction, 1h = after CuAAC reaction) followed by the removal of copper using an 
amicon centrifugal filter device (F) and the removal of free AF488 through SEC (PD Spintrap™ G-25). Free AF488 was 
efficiently removed. (Each lane was loaded with 3 µl of the mixture, making the bands not entirely quantitative due to 
differences in elution volume.) 
 
To compare the sortase A strategy to the incorporation of pAzF, the quantities of labelled 
nanobody per L bacterial growth culture is reported in Table 3 and Table 4. The efficiency 
of each step was similar, but the SrtA method required one additional step (the 
enzymatic sortase reaction followed by the CuAAC) than the pAzF incorporation method 
(only CuAAC). The extra step caused a higher reduction in yield compared to the pAzF 
method. 
 
Table 3: Quantification of purified nanobody obtained per L of bacterial culture via the sortase A labeling method. 
(*Cortactin nanobody 2 expresses significantly below average compared to other nanobodies.) 
Nanobody yield through the sortase A method 
Nanobody After production After sortase reaction After CuAAC 
Cortactin Nb2* 1.7 mg Nb / L culture 0.8 mg Nb / L culture 0.2 mg Nb / L culture 
 
 
 
Table 4: Quantification of purified nanobody obtained per L of bacterial culture following pAzF incorporation method.  
(*Cortactin nanobody 2 expresses significantly below average compared to other nanobodies.) 
Nanobody yield through the pAzF incorporation method 
Nanobody After production After CuAAC 
Cortactin Nb2* 1,4 mg Nb / L culture 0,7 mg Nb / L culture 
Β-catenin Nb77 13,9 mg Nb / L culture 9,1 mg Nb / L culture 
Β-catenin Nb86 8,9 mg Nb / L culture 5,6 mg Nb / L culture 
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6.2.3.2 Single step immunocytochemistry with click chemistry labelled 
cortactin and β-catenin nanobodies. 
Fluorescent nanobodies were next used in immunocytochemistry. The first experiments 
were performed on 4% PFA fixed head and neck squamous cell carcinoma cells 
(HNSCC61). The nanobody concentrations used for staining ranged from 1-10 µg/ml, 
similar to the use of conventional antibodies and to previous instances when nanobody 
staining has been performed95, 189, 439-442. It should be noted that, unlike IgG, nanobodies 
are monovalent.  
Cortactin is an actin cytoskeleton associated protein and assists the Arp2/3 complex in 
actin polymerization, which is required in a variety of processes such as invadopodium 
formation and cell motility310. Cortactin is used as marker of these cancer cell 
invadopodia, ventral protrusions of the plasma membrane supported by actin 
polymerization and which are involved in matrix degradation. The Cort Nb2 targets the 
SH3 domain and diminishes invadopodia numbers, matrix degradation, MMP9 secretion 
and the invasive capacity of MDA-MB-231 and HNSCC61 cells45, 46, 48, 433. When using 
cortactin Nb2-AF488, generated through the sortase reaction followed by CuAAC, 
cortactin was difficult to visualize in HNSCC61 invadopodia (Figure 45, second panel). 
Staining with cortactin Nb2-AF488, through labelling after the pAzF incorporation, was 
more successful (Figure 45, third panel). The cortactin Nb2-AF488 staining pattern at 1 
µg/ml (Figure 45, third panel) was similar to a commercial cortactin antibody (anti-
cortactin antibody clone 4F11) (Figure 45, top). As a control, another cortactin nanobody 
was used (Figure 45, bottom), namely FHP Nb11, which was generated to a cortactin 
fragment consisting of the F-actin, the helical and the proline rich domain433. FHP Nb11 
did not show any co-localisation with the actin cytoskeleton in PFA fixed cells, confirming 
that cortactin Nb2 recognised cortactin selectively. An additional control, a dual staining 
of cortactin Nb2-AF488 (labelled via pAzF strategy) was performed together with the 
commercial antibody (Figure 46A) and showed good co-localisation between the 
nanobody and the antibody. 
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Figure 45: Comparison of cortactin staining in HNSCC61 cells. The cells were seeded on a gelatine coating. Since cortactin is 
a known invadopodial marker, invadopodia are visible (some are indicated by arrows). Top, cortactin was visualized by a 
commercial anti-cortactin Ab (a mouse monoclonal anti-cortactin antibody clone 4F11). A clear co-localisation between the 
antibody and invadopodia (actin rich structures) was observed. Second panel, cortactin localization using cortactin Nb2-
AF488 (5 µg/ml) which was labelled through SrtA and CUAAC. Third panel, cortactin Nb2-AF488 (1 µg/ml) obtained through 
the incorporation of pAzF followed by CuAAC, revealed a pattern highly reminiscent of the top panel. At the bottom panel, 
an FHP nanobody 11, which was generated against another region of cortactin (a fragment consisting of F-actin-helical-
proline rich domain of cortactin) was used as control
433
 and did not show co-localisation with the actin cytoskeleton in PFA 
fixed cells. (Scale bar = 10 µm) 
A second nanobody used used similarly was raised against human β-catenin. β-catenin 
Nb77 targets the C-terminal part of human β-catenin (a fragment from Ser389 to Leu781 
was used for immunization). A dual staining was performed using a commercial antibody 
(anti-β-catenin antibody (ab32572)) and the β-catenin Nb77-AF488 (5 µg/ml), labelled 
via pAzF and CuAAC. β-catenin is important for cell-cell interactions and both antibody 
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and nanobody stained cell-cell contacts, showing similar patterns (Figure 46B), attesting 
to the ability of the nanobody to bind catenin in PFA fixed cells.  
 
Figure 46: Dual staining using a nanobody and a commercial antibody to visualise cortactin and β-catenin in 4% PFA fixed 
HNSCC61 cells, seeded on collagen coating. (A) The imaging of cortactin by the cortactin Nb2-AF488 (1 µg/ml), labelled 
through the pAzF method, and a commercial antibody (a mouse monoclonal anti-cortactin clone 4F11) (red channel) 
showed co-localisation. As additional confirmation, the actin staining (far red channel) showed the invadopodia on the 
same spot. A few invadopodia arrowed. (B) A commercial antibody (a rabbit monoclonal anti-β-catenin antibody (ab32572)) 
was used to localize β-catenin (red channel) together with the AF488 labelled β-catenin Nb77 (5 µg/ml), labelled through 
the pAzF method. Both showed heightened intensity at the cell-cell contacts. Phalloidin was used to visualize the actin 
cytoskeleton (far red channel). (Scale bar = 10 µm) 
6.2.3.3 Delivering a fluo-nanobody in living cells by photoporation improves 
the applicability of nanobodies in immunocytochemistry. 
In the course of the study it became clear that not every nanobody is suitable for 
immunocytochemistry, which also applies to conventional antibodies. For instance, β-
catenin Nb86 (another nanobody against human β-catenin obtained after immunization 
with the same β-catenin fragment from Ser389 to Leu781), labelled through pAzF, 
yielded poor results in a conventional staining protocol on permeabilized and PFA fixed 
cells (Figure 47A, cf. Figure 46B). With methanol fixation, β-catenin Nb86 was able to 
visualize β-catenin (Figure 47A, bottom). It was hypothesized that this could be due to 
cross-linking by para-formaldehyde and that delivery of the nanobody into living cells 
would allow it to bind its target under native conditions, prior to cross-linking. Crossing 
the plasma membrane, however, remains a major hurdle for nanobodies. A recently 
developed transfection technique termed photoporation has been reported to 
accomplish this67. This is an upcoming flexible and safe physical transfection method that 
can deliver a wide variety of molecules into a broad range of cells. Cells are first 
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incubated with photothermal nanoparticles, such as graphene quantum dots used here, 
which can bind to the cell membrane. After washing, pulsed laser irradiation is applied 
rendering the cell membrane temporarily permeabilized by photothermal effects 
induced locally by the graphene quantum dots. Compounds in the cell medium, including 
labelled nanobodies, can then diffuse into the cell cytoplasm until the cell membrane is 
resealed.  
 
Figure 47: β-catenin visualization using β-catenin Nb86-AF488 and the commercial antibody (a rabbit monoclonal anti-β-
catenin antibody (ab32572)). The nanobody was labelled through the pAzF method. (A) Top, the β-catenin Nb86-AF488 
was used in 4% PFA fixed HNSCC61 cells in single step immunocytochemistry and did not show a specific β-catenin signal. 
Bottom, methanol fixation on HNSCC61 cells was performed and the same β-catenin Nb86-AF488 staining performed, 
showing heightened intensity at the cell-cell contacts. (Scale bar = 10 µM). (B) The β-cat Nb86-AF488 was photoporated 
into HeLa cells and then fixed. As a control, a conventional staining was performed with a commercial anti-β-catenin 
antibody (a rabbit monoclonal anti-β-catenin antibody (ab32572)) (in red, middle panel). (Scale bar = 50 µM) 
β-catenin Nb86-AF488 was delivered into living cells by photoporation and the cells fixed 
thereafter. It was observed that β-catenin became clearly discernible at cell-cell contacts 
(Figure 47B). In a photoporation time lapse experiment, it was possible to observe β-
catenin at cell-cell contacts (e.g. time frame between 5h50 and 9h35 indicated with an 
arrow in Video 1; Video 2 is as control showing a fascin nanobody in photoporation). It 
was concluded that β-catenin Nb86 bound to its epitope in living cells but failed to do so 
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subsequent to cell fixation. Hence, photoporation may represent a new avenue for 
introduction of nanobodies into living cells, allowing the study of short and medium 
range (24h) dynamic cellular processes and the immediate effects of protein binders on 
their targets. 
 
Video 1: HeLa cells photoporated with β-catenin Nb86-AF488 (labelled through the pAzF method). An image was taken 
every 25 min over 12h30. The arrows highlight visualization of β-catenin at cell contact site during 2 cells passing by (e.g. 
time frame between 5h50 and 9h35). (Scale bar = 50 µM) 
Video 2: HeLa cells photoporated with fascin Nb2-AF488 (labelled through the pAzF method). An image was taken every 
25 min over 12h30. Since fascin is an F-actin bundling protein, fascin Nb2-AF488 visualizes filopodia and microspikes. This 
video is to be considered as a control for the β-catenin Nb86-AF488 photoporation. (Scale bar = 50 µM) 
 
In view of these findings, cortactin Nb2, similar to β-catenin Nb86, was photoporated 
and the cells then fixed. Phalloidin-AF647 was added to the medium in order to co-stain 
F-actin with cortactin in invadopodia of HNSCC61 cells. Comparison with Figure 45 shows 
that a slightly better contrast was obtained and that invadopodia were highlighted by 
photoporation of cortactin nanobody 2-AF488 and phalloidin-AF647, as well as by the 
commercial cortactin antibody (anti-cortactin antibody clone 4F11) (Figure 48). 
 
Figure 48: Cortactin Nb2 photoporation in HNSCC61 cells. A few invadopodia are arrowed. The cells were photoporated 
with cortactin Nb2-AF488 and phalloidin-AF647, followed by a fixation with 4% PFA and a commercial cortactin Ab staining 
(a mouse monoclonal anti-cortactin antibody clone 4F11). (Scale bar = 10 µM) 
6.2.4 Discussion 
This work compares two possibilities for incorporation of an alkyne/azido group into a 
nanobody, an enzymatic method in which sortase A adds an alkyne containing peptide 
and another in which an azido containing amino acid is incorporated at the nanobody C-
terminus. The click chemistry or CuAAC reaction led to the most promising results when 
incorporating the unnatural para-azido Phe (pAzF) C-terminal to a nanobody. The 
procedure is straightforward, reliable, relatively fast and has a higher yield when start 
and end are taken into account. It may become broadly applicable as it can be used for 
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different nanobodies and coupling to a variety of moieties e.g. different fluorophores, 
magnetic beads, quantum dots, gold nanoparticles. The use of fluorescently-labelled 
nanobodies and the new avenue of introducing them into living cells by photoporation 
will allow study of short and medium range (24h) dynamic cellular processes targeting a 
broad range of proteins. Moreover, this technique reduces linkage error and will enable 
the imaging of endogenous proteins at higher resolution and can be of interest for super 
resolution microscopy. The present study used a CuAAC reaction which has the 
advantage of site selectivity. Unlike the maleimide method, the presence of a reactive 
moiety in this case depends on the incorporation of the alkyne/azido carrying amino acid 
through sortase or through pAzF. As there is only one sortag or one amber stop codon 
present, the stoichiometry is 1:1. It is known that alkyne and azido groups are highly 
specific towards each other and that they remain inert to other chemical groups present 
in proteins443. Hence, labelling will be near stoichiometric as only one reactive group is 
present on the nanobody to react in the CuAAC reaction. The method also has the 
advantage that no obvious decrease in yield of the purified pAzF carrying nanobody was 
observed compared to the unmodified nanobody or to the nanobody with sortag (which 
is also produced without non-natural amino acids). Recently the CuAAC reaction was 
used after incorporating an alkyne/azido group into a nanobody444. An alkyne containing 
peptide was employed in combination with the intein-mediated protein ligation (IPL) 
technique. By equipping the nanobody with a Cys residue between the nanobody and 
intein sequences, an N-S shift leading to a thioester linkage was facilitated. By using an 
alkyne bearing cysteine derivative, an on-column cleavage was performed, resulting in 
an alkynated nanobody.  
The incorporation of an alkyne/azido group can also offer several other opportunities. 
Previously nanobodies have been used to couple other moieties than fluorophores. They 
have been coupled to quantum dots and four nanobodies were selectively conjugated 
onto one quantum dot207. This was achieved by means of sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate which crosslinks the C-terminal Cys of the 
nanobody to an amino group on the quantum dots207, 208. Quantum dots are capable of 
emitting enough signal to be detected deeper in tissues than Alexa fluorophores and are 
therefore preferred. This can easily be performed as well using the CuAAC principle. Non-
fluorescent moieties are also possible. A linear polyethylene glycol (PEG) molecule was 
coupled to nanobodies using maleimide chemistry in order to prolong the in vivo 
circulation time and to study the changes in pharmacokinetics203. As discussed above, 
biotin added to GFP nanobodies enabled immunoprecipitation of GFP fusion proteins189. 
Through maleimide chemistry, EGFR nanobodies were conjugated to liposomes in order 
to induce receptor internalization in cancer cells resulting in an inhibition of tumor cell 
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proliferation445, 446. As these are examples of the potential of nanobodies, these can all be 
obtained using the CuAAC reaction as well. The alkyne-azido functionality can be further 
exploited as for example in Western blotting.  
 Others produced a green fluorescent protein (GFP) nanobody with a C-terminal tubulin-
derived recognition sequence (Tub-tag), consisting of 14 amino acids 
(VDSVEGEGEEEGEE)188, 189, 430. By using a tubulin tyrosine ligase (TTL), small unnatural 
tyrosine derivatives were attached to the Tub-tag189. The authors were able to couple a 
3-formyl-L-tyrosine to a Tub-tagged anti-GFP nanobody, followed by chemical labelling 
with Alexa Fluor 594-hydrazide. This was further reduced to a one-step protocol using a 
coumarin-coupled amino acid or β-(1-azulenyl)-l-alanine188. However, the fluorescent 
substrates allowed in this one-step process are limited.  
The sortase time course experiment in the present study showed reversibility of the 
amide-bond formation between the nanobody and GGGY-PAG peptide, resulting in a 
need for higher substrate concentrations430. Another disadvantage of sortase is that 
peptides used are not readily available179. In addition to TTL and sortase coupling, other 
methods include the bacterial biotin ligase (BirA) method which is limited to 
biotinylation430, the use of transglutaminases to couple moieties on glutamines198 or the 
lipoic acid ligase (lplA) method, which couples moieties to lysines in a lipoic acid acceptor 
peptide tag447. Others have used SrtA and butelase-1, which is believed to have a much 
higher turnover number compared to SrtA448, 449.  
Nanobodies are already used as a counterpart to antibodies, resulting in improved 
imaging resolution. NHS chemistry was employed for AF647 labelling of anti-tubulin 
nanobodies164 and it was observed that the AF647-nanobody resolved microtubules 
much better than a conventional (directly labelled) anti-tubulin antibody using single 
molecule localization microscopy (SMLM). Others were able to visualize the nuclear pore 
complex with AF647-labelled nanobodies at high resolution using stochastic optical 
reconstruction microscopy (STORM) microscopy179. The nanobodies were labelled using 
both NHS and maleimide. Endogenous tubulin has been targeted with labelled 
nanobodies by using the DNA-PAINT (DNA point accumulation for imaging in nanoscale 
topography) method based on sortase coupling450. Thus nanobodies may further develop 
into excellent tools for future super resolution microscopy in which high precision and 
accuracy is desired. For this it is important to minimize the linkage error, a result not only 
of the size of the protein moiety (the nanobody) but also of the size of the fluorescent 
molecule. The smaller a fluorophore, the more accuracy and resolution can be gained. If 
resolution at the level of tens of nm is not required, GFP fusion nanobodies can 
nevertheless yield interesting data as shown for protein-protein interactions108.  
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For entry into cells, chemical permeabilization and fixation is one method, but this kills 
the cells and may cause blockage of the binding site or alter protein structure272. 
Moreover, permeabilisation can also be disadvantageous as it can cause loss of proteins 
or even promote their relocalisation272. As shown in Figure 47, β-catenin Nb86 was 
ineffective in reaching its target in 4% PFA fixed cells, but this could be circumvented by 
first delivering the nanobody by photoporation. This illustrates the effect of fixation and 
the advantage of addressing living cells. Introduction of recombinant nanobodies into 
living cells, and target binding under native conditions, combined with live cell imaging, 
could solve problems of fixation and permeabilisation, although the delivery of proteins 
is challenging272. Coupling of cell-penetrating peptides (such as cyclic arginine-rich 
peptides59 or penetratin60, 451) to nanobodies, transportation of nanobodies in 
mesoporous silica nanoparticles65 or using an E. coli type III secretion system39, 66 have 
been employed previously to address this issue. Another option is the use of streptolysin 
O to create pores into the cell membrane to allow diffusion of nanobodies from the cell 
medium into the cytosol[50]. Photoporation is a recent technique which has major 
advantages compared to other protein delivery techniques. It allows targeting of many 
cells (>80%), with low toxicity (< 2%) and a broad range of cells, even primary cells67, 68, 70, 
71, 74. A comparative experiment was performed in which FITC-Dextran-10kDa was 
delivered into HeLa cells using photoporation or electroporation, as a standard 
transfection method67. It was observed that cell viability was higher with photoporation. 
Electroporation resulted in more (>90%) positive cells, but the amount of FITC-Dextran-
10kDa was lower in each cell compared to photoporation. Another advantage of 
photoporation is the ability to use a recipient of choice and compatibility with optical 
microscopy, while electroporation only allows use of non-adherent cells in a specific 
electroporation recipient67. Photoporation was also compared to the commercial protein 
transfection (PULSin) reported to be efficient for cytosolic delivery of proteins and 
peptides such as antibodies and nanobodies68. An inhomogeneous intracellular staining 
pattern of histone nanobodies was observed with this method together with toxicity 
which was not observed when using photoporation. 
In conclusion, we propose that the combination of fluorescent nanobodies and 
photoporation may develop into a new method for studying protein behavior and 
function in mammalian cells. As pharmacological inhibitors are lacking for many 
cytoplasmic proteins that, by virtue of their properties, do not display catalytic activity, it 
is expected that new biological information will be obtained through photoporation of 
nanobodies. 
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6.2.5 Material & methods  
6.2.5.1 Antibodies and reagents 
Rabbit monoclonal anti-β-catenin (ab32572) was obtained from Abcam (Cambridge, UK), 
the mouse monoclonal anti-cortactin clone 4F11 from Millipore (Billerica, MA, USA). 
Alexa Fluor-labelled secondary goat anti-rabbit or anti-mouse IgG antibodies were 
obtained from Molecular Probes (Eugene, OR, USA). Alexa Fluor-labelled phalloidin was 
from Invitrogen (Merelbeke, Belgium). The synthetic peptide GGGY-propargylglycine 
(GGGY-PAG) was chemically synthesized by Peptide Specialty Laboratories GmbH 
(Heidelberg, Germany). pEVOL-pAzF was a gift from Prof. Dr. Peter Schultz (Scripps 
Research Institute, Cincinnati, OH, USA) (Addgene plasmid #31186; 
http://n2t.net/addgene:31186; RRID:Addgene_31186)225. Sortase A pentamutant in 
pET29 was a gift from Prof. Dr. David Liu (Harvard University, Cambridge, MA, USA) 
(Addgene plasmid #75144; http://n2t.net/addgene:75144; RRID:Addgene_75144)452. 
6.2.5.2 cDNA cloning 
Nanobodies were cloned into a pMECS or pHEN6 vector, as described before47, 215. The 
nanobodies were subcloned by means of a Cold Fusion Cloning Kit (System Biosciences, 
Mountain View, CA, USA). To add the sortag to a nanobody, the first subcloning was 
performed into pMECS vector by using the following primers: forward 5’-GATGTGCAGCT 
GCAGGAGTCTGGAGGAGG-3’ and reverse 5’-CTAGTGCGGCCGCGCCACCGGTTTCCGGAAGC 
GCGCTGCCTGAGGAGACGGTGACCTGGGT-3’. For amber stop codon introduction, cloning 
of the nanobodies in the pHEN6 vector was done using the following primers: forward 
pHEN6 5’-CCAGGTGCAGCTGCAGGAGTCTGGGGGAGGATT-3’ and reverse pHEN6 5’-GTCAC 
CGTCTCCTCAGGAGGAAGCGGTGGCTAGACCGGTCATCATCACCATC-3’. 
6.2.5.3 Recombinant nanobody and sortase A pentamutant production 
The production and purification of the nanobodies, was performed as described 
previously47. E. coli WK6 cells were transformed with nanobodies in pMECS/pHEN6 
vector. They were grown at 37 °C in TB with 100 μg/ml ampicillin (Duchefa, Haarlem, the 
Netherlands) and if the pEVOL-pAzF was co-transformed, with 34 μg/ml chloramphenicol 
(Duchefa) and 1 mM pAzF. After induction with 0.2% (w/v) arabinose (Sigma-Aldrich, St. 
Louis, MO, USA) and 1 mM IPTG (Biosynth, Staad, Switzerland), incubation was 
performed at 28 °C overnight. French press was used to obtain total cell lysis followed by 
short sonication. Next, an IMAC purification was performed as described before47. 
Briefly, the recombinant His6-tagged nanobodies were purified from E. coli WK6 cells by 
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binding to Co2+-chelating resins (Takara Bio Inc., France) and were recovered from the 
beads with standard elution buffer (50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazol, 
pH 8.0), the potassium phosphate elution buffer (100 mM potassium phosphate, 100 
mM KCl, 250 mM imidazole, pH 7.4) or the HEPES elution buffer (50 mM HEPES 
(Duchefa), 50 mM NaCl (Duchefa), 250 mM imidazole, pH 8.0). 
Sortase A pentamutant in pET29 was transformed in E. Coli BL21 cells and grown at 37 °C 
in LB with kanamycin. After induction with IPTG, they were incubated at 20 °C overnight. 
French press was used to obtain total lysis followed by short sonication. Next an IMAC 
purification was performed as mentioned above.  
6.2.5.4 Sortase A reaction  
The nanobodies were dialyzed into a sortase compatible buffer (50 mM Tris-HCl 
(Duchefa Biochemie, Haarlem, The Netherlands), 150 mM NaCl, pH 8.0). Subsequently, 
the sortase reaction was performed at 30 °C for 90 min. The reaction mixture (total 
volume 100 µl) consists of 50 µM peptide, 4 µM sortase A pentamutant, 20 µM 
nanobody in sortase reaction buffer (50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl2 
(Sigma-Aldrich, St. Louis, MO, USA), pH 8.0). Thereafter, immobilized metal affinity 
chromatography (IMAC) purification was used to remove His6-tagged proteins still 
present in the mixture.  
6.2.5.5 CuAAC after sortase: test experiment for optimisation – benefit of 
HEPES 
After sortase reaction, the nanobodies were used directly or were diafiltered through an 
Amicon Ultra-0.5 Centrifugal Filter Unit (MWCO 3kDa) (Sigma-Aldrich) according to the 
manufacturer’s instructions, into a buffer with lower Cl- ions concentration (10 mM 
HEPES-NaOH, 50 mM NaCl, pH 8). Subsequently, Cu(I)-catalyzed Azide-Alkyne Click 
Chemistry (CuAAC) was performed. Two tubes were prepared of which the first tube 
contained CuSO4 (20 mM stock solution) (Merck, Overijse, Belgium), tris(3-
hydroxypropyltriazolylmethyl)amine (THTPA) (50 mM stock solution) (Sigma-Aldrich) and 
sodium ascorbate (100 mM stock solution) (Sigma-Aldrich) and the second contained 
HEPES (100 mM stock solution), an alkyne-bearing nanobody and an azide-Alexa Fluor 
AF488 (5 mM stock solution) (Jena Bioscience, Jena, Germany). Bringing the content of 
both tubes together, the final concentrations (Buffer 1 at Table 2) were 0.1 mM CuSO4, 
0.5 mM THTPA, 5 mM sodium ascorbate, 10 mM HEPES-NaOH, 3 µM nanobody and 6 
µM azide-AF488. This was incubated overnight at 33 °C and analysed on sodium dodecyl 
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sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) and with a FastGene FAS-digi 
Geldoc device (NIPPON genetics, Dueren, Germany). 
6.2.5.6 CuAAC after sortase: test experiment for optimisation – benefit of 
THPTA or sodium ascorbate 
After sortase reaction, the nanobodies were diafiltered through an Amicon Ultra-0.5 
Centrifugal Filter Unit (MWCO 3kDa) (Sigma-Aldrich) according to the manufacturer’s 
instructions into a low Cl- ions solution (10 mM HEPES-NaOH, 50 mM NaCl, pH 8). 
Subsequently, CuAAC was performed. Two tubes were prepared of which the first tube 
contained CuSO4 (20 mM stock solution) (Merck), THTPA (50 mM stock solution) (Sigma-
Aldrich) and sodium ascorbate (100 mM stock solution) (Sigma-Aldrich) and the second 
contained HEPES (100 mM stock solution), an alkyne-bearing nanobody and an azide-
AF488 (5 mM stock solution) (Jena Bioscience). Bringing the content of both tubes 
together started the reaction. The end concentration in this mixture was determined by 
the conditions in the experiment. For the following compounds, the final concentrations 
remained constant at 0.1 mM CuSO4, 50 mM HEPES-NaOH, 5 µM nanobody and 10 µM 
azide-AF488. THTPA and sodium ascorbate were different in the different conditions as 
can be seen in Table 2. The mixtures were incubated overnight at 33 °C and analysed by 
SDS-PAGE and with a FastGene FAS-digi Geldoc device (NIPPON genetics). 
6.2.5.7 CuAAC after pAzF incorporation: test experiment for optimisation – 
time point determination 
After the pAzF incorporation (see supplementary material), nanobodies were dialyzed 
against a HEPES buffer (50 mM HEPES-NaOH, 50 mM NaCl, pH 7.4) to make them 
compatible with the CuAAC reaction. Two tubes were prepared (one with CuSO4 (20 mM 
stock solution), THTPA (50 mM stock solution) and sodium ascorbate (100 mM stock 
solution), the other with HEPES (100 mM stock solution), pAzF containing nanobody and 
alkyne-AF488 (5 mM stock solution) (Jena Bioscience)) and mixed gently to obtain final 
concentrations of 0.1 mM CuSO4, 1 mM THTPA, 7.5 mM sodium ascorbate, 50 mM 
HEPES-NaOH, 30 µM nanobody and 60 µM alkyne-AF488. At each time point (0, 5, 15, 
20, 30, 45, 60 and 75 min) during the CuAAC reaction, a 3 µl sample out of the total 
reaction mixture volume of 400 µl was removed and analysed by SDS-PAGE and with a 
FastGene FAS-digi Geldoc device (NIPPON genetics). 
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6.2.5.8 CuAAC to obtain fluorescently labelled nanobodies - final protocol 
After the pAzF incorporation, nanobodies were dialyzed against HEPES buffer (50 mM 
HEPES-NaOH, 50 mM NaCl, pH 7.4) to make them compatible with the CuAAC reaction. 
Before the start of CuAAC, two tubes were prepared. The first tube contains CuSO4 (20 
mM stock solution) (Merck), THTPA (50 mM stock solution) (Sigma-Aldrich) and sodium 
ascorbate (100 mM stock solution) (Sigma-Aldrich), while the second tube contained 
HEPES (100 mM stock solution), a pAzF containing nanobody and an alkyne-AF488 (5 mM 
stock solution) (Jena Bioscience). After mixing both tubes, the final concentrations in this 
mixture are 0.1 mM CuSO4, 1 mM THTPA, 7.5 mM sodium ascorbate, 50 mM HEPES-
NaOH, 30 µM nanobody and 60 µM alkyne-AF488. This was incubated for 60 min at 33 
°C. Thereafter, an EDTA solution (20 mM HEPES-NaOH, 500 µM EDTA (Sigma-Aldrich), pH 
7.4) was used to complex the Cu2+ ions. Their removal from the mixture was achieved by 
diafiltration using an Amicon Ultra-0.5 Centrifugal Filter Unit (MWCO 3kDa) (Sigma-
Aldrich). At least 3 times the reaction volume of the EDTA solution was used during the 
diafiltration. This was followed by a PD Spintrap™ G-25 (Sigma-Aldrich) used according to 
the manufacturer’s instructions. The product was analysed by SDS-PAGE and a FastGene 
FAS-digi Geldoc device(NIPPON genetics), and protein concentrations were determined 
using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). 
6.2.5.9 Immunocytochemistry and microscopy 
The immunocytochemistry was performed as described before389. Cells were seeded on a 
100 µg/ml gelatine (Sigma-Aldrich) or 50 µg/ml rat tail type I collagen (BD Biosciences, 
Franklin Lakes, NJ, USA) coated coverslip. In case of a 4% paraformaldehyde (PFA) 
fixation, cells were fixed using 4% PFA, permeabilized using 0.2% TritonX-100 (Sigma-
Aldrich) for 5 minutes and neutralized and blocked in 20 mM glycine (Sigma-Aldrich) for 
20 minutes. In case of a methanol fixation, cells were fixed and permeabilised with 100% 
ice-cold methanol for 5 minutes and blocked in 20 mM glycine (Sigma-Aldrich) for 60 
minutes. After the blocking steps, an incubation with primary antibodies or labelled 
nanobody (1 h at 37 °C) was performed and if necessary followed by Alexa Fluor-
conjugated secondary antibodies (30 min at room temperature). DAPI (0.4 µg/ml; Sigma) 
and Alexa Fluor labelled phalloidin (Invitrogen) were used to stain nuclei and actin 
filaments, respectively. Cells were mounted using VectaShield (Vector Laboratories, 
Burlingame, CA, USA). For imaging, an Olympus IX81 FluoView 1000 confocal laser 
scanning microscope (UPlanSApo x60 1.35-NA UplanSApo objective; Olympus, Tokyo, 
Japan) with FluoView FV1000 software (Olympus) was used at room temperature. 
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6.2.5.10 Photoporation  
The photoporation was performed as described in more detail elsewhere67. Briefly, a µ-
slide (µ-Slide Angiogenesis, ibidi, Beloeil, Belgium) was seeded with 5000 HeLa cells per 
well one day in advance. Before laser treatment, cells were incubated with graphene 
quantum dots-PEG suspended in cell culture medium for 30 min. The fluorescently 
labelled nanobody was dispersed in Dulbecco's phosphate-buffered saline (DPBS) at a 
concentration of approximately 40 μg/mL. 10 μL nanobody solution was added into each 
well before the photoporation laser treatment. The sample was scanned through the 
photoporation laser beam (20 Hz pulse frequency) using an electronic microscope stage 
(HLD117, Prior Scientific, USA). The scanning speed was 2.1 mm/s, and the distance 
between subsequent lines was 0.1 mm to ensure that each cell received a single laser 
pulse. The total scanning time per well was 2 min. The fluorophore solution was then 
removed and the cells were gently washed with DPBS and supplemented with fresh cell 
culture medium. Samples were analysed using a spinning disk confocal microscope 
(Nikon eclipse Ti-e inverted microscope, Nikon, Japan) equipped with an MLC 400 B laser 
box (Agilent technologies, Santa Clara, CA, USA), a Yokogawa CSU-22 Spinning Disk 
scanner (Andor Technology, Belfast, UK) and an iXon ultra EMCCD camera (Andor). A 
60×/1.4 oil immersion objective lens (CFI Plan Apo VC 60 × oil, Nikon, Japan) was used for 
imaging.  
6.2.5.11 Cell culture 
HNSCC61 and HeLa cells were maintained at 37 °C in a humidified 5% CO2 incubator. All 
were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco Life Technologies, 
Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 10 µg/mL 
streptomycin and 10 IU/mL penicillin. In case of HNSCC61 cells, an extra 0.4 µg/mL 
hydrocortisone (Sigma-Aldrich) was added and 20% fetal bovine serum was used. 
6.2.5.12 Generation of β-catenin nanobodies 
A cDNA fragment covering the C-terminal half of human catenin (amino acids 398-end) 
was cloned into the pTYB12 prokaryotic expression vector and expression/purification 
was done as described for other constructs described above. A llama was immunized 
with this protein fragment by a subcutaneous injection on days 0, 14, 28 and 35. 
Anticoagulated blood was collected on day 39 for lymphocyte preparation. By extracting 
total RNA from peripheral blood lymphocytes, a nanobody library was constructed and 
screened for the presence of antigen-specific nanobodies by phage panning. The 
 110 
obtained nanobodies were subcloned into the phagemid vector pMECS. They are 
currently licensed to Gulliver Biomed (www.gulliverbiomed.com). 
6.2.6 Supplementary information 
6.2.6.1 Incorporation of an azido/alkyne functional group into a nanobody 
Sortase A (SrtA) is a transpeptidase that recognizes the specific amino acid sequence 
LPETG (Leu – Pro – Glu – Tyr – Gly). This sequence was genetically incorporated at the    
C-terminus of the cortactin nanobody 2 by PCR, resulting in a nanobody sequence that is 
C-terminally followed by a GSA linker sequence and the LPETG sortag sequence followed 
by a His6-tag. This cortactin Nb2 was shown to diminish invadopodium numbers, matrix 
degradation, MMP9 secretion and invasive capacity in invasive MDA-MB-231 and 
HNSCC61 cells45, 46, 48, 433. The modified cortactin nanobody was expressed and purified 
from bacteria following a procedure similar to standard nanobody production as 
performed before47, 215, 406. As described earlier191, SrtA cleaves the nanobody at Gly 
residue of the sortag sequence, removing this residue in addition to the His6-tag (Figure 
41A). This creates a nanobody-SrtA intermediate. Next, sortase A couples the donor 
peptide Gly-Gly-Gly-Tyr-Propargylglycine (GGGY-PAG) onto the acceptor nanobody 
(Figure 41A), which as a result of this reaction process acquires an alkyne group. Since 
sortase A also carries a His6-tag as well as the unmodified nanobody, all nanobody 
molecules which have not taken part in the sortase reaction together with sortase A 
itself can be easily removed by Ni2+ or Co2+ IMAC. In the final reaction, 50 µM peptide : 4 
µM sortase A : 20 µM nanobody was used. As expected, the nanobody is cleaved at the 
sortag sequence and the donor peptide is coupled. After a few consecutive Co2+ IMAC 
incubation steps, the remaining protein band corresponds to the new nanobody 
derivative that contains the alkyne group. 
Next to an enzymatic way to incorporate an alkyne moiety, a second method was 
explored based on the incorporation of an unnatural amino acid bearing an azido group 
(Figure 41B). For this purpose, para-azido phenylalanine was used. As pAzF is a non-
canonical amino acid, an amber stop codon (TAG) was genetically engineered at the C-
terminus of the nanobody, before the His6-tag. By using the correct tRNA/tRNA 
synthetase orthogonal pair (pEVOL-pAzF (Addgene plasmid #31186)), pAzF is specifically 
and site-selectively incorporated at the amber stop codon in the nanobody sequence225. 
By engineering this construct, all purified nanobodies are expected to contain the azido 
group, because if they do not incorporate the pAzF, the resulting nanobody will not carry 
a His6-tag and thus cannot be purified by IMAC. Moreover, the tRNA synthetase from 
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Methanococcus jannaschiityrosyl used in this study does not aminoacylate any 
endogenous E. coli tRNAs, but only the mutant tyrosine amber suppressor (mutRNACUA) 
225, 453. 
6.2.6.2 Additional information for CuAAC 
Once a nanobody bearing an alkyne/azido group was generated, the Cu(I)-catalysed 
Azide-Alkyne Click Chemistry (CuAAC) reaction can be performed. The catalytic 
component is a Cu(I)-source which is a copper(II) sulfate (CuSO4) salt in combination with 
sodium ascorbate to reduce Cu(II) to Cu(I), and tris(3-hydroxypropyltriazolylmethyl) 
amine (THPTA) which stabilizes Cu(I). THPTA addition is important as this ligand blocks 
the bioavailability of Cu(I) and prevents potential toxic effects425. Based on the findings of 
Presolski and Hong et al.423-425, a test protocol was developed. The azido-fluorophore and 
the alkynylated cortactin nanobody 245, 46, 48, 433 were incubated overnight in a 2:1 ratio 
with 0.1 mM CuSO4, 0.5 mM THTPA, 5 mM sodium ascorbate, 10 mM HEPES buffer at   
33 °C. Different fluorophores are commercially available and are suitable to label 
alkyne/azido-derivatized nanobodies in this manner. 
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 General discussion and conclusions Chapter 7
This work showed the use of nanobodies in research for studying protein functions and 
for imaging of proteins. This was shown separately, but in future experiments these two 
projects can be brought together to establish a new research purposes and obtaining 
new insights in the biological mechanisms. In following paragraphs, both projects are 
discussed separately as the targeted proteins in both projects were different as well. 
 VCA nanobodies, a tool to study N-WASp functioning in 7.1
the invadopodium pathway  
Different strategies are available to study a protein of interest. It can be obtained 
through knockdown or knockout techniques. A frequently used method is RNA 
interference (RNAi). This method causes gene silencing at a post-transcriptional level84, 
388. It is a straightforward technique but it is limited in its specificity84. A variant to RNAi is 
the antisense oligonucleotide method (ASOs) in which the RNA is degraded by RNase 
H388. Further, a more recent and well-known knockout strategy is the CRISPR/Cas9 
genome editing method388, 454. This is a method in which a bacterial endonuclease 
enzyme targets a desired site in the genome388. This enables the removal or replacement 
of the gene of interest388. While CRISPR/Cas9 is an easy-to-use and affordable strategy 
for gene editing, it has some not negligible off-target effects resulting in the deletion or 
modification of the wrong genes and/or genomic instability417, 454, 455. Since those are all 
strategies aimed at the DNA level, the nanobody technology used here, enables to study 
a protein of interest at a post-translational level. The big difference to the above 
mentioned methods is found in the way nanobodies create a knockout of protein 
functions84 meaning that nanobodies enable to investigate the function of only a part or 
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a domain of the protein of interest, while the other domains still can interact with their 
usual interaction partners. This was observed previously for fascin Nb5. If the nanobody 
was present, it reduced the invasiveness of cancer cells via a reduced invadopodia 
density and a decreased elongation and lifetime of invadopodia45. Moreover, the 
nanobody can also be used to relocate the protein and in that case the nanobody 
technology can introduce other outcomes. When the same fascin Nb5 was used but 
tagged with a mitochondrial outer membrane (MOM) delocalisation tag, an additionally 
reduced secretion and activity of MMPs could be observed45. In this case, not only the 
domain is ‘silenced’, fascin cannot interact similar to native conditions due to the 
delocalisation to the mitochondrial outer membrane.  
Adding to the advantage of selectively studying protein function, nanobody technology 
enables to analyse the target protein at an endogenous level, which avoids possible 
effects that could be introduced by overexpression. Those overexpression effects can 
differ from the ones with expression levels that are found in healthy cells or maybe even 
cancer cells. Indeed, changes in expression levels for many proteins have been observed 
previously to enhance the cancer pathway. By performing overexpression, there is a risk 
of activating other processes to keep the cell balanced. Similar to GFP fusion proteins, by 
inserting an exogenous gene into the cell, two populations are found: the endogenous 
protein and the extra inserted exogenous gene translated product456. If the inserted 
protein is tagged or labelled, it can result in different interactions than with other 
proteins as compared to the endogenous protein. This can be caused by steric hindrance 
of the tag or label, and/or the presence of the endogenous protein that is still able to 
interact as well456. An additional advantage of using the nanobody technology for protein 
studies, is the longer active half-life of a nanobody (compared to RNA based methods)84. 
Here, VCA nanobodies were used to study N-WASp. In this case, only the VCA domain 
was targeted, while the other domains of N-WASp still can interact as usual. Previously, it 
was observed that N-WASp is important in embryonic development since total loss of   
N-WASp caused embryonic lethality291. This shows that studies through knockout mice 
were not an option. However, an N-WASp – knockout in keratinocytes of the skin proved 
to be possible, although it introduced some other defects as well such as growth 
problems and body weight reduction291. Furthermore, other techniques were used for  
N-WASp studies as well, such as overexpression of the full length N-WASp457 or through 
the expression of a dominant negative N-WASp. The latter can be an N-WASp variant 
with a deletion of a domain458 or a deletion of only a few amino acids336, 337, 373, 394, 459. 
However, a deletion or change in amino acid sequence can introduce differences in the 
conformation of the protein compared to the native structure. In contrast, instead of 
modifying the native N-WASp, here we used the nanobody technology which enables to 
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investigate N-WASp in its native conformation and location without silencing the whole 
protein.  
First, a characterisation was done to select the nanobodies that were able to bind          
N-WASp. Eventually, we selected four nanobodies which were used in the experiments. 
To confirm the binding capacity of the nanobodies in the cytoplasm, a MOM tag was 
used to relocate the nanobodies and N-WASp to mitochondria. After the 
characterisation, the VCA nanobodies were used for further examination of N-WASp 
functions. As the N-WASp nanobodies target its C-terminal VCA domain, they were found 
to interfere with the Arp2/3 interaction (Figure 49). They were able to perturb the N-
WASp function and affect actin polymerisation in three cell lines, breast cancer cells 
(MDA-MB-231), head and neck squamous carcinoma cells (HNSCC61) and prostate 
cancer cells (PC-3). This resulted in the reduction of invadopodium numbers and in the 
disturbance of the overall matrix degradation (Table 5). The effects on the number of 
invadopodia indicated clearly that N-WASp is involved in the formation pathway.  
 
Figure 49: VCA Nbs binding on VCA domain of N-WASp. While the verprolin-homology (V) region of N-WASp interacts with 
actin, the cofilin-like (C) and acidic (A) part binds to Arp2 and Arp3 of the Arp2/3 complex. Since the immunoprecipitation of 
the VCA domain with the nanobodies resulted in only a decrease of Arp2/3, the VCA nanobodies interact with the CA part 
of N-WASp. Since N-WASp made a double interaction with Arp2/3, each binding has another influence on the activation of 
the N-WASp:Arp2/3 complex. The first interaction occurs at the A region which is important for the affinity between N-
WASp and the Arp2/3 complex while the second interaction with the C region does not need high affinity but is required for 
a better Arp2/3 activation. Since VCA Nb7 and VCA Nb14 have a bigger influence on the degradation and a lower influence 
on the Arp2/3 binding, we hypothesised that those VCA nanobodies interfere the Arp2/3 – C region interaction, while VCA 
Nb2 and VCA Nb13 disturb the Arp2/3 – A region interaction. 
 
Table 5: Overview of the effects on the invadopodium pathway due to the VCA nanobodies. The binding assay showed 
that the VCA nanobodies were able to decrease the binding between N-WASp and Arp2/3 and they did not have any effect 
on the actin – N-WASp interaction. The invadopodia amounts were significantly decreased in the presence of the VCA 
nanobodies as intrabodies in two different cancer cell lines (MDA-MB-231 breast cancer cells and HNSCC61 head and neck 
squamous carcinoma cells). Next, only two nanobodies were able to cause significant reduction of the overall ECM 
degradation (PC-3 prostate cancer cells). The values in this table are based on the ‘degradation index’ which is the 
parameter that is the normalised difference between the mean grey value of the background (here the red fluorescent 
labelled gelatin matrix) and the mean grey value of the cell area. (* p < 5%, ** p < 1%, *** p < 0.01%) 
 VCA Nb2 VCA Nb7 VCA Nb13 VCA Nb14 
Binding assay: 
Arp2/3 –N-WASp 
↓↓ ↓ ↓↓ ↓ 
Invadopodia 
MDA-MB-231 * *** *** *** 
HNSCC61 ** *** *** *** 
Overall ECM degradation (PC-3)  **  *** 
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Due to inhibitory effect on invadopodium formation, defects in the invadopodia may 
result in a decreased degradation capacity. Only two of the four nanobodies (VCA Nb7 
and VCA Nb14) were able to show a significant effect on the overall ECM degradation, 
but small non-significant changes in MMP9 secretion and activity were found for all four 
VCA nanobodies (Figure 39). As described previously, N-WASp is involved in the matrix 
degradation pathway as well. MMP degradation is based on both membrane bound 
MMPs (such as MT1-MMP) and soluble MMPs (e.g. MMP2 and MMP9). The association 
of N-WASp with the MMP pathway is reflected in MMP delivery by vesicular transport356, 
358. As discussed before (3.3.4.4 Maturation and ECM degradation), different pathways 
exist to deliver MMPs to invadopodial sites302. In endocytosis, N-WASp is suggested to 
create a branched actin network resulting in a force that is able to reshape the 
membrane leading to vesicle invagination331, 344, 353-355. This means that the actin 
cytoskeleton causes the driving force for pinching off the endosome355. Additionally, N-
WASp helps in the establishment of actin comet tails to endosome vesicles356-358. This 
creates a propelling force that enhances the transport of the endosome through the 
invadopodium358. Besides the transport, N-WASp is supposed to stabilise and fix MT1-
MMP at invadopodial locations344. By doing this, the functionality of MT1-MMP is 
enhanced344. Since we were not able to detect MMP2, we checked MMP9 and MT1-
MMP in this study, as those are the most abundant MMPs. By using the VCA Nbs, we 
observed small non-significant changes in MMP9 secretion and activity. When we 
checked the master switch MT1-MMP, we did not observe changes using the VCA 
nanobodies as intrabody (Figure 39). We conclude that our VCA nanobodies were able to 
interfere in the invadopodium formation, while the degradation effects were a result of 
the invadopodium defective structure. So, the role of the VCA domain of N-WASp is 
mainly important in the initial steps of the invadopodium pathway. This confirms the 
findings of Castro-Castro et al.316 and Gomez et al.460. They indicated that another 
member of the WASp protein family, the Wiskott–Aldrich syndrome protein and Scar 
homologue (WASH), is involved in these processes instead of N-WASp. WASH has been 
found to be important for exocytosis to transport MMP bearing vesicles from Golgi to 
the invadopodium membrane316. Gomez suggested that WASH was required for 
endosomal and lysosomal networks in mammalian cells292, 460. As WASH is found in the 
endosomal, lysosomal and exocyst pathways, this can explain why the influence of the 
VCA nanobodies on the MMP9 secretion and degradation is minimal or even not existing. 
However, Jacob and co-workers have found that the delivery of MT1-MMP differs from 
the delivery routes of MMP2 and MMP9351, 352. MT1-MMP transport is a balance 
between exocytosis and endocytosis352, while the secretion of MMP2 and MMP9 will rely 
on the delivery in Rab40 bearing secretory vesicles from the Golgi to the membrane351. 
Another possible explanation is that the VCA domain is not important for the ECM 
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degradation, but another domain of N-WASp is. In that case, it can explain why our VCA 
Nbs are not able to cause huge reductions in the ECM degradation. Benesch and co-
workers observed that the WH1 domain and the poly-proline domain contributed to the 
interaction of the vesicle surface and the actin comet tail formation. This would suggest 
that N-WASp still can play a role in the MMP recruitment359.  
Since N-WASp interacts directly with cortactin, this could lead to the suggestion that 
nanobodies targeting cortactin and the VCA nanobodies would have a similar influence 
on the MMP9 secretion and activity48. However, our earlier studies on cortactin 
significantly reduced the MMP9 secretion and activity by using nanobodies targeting its 
C-terminal SH3 or the N-terminal NTA domains48. Hence, by using nanobodies we can 
attribute specific roles of cytoskeletal proteins in cancer cell invadopodium formation 
and functioning. This information can be very instrumental for the generation of future 
protein domain-selective compounds and therapeutic targeting of tumor cell motility.  
 Fluorescent nanobodies, an emerging tool for 7.2
microscopic purposes in fixed and living cells 
The enthusiasm for smaller fluorescent imaging tools is heightened in the last years, 
congruent with increasing resolution of microscopic techniques. In this case, nanobodies 
are receiving more and more attention since they are a good alternative to antibodies. 
Since the linkage error is relatively large when using antibodies, the nanobodies offer 
benefits in techniques where a high resolution is required. Recently, some companies 
(e.g. ChromoTek461 and NanoTag Biotechnologies462) started to offer nanobodies for 
super resolution purposes. However, the commercially available labelled nanobodies are 
limited to a small range of targets463. In most cases, they target fluorescent proteins (e.g. 
GFP and RFP). This will indeed minimise the linkage error to the fluorescent protein463. 
Nevertheless, the benefits of small linkage error and high resolution are contradictory to 
the size of the fluorescent protein that is coupled to the protein of interest, which also 
can include possible side effects compared to the case of the endogenous protein (such 
as loss of function, multimerization or mislocalization)166. In other words, the localisation 
of the fluorescent protein is more precise and accurate than in case of using an antibody, 
but the benefits of using nanobodies for super resolution are partially undone by the use 
of a fluorescent protein fused to the protein of interest. This leads to a resolving power 
that is not fully used. Therefore, it would be beneficial to use nanobodies against the 
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protein directly. In our study, the nanobodies do target the endogenous protein which is 
cortactin and β-catenin. This enables the visualisation of the protein in its native 
conditions. The visualisation of the protein of interest with a fluorescent nanobody 
results in a detected signal that can be converted into a more accurate position 
compared to the observed intensities when detecting the fluorescent protein fused to 
the protein of interest. Besides, by targeting the protein of interest directly, the risks and 
problems which are possible due to the fusion protein, are avoided. It is therefore 
beneficial to have nanobodies targeting the endogenous protein. 
Companies such as ChromoTek offer nanobodies tagged with a fluorescent protein, 
which they call chromobodies. These are delivered by plasmids that have to be 
transfected into the cells to allow the nanobody to target the protein of interest. This 
immediately shows the differences in visualisation we propose in our work. First, the use 
of a fluorophore such as GFP will be detected as a bigger, more blurred position than 
when a high-quality small dye is used. Additionally, fluorescent proteins suffer from a 
limited photostability, spectral range and brightness170. A smaller dye offers benefits in 
higher resolution microscopic techniques. As such, labelled nanobodies with a small 
chemical dye are difficult to be expressed or delivered in living cells. This indicates the 
second problem that is also found with the commercial chromobodies: nanobodies 
cannot breach the cell membrane as recombinant protein. As mentioned above, 
chromobodies avoid this problem by entering the cells as DNA. Initially, the labelled 
nanobodies used in our work have found their application in standard 
immunocytochemistry.  
In this study, two strategies were compared to obtain labelled nanobodies. Our first 
labelling strategy used sortase A as basic instrument. For this, a two-step process was 
executed in which the SrtA enzyme first couples a peptide onto a nanobody followed by 
the CuAAC reaction. While SrtA is versatile in respect to the moieties that can be coupled 
to a nanobody464, the commercial substrates are rather limited. However, other groups 
have already performed the sortase reaction as a one-step method by using a 
fluorescent peptide. Massa et al.191 used a Cy5 labelled peptide (GGGYK-Cy5) for this. 
Since their goal was to use those nanobodies for visualisation in living animals through 
fluorescence reflectance imaging (FRI)191, no confocal or super resolution microscopy 
was executed. In our hands, the one step sortase method using the GGGYK-Cy5 peptide 
resulted in a very low intensity signal for confocal microscopy purposes (unpublished 
data). In another study, Truttmann and co-workers attached a GGG-AF647 peptide into 
an anti-HypE nanobody (Huntingtin-associated yeast-interacting protein E) via the 
sortase reaction for visualisation on confocal microscopy192. They also observed low 
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intensity and suggested that this was caused by the ratio of a single dye to one 
nanobody192.  
The sortase A enzyme, and other similar enzymes probably as well, catalyse reversible 
reactions36. Hence, a peptide that was previously coupled onto a nanobody or another 
cargo can be released again. This results in a lower yield of the fluorescently labelled 
protein. Such enzymatic reactions can be avoided by incorporating an unnatural amino 
acid into a nanobody as part of its primary structure. This was also implemented in our 
second labelling strategy. Compared to our first strategy (with sortase A), the non-
canonical amino acid incorporation is a one step process. After the nanobody 
production, the click chemistry can follow directly. In this study, a pAzF is incorporated 
into the nanobody with a tRNA/tRNA synthetase orthogonal pair which was already 
available. Next, a copper catalysed chemical reaction was used, called copper catalysed 
azido-alkyne click chemistry or CuAAC. For this reaction already many fluorophores 
(AF488, AF546, AF555, AF594, AF647, Cy5, Cy7 …) are commercially available. Because 
some studies indicated that Cu ions may cause toxicity, it is advised to keep the Cu ions 
at a low level. In order to reduce the amounts of Cu(I) and so the ROS level, some water-
soluble ligands can be used, such as tris-(3-hydroxypropyltriazolylmethyl)-amine 
(THPTA), tris-(benzyltriazolylmethyl)amine (TBTA), bis(L-histidine), 2-[4-((bis[(1-tertbutyl-
1H-1,2,3-triazol-4-yl)methyl]amino)-methyl)-1H-1,2,3-triazol-1-yl]ethyl hydrogen sulfate 
(BTTES) and 2-[4-((bis[(1-tert-butyl-1H-1,2,3-triazol-4-yl)methyl]amino)methyl)-1H-1,2,3-
triazol-1-yl]acetic acid (BTTAA)183, 217, 247. Nevertheless, reactions without metals or other 
ligands can be taken into consideration. A Cu-independent alternative of CuAAC is known 
as strain promoted azide–alkyne click reaction (SPAAC). When performing the SPAAC 
reaction, other fluorescent moieties are required than in case of CuAAC which are 
commercially available already; e.g. DBCO, difluorocyclooctyne (DIFO) derivatives, 
dibenzocyclooctynes (DIBO) and biarylazacyclooctynone compounds (BARAC)183.  
Labelled nanobodies can have different purposes such as Western blotting but in this 
work they were used for microscopic goals. Only recently, the benefits of nanobodies for 
super resolution are becoming clear. The most important one is the reduction in linkage 
error which allows an improvement of the accuracy and precision of the image. Yet, 
there are only few studies which have used nanobodies for super resolution microscopy 
(Table 6). Due to the recent and successful imaging studies, it indicates that the use of a 
directly labelled nanobody in microscopic applications is still a relatively young research 
tool and will likely attract more attention in the future, as up till now mostly GFP Nbs 
were used. At the time we performed our first labelling method (through sortase), we 
implemented cortactin Nb2-AF488 for super resolution microscopy (Airyscan and 
PALM/TIRF) in collaboration with the group of Prof. Dr. Alessandra Cambi (Radboud 
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University, Faculty of Medical Sciences, Nijmegen, the Netherlands). However, the 
invadopodia were not as clear as in case of labelling through the pAzF method (as judged 
by confocal microscopy (Figure 45)). Although, using cortactin Nb2-AF488 (labelled 
through sortase reaction), it was possible to detect a low signal for podosomes in 
dendritic cells (Hebbrecht and Joosten et al., unpublished data). 
 
 
Table 6: The use of labelled nanobodies for super resolution microscopy. (CuAAC, Cu(I)-catalyzed Azide-Alkyne Click 
Chemistry; DNA-PAINT, DNA point accumulation for imaging in nanoscale topography; GFP, green fluorescent protein; NHS, 
N-hydroxysuccinimide; NPC, nuclear pore complex; pAzF, para-azido phenylalanin; SIM, structured illumination microscopy; 
SMLM, single molecule localization microscopy; SPAAC, strain-promoted alkyne-azide cycloaddition; STED, stimulated 
emission depletion microscopy; STORM, stochastic optical reconstruction microscopy; TIRF, total internal reflection 
fluorescence; TTL, tubulin tyrosine ligase; *, unknown since it was bought from ChromoTek GmbH; **, unknown since it was 
bought from NanoTag Biotechnologies GmbH) 
Nanobody Labelling strategy Microscope References 
GFP Nb NHS PALM Ries et al.
178
 
GFP Nb TTL 
3D‐SIM super resolution 
microscopy 
Schumacher et al.
189
 
NPC Nb NHS / maleimide STORM Pleiner et al.
179
 
Tubulin Nb NHS SMLM Mikhaylova et al.
201
 
Nbs against a short linear epitope 
of β-catenin 
Sortase STORM Virant et al.
165
 
Tubulin Nb 
Sortase + SPAAC 
+ DNA-PAINT 
SMLM Fabricius et al.
193
 
GFP Nb 
RFP Nb 
* STED Cramer et al.
461
 
GFP Nb 
mCherry Nb 
mTagBFP Nb 
Maleimide + SPAAC 
+ DNA-PAINT 
TIRF Sograte-Idrissi et al.
463
 
Fascin Nb2 
pAzF incorporation 
+ CuAAC 
Airyscan super resolution 
microscopy and TIRF 
Liu et al.
68
  
GFP Nb ** STED Seitz et al.
462
 
 
As suggested, the use of nanobodies for microscopic intents likely will increase. 
However, nanobodies still suffer from crossing of the cell membrane, one of their major 
disadvantages. This means that the cells first need to be fixed and permeabilised before 
nanobodies can enter the cell. During fixation, proteins and cellular content are 
immobilised163. However, it was noticed previously that fixation can alter the epitopes 
resulting in total loss of antibody immunoreactivity163. After the fixation, 
permeabilisation is followed to allow an enhanced antibody entering into the cell465. 
Together, those processes can alter the normal appearance of the protein of interest163, 
272. While fixation can block the binding site or even alter the protein structure, 
permeabilisation can cause the loss of proteins via extraction or relocalization163, 272. This 
means that compared to living cells, a protein in fixed cells can be modified in shape, 
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interaction sites, location and its abundance163. Taking this into account, a choice of 
different fixatives and detergents are available. A fixation is typically performed by using 
paraformaldehyde (PFA) or glutaraldehyde (GA) or a combination of PFA and GA163. Both 
have their advantages and disadvantages. PFA is a faster fixation strategy than GA and it 
causes fewer changes in epitope immunoreactivity compared to GA163, 465, 466. However, 
both PFA and GA cause morphological changes163, 467. GA is a stronger fixative resulting in 
a superior structural preservation due to higher cross-linking level466, 467, while PFA is not 
able to fully immobilize all cellular structures163. The latter can result in a movement 
after fixation leading to artefacts such as mislocalizations163. Using a combination of PFA 
and GA, the fixation profits from fast PFA fixation properties and the fully immobilization 
due to GA163. Additionally, alcohol-based fixations are used as well (e.g. ice-cold 
methanol). This results in a stable fixation for only a few cellular structures and a poor 
morphological preservation467. Methanol typically causes changes in tertiary structures 
due to protein denaturation466. Additionally, a dialdehyde fixative, glyoxal, can be used 
which is complementary to PFA or GA. As a matter of fact, it is only recently rediscovered 
as Sabatini and co-workers already used it in 1963467, 468. It is a faster fixative than PFA 
and since it is a dialdehyde, it cross-links proteins more effectively and more accurate 
which results in an improved immobilisation and preservation of the cellular 
morphology467. As it is a stronger fixative than PFA, it does not induce reduction in 
epitope immunoreactivity as observed for GA467. An advantage of glyoxal fixation is the 
typically brighter results or, in other words, less background467. Besides, glyoxal is safer 
to work with, since it is less harmful by inhalation than PFA465-467. For cortactin Nb2-
AF488, we executed an immunofluorescence assay on HNSCC61 cells through PFA and 
glyoxal fixation. The results show the lower background and more intense signal for the 
cortactin Nb2-AF488 in case of glyoxal compared to PFA (unpublished data, figure added 
in addendum (Figure 51)). As detergent, Triton X-100 was used. This is a non-ionic, mild 
detergent and is used to improve penetration of antibodies and nanobodies which is 
supposed not to change epitope immunoreactivity465. Other mild detergents can be used 
as well since they generally do not denature proteins: Tween 20, digitonin and 
saponin163, 469, 470. The biggest impact of Triton X-100 is found after an incomplete 
immobilization, which leads to the loss of cytosolic elements163.  
When using conventional imaging techniques, the changes due to the fixation are most 
of the time negligable163. However, in case of super resolution techniques, such changes 
can be a huge problem due to the high resolution. Otherwise, the proper and correct 
interpretation of the data can be doubtfull163. As we know our in-house characterised 
nanobodies are able to find their cytoplasmic target and are able to interfere in the 
functionality of the protein, they work perfectly on the native structure. Since the 
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fixation can alter the protein its native conformation, it is not always certain the same 
nanobodies can find their target in these fixed cells. To circumvent this problem, a 
nanobody delivery is required. Here, we used the photoporation technique that allows 
the nanobodies to enter living cells. In that way it enables the nanobodies to interact 
with their target in its native form. By using the β-catenin nanobodies, we came across 
this problem. β-Catenin Nb77 is able to bind β-catenin after the cells are fixed and 
permeabilised. However, β-catenin Nb86, which was found from the same immunisation, 
was not. While the fluorescently labelled nanobodies may create a faster 
immunocytochemistry protocol, they face the same problems as antibodies. 
Nevertheless, Liu et al. have shown the possibility to bring exogenous proteins into cells 
via photoporation67. By photoporating the β-catenin Nb86 in living cells, β-catenin Nb86 
showed its capacity to target β-catenin. Photoporation has important advantages 
compared to other techniques that were used for protein delivery. It allows exogenous 
protein delivery without the need to escape from endosomes and it can be performed in 
standard recipients for cell growth67. It only needs a short optimisation depending on cell 
line and growth conditions (e.g. coating). Since we have other in-house nanobodies, of 
which we know that they are able to bind their target in its native form, those 
nanobodies can be used for photoporation as well. In the collaboration with Liu and co-
workers, we have used our fascin Nb2 for this purpose68 and in this study we have shown 
it for cortactin Nb2 and β-catenin Nb86 as well. A possible drawback has to be 
mentioned. In case of staining fixed cells, it is possible to wash out the unbound 
nanobody fraction. When using the photoporation, this is not possible which introduces 
the risk of unintended fluorescent background. Those unbound nanobodies will be 
present in the cell but does not correspond to specific signal. To circumvent this 
problem, the concentration for each nanobody has to be optimised (which is a standard 
procedure in case of fixation as well). Next to the determination of the concentration, 
the time between photoporation and imaging can be prolonged in order to let the cell 
remove the overshoot of nanobody. However, the latter is not the most recommended 
option, since this can create stress on the cells which possibly can introduce small change 
the proper cell functioning. 
It has been noticed that using the photoporation during this work showed some 
accumulation in the nucleus of the fluorescent nanobodies. This is most clear in case of 
the β-catenin nanobodies (Figure 47B). A possible explanation is that β-catenin also has 
transcriptional activity in the WNT signal transduction pathway and so can be found in 
the nucleus427. However, this phenomenon is also present in case of the other 
nanobodies as well (cortactin Nb2 and fascin Nb268) but only slightly. As mentioned 
above, if accumulation is observed in the nucleus, this can be reduced by incubating the 
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cells (longer) between photoporation and imaging (Liu J., Hebbrecht T. and Van Leene C. 
et al., unpublished results). 
Additionally, the photoporation does not only allow delivery of nanobodies to target the 
native form of a protein, it also enables to investigate follow up of processes in real time. 
By performing life-cell imaging, Liu et al. have used fascin Nb2 and histone Nb which still 
allows to visualise their target 24h and even 72h after photoporation68. As we observed, 
β-catenin Nb86 enabled us to follow β-catenin interaction in the adherens junctions 
between two cells. The combination of fluorescent labelled nanobodies and the 
photoporation technique enables the study of long and/or short term processes which 
can be followed through time. Important to mention here, if one desires to study a 
protein purely by tracing it, the nanobody must not interfere with the function of the 
protein of interest. For instance, Fascin Nb2 interact with fascin without hindering its 
actin bundling function, while fascin Nb5 decreases invadopodium elongation, a shorter 
invadopodium lifetime and less ECM degradation45. For β-catenin Nb86, this is not yet 
clear and requires further investigation.  
Moreover, when more nanobodies against other targets are available in fluorescent 
format, the possibility to study processes and pathways will expand due to the enabling 
of the visualisation in living cells. It has been shown before that nanobodies are an ideal 
tool to study fast (and so short term) processes. Seitz and co-workers have used GFP 
nanobodies for the investigation of post-exocytosis events in neurons (Figure 50)462. 
After the expression of exocytosis vesicle proteins fused to GFP, they incubated the 
neurons with non-fluorescent GFP Nbs to block the extracellular vesicle proteins which 
are already present on the membrane462. Next, they added the fluorescent GFP Nbs 
which will target newly-exocytosed vesicle proteins462. After a ten seconds incubation 
with the fluorescent GFP Nb, they were able to visualise newly-exocytosed vesicle 
proteins at synaptic sites of neurons which indicates that using nanobodies allow to 
investigate processes that happen in a matter of seconds462. 
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Figure 50: GFP nanobodies enable the selective labelling of newly-exocytosed vesicle proteins. The neuron cells in the 
study of Seitz and co-workers express a GFP fused synaptic vesicle (SV) proteins. (1) During an incubation with non-
fluorescent GFP Nbs (NbGFP), (1) the extracellular vesicle proteins will be targeted. (2) This makes them inaccessible to 
fluorescently-conjugated nanobodies (NbGFP*). (3) When a new vesicle protein is exposed on the plasma membrane due to 
a newly-exocytosed vesicle, it interacts with the fluorescent GFP Nb (NbGFP*) which reveals its position. The figure is 
adapted and modified from Seitz et al.
462
.   
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 Conclusion and future perspectives  7.3
N-WASp plays a key role in the invadopodium pathway. As the VCA nanobodies 
indicated, N-WASp is important in the formation, but not in the ECM degradation step. 
However, those nanobodies could be used to further study N-WASp and the role 
between the VCA domain and Arp2/3. The VCA domain is the most important domain of 
N-WASp due to participation in the invadopodium precursor and its direct interaction 
with actin and Arp2/3 for actin polymerisation. As the results were found by expressing 
the EGFP-tagged VCA nanobodies through transfection, photoporation and labelled 
nanobodies can be used as well in additional experiments to explore the role of VCA 
domain further (e.g. determining the lifetime of invadopodium, unravelling the 
invadopodium architecture …). Next to the VCA domain, the generation of nanobodies 
against other domains of N-WASp can have an additional value in evaluating the role of 
N-WASp in the invadopodium pathway. Nanobodies against almost every domain would 
have their own special interest; e.g. the remaining of N-WASp in its inactive state or the 
disturbance in binding to the membrane. 
As published before, when using a nanobody against an invadopodium protein (e.g. 
fascin and cortactin45, 48, 407, 433), the proper functioning of invadopodia is hindered. Each 
time, only one protein is targeted in the study resulting in a partial disappearance of 
invadopodia. Since N-WASp and cortactin are found in the same invadopodium 
precursor, it can be interesting to introduce both nanobodies together to analyse if the 
effect enlarges. Preliminary data already indicated an additive effect of the VCA Nb14 in 
combination with cortactin Nb2 (Van Audenhove et al., unpublished data). This result 
suggests that other important processes must be happening besides the invadopodium 
precursor. However, further investigation is necessary to draw definite conclusions. A 
combination of nanobodies is not only interesting to evaluate the biological changes, the 
use of photoporated fluorescent nanobodies against different targets can aid in 
unravelling the invadopodium structure. If that is accomplished in combination with 
super resolution imaging, a more accurate localization can be found. While only AF488 is 
used in this study, a plethora of fluorophores is already available which makes it possible 
to obtain nanobodies with different fluorophores rapidly. Since invadopodia closely 
resemble podosomes, it is interesting to compare those two structures. As have been 
noticed before, invadopodia and podosomes are not entirely the same. For example, the 
location of fascin in podosomes is the opposite of that in invadopodia46. By exploiting the 
fluorescent nanobodies, other differences can be discovered since nanobodies can allow 
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a more precise localization via super resolution techniques. Together with the 
photoporation, this can provide new biological information.  
As mentioned before, nanobodies will be important in the future for super resolution 
microscopy as an alternative for antibodies due to the smaller linkage error. As we have 
tried the cortactin Nb2-AF488 (labelled via sortase) for TIRF/PALM, we obtained only low 
intensity signals to visualise podosomes in dendritic cells (Hebbrecht and Joosten et al., 
unpublished data). Due to time restrictions, we did not check the cortactin Nb2-AF488 
(labelled via pAzF) using super resolution microscopy yet, but the results are supposed to 
be promising since the labelling via pAzF showed much better results (Figure 45). 
However, not only cortactin Nb2-AF488 will be interesting to check on the super 
resolution microscope, also other invadopodium proteins can be implemented. This can 
eventually lead to a better understanding of the invadopodium architecture. 
As mentioned earlier, nanobodies are a powerful tool, but their biggest bottleneck was 
the delivery into living cells. As we have shown here, photoporation creates alternative 
opportunities. The delivery via photoporation is a step towards a better and more 
precise method to clarify the importance of proteins (or their domains) in certain 
pathways. Current studies to examine protein functions (e.g. RNAi and CRISPR/CAS9) are 
genetically based methods or use chemical inhibitors. By photoporating nanobodies, the 
target does not disappear from the cell and can be imaged at the same time through the 
labelled nanobodies. Due to the fast delivery of nanobodies, photoporation enables to 
notice the effects almost instantly67, 68. This allows much faster examination compared to 
e.g. RNAi84. In this study, the role of N-WASp is examined by transfecting the cDNA which 
is also an alternative to the current strategies. However, the photoporation of 
nanobodies is even a more valuable alternative which can be expanded for any 
nanobody that provokes inhibitory effects on their target and for any experiment in 
which nanobodies are inserted into the cell through transfection. The additional 
advantage of the photoporation is that it allows perturbing processes and pathways via 
the photoporated nanobodies for any chosen time with high precision, which is more 
difficult to control through conventional nanobody cDNA transfection. In other words, 
photoporation allows to examine the effects at a pre-determined time or even through 
time. 
In this study, the preferred method to label nanobodies was through the incorporation 
of pAzF followed by the CuAAC reaction. However, the presence of a reactive group such 
as an azide (or an alkyne) allows the use for other purposes. This can be a coupling to 
quantum dots, to PEG, to biotin, to agarose/magnetic beads … . Fortunately, those 
components are already commercially available. The protocol to obtain labelled 
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nanobodies can be easily adapted to use for those other purposes. Additionally, the 
labelled nanobodies can have other applications than microscopy as well, such as 
Western blotting, ELISA … .  
As for pharmaceutical interest, the intracellular delivery of a nanobody is still not an 
option in organisms. It would be a great discovery when nanobody intracellular delivery 
would be enabled in living organisms, as it can be used as pharmacological inhibitor in 
case when there are not yet ones available or when there are already available, as 
complementary therapy. Since nanobodies are still only an ideal research tool for 
intracellular proteins, it is therefore expected to provide new biological information 
which can be useful for further engineering of pharmaceutical drugs against intracellular 
targets rather than becoming a pharmaceutical drug in the near future. In other words, 
nanobodies can be the stepping stone to focus the search in finding good 
pharmaceuticals. Since we have used the nanobody technology as research tool here, we 
therefore hope that this work will contribute to develop new applications with 
nanobodies, thereby helping to unlock their full potential as research instruments in cell 
biology. 
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Addendum 
- Supplementary for “Nanobody click chemistry for convenient site specific 
fluorescent labelling, single step immunocytochemistry and delivery into living 
cells by photoporation and live cell imaging” 
o Video 1 
o Video 2 
- Unpublished result of a staining using cortactin Nb2-AF488 (labelled through the 
pAzF method) in HNSCC61. 
 
Figure 51: Comparison of PFA and glyoxal fixation of a cortactin Nb2-AF488 staining in HNSCC61. Nuclei were 
visualized with DAPI (blue) and actin (red) with phalloidin-AF594. (Scale bar = 10 µm) 
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